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Abstract 
 
The  interplay  of  fundamental  extracellular  factors  involved  in  the  control  of  cells 
producing type I collagen is still not fully understood.  Bone formation by osteoblasts is 
known to be dependent on a good vascular supply and to be inhibited by hypoxia.  This 
strongly suggests that oxygen carried by the blood acts as a key regulator of connective 
tissue cell function.  To investigate further the role played by vascular oxygen supply in 
connective  tissues,  calvarial  osteoblasts  and  dermal  fibroblasts  were  grown  under 
hypoxic (2% oxygen) and normoxic conditions (20% oxygen).  Hypoxia caused striking 
decreases in growth and collagen formation by both cell types, along with increased 
expression of VEGF mRNA by fibroblasts.  A novel assay using osteoblasts isolated 
from  neonatal  rat  long  bones  was  developed  to  examine  more  closely  the  bone 
formation  process.    These  osteoblasts  were  characterised  alongside  autologous 
calvarial  cells.    In  vivo,  limb  bones  and  flat  bones  form  by  distinct  developmental 
processes; unexpectedly, osteoblasts from both sources behaved similarly in culture, 
with no clear differences in growth, gene expression or bone formation.  As part of the 
characterisation of the long-bone-derived osteoblasts, the direct effects of  PTH were 
examined.  The mechanism for the anabolic response of bone in vivo to PTH treatment 
has yet to be fully elucidated.  Unexpectedly, PTH exerted powerful inhibitory effects on 
cell  growth,  differentiation  and  bone  formation.    Moreover,  mRNA  expression  of 
sclerostin, a key endogenous inhibitor of bone formation, was downregulated by PTH 
treatment.  These findings indicate that the in vivo anabolic response to PTH involves 
additional factors that override its direct inhibitory action on osteoblasts.  Collectively, 
the results presented in this thesis strengthen the notion that the production of collagen 
by  connective  tissue  cells  is  dependent  on  oxygen  and  the  vascular  supply,  and 
implicate the vasculature in mediating the effects of anabolic hormones on bone.  
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Chapter 1 
Introduction 
The  ability  to  adapt  to  a  changing  local  environment  is  fundamental  for  the 
survival of mammalian cells.  A good vascular network enables adaptation by 
feeding cells with an adequate oxygen supply and nutrients, providing factors 
required for growth, activity and sustainability, and removing the by-products of 
these processes.   
Vascularisation  of  osseous  tissue  has  been  long  implicated  in  the 
successful growth  and  regeneration of  this tissue.  The  early  observations of 
Albrecht von Haller in 1763 first suggested a relationship may exist between the 
vascular system and osteogenesis, implying that blood vessels are needed for 
bone  formation.    Since  this  initial  hypothesis  was  proposed  much  work  has 
followed, with details of the circulation in and around bone as we understand it 
today described in the last century (Trueta et al., 1953; Brookes et al., 1957).  
The  current  focus  of  research  in  this  area  is  on  the  relationship  between 
osteogenesis and angiogenesis and the coupling mechanisms that exist between 
these two processes.   
This thesis is ultimately concerned with the role of the vasculature in the 
formation of collagenous connective tissues and the relationship between these 
tissues and the vascular supply in mature organs, particularly skin and bone.  
The  main  focus  of  this  introduction  will  be  on  fibroblast  and  osteoblast 
differentiation,  formation  and  production  of  extracellular  matrix.    The  different 
mechanisms  for  the  formation  of  bone  will  be  outlined  and  some  of  the  key 
factors in the relationship between osteogenesis and angiogenesis highlighted.   Chapter 1 Introduction 
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Mesenchymal stem cells  
There are multiple different types of connective tissues within the mammalian 
body that derive from mesenchymal stem cells (MSCs).  MSCs have the ability to 
self-multiply  and  are  multipotent,  thus  can  differentiate  into  a  wide  variety  of 
different cell types including: adipocytes, osteoblasts, chondrocytes, myocytes 
and  fibroblasts  (Baksh  et  al.,  2004;  Chamberlain  et  al.,  2007)  and  the  tooth 
specific cells, odontoblasts and cementoblasts (Bluteau et al., 2008). 
The commitment of MSCs to a specific lineage is dependent upon the 
presence of specific transcription factors whose expression is tightly regulated in 
order to maintain strict control over the differentiation pathways.  The key factors 
involved  in  chondrocyte,  fibroblast,  osteoblast,  osteocyte  and  adipocyte 
differentiation from MSCs are outlined in Figure 1.1 (overleaf). 
 
Fibroblasts 
Fibroblasts  are  the  principal  cellular  component  of  connective  tissues,  which 
function to establish, maintain and modify the extracellular matrix (Sorrell et al., 
2009).    The  differentiation  of  fibroblasts  from  MSCs  has,  until  recently,  been 
poorly  understood.    Earlier  this  year,  it  was  reported  that  connective  tissue 
growth factor (CTGF) was sufficient to cause differentiation from MSCs into fully 
functional  fibroblasts  capable  of  producing  type  I  collagen.    Further,  these 
fibroblasts  were  terminally  differentiated  and  as  such,  had  lost  the  ability  to 
differentiate into non-fibroblastic lineages (including osteoblasts, adipocytes and 
chondrocytes) (Lee et al., 2010).  CTGF is produced by human umbilical vein 
endothelial  cells (Bradham  et  al.,  1991) and  by  skin fibroblasts after activation 
with TGF-β (Grotendorst, 1997); environments in which fibroblast differentiation 
would be required for tissue formation in the developing embryo and in wound 
healing.   Chapter 1 Introduction 
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Despite  commitment  to  the  fibroblastic  lineage,  terminally  differentiated 
fibroblasts maintain a remarkable diversity; fibroblasts from different anatomical 
sites  display  individual  transcriptional  patterns  (Chang  et  al.,  2002)  and 
consequently distinct phenotypes result. 
Figure 1.1.  Differentiation of mesenchymal stem cells into chondrocytes, fibroblasts, 
adipocytes and osteocytes 
Stages  of  cellular  development  are  indicated  beneath  each  cell  type.    Some  of  the  key 
transcription factors involved in differentiation are indicated; ‘master’ regulators of commitment to 
specific lineages are shown in red.  For details of abbreviations please see Appendix II.  Adapted 
from (Caplan et al., 2001; Takada et al., 2009). 
 
Chondrocytes 
Chondrocytes are the cartilage producing cells.  The synthesis of cartilage is 
required for endochondral bone formation and the formation of articular cartilage Chapter 1 Introduction 
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that covers the ends of bones.  Cartilage is composed of 70-80% water which 
allows it to act as a ‘shock absorber’, providing cushioning at joints.  The organic 
component of cartilage is mostly type II collagen fibrils and aggrecan.  Aggrecan 
combines  with  hyaluronic  acid,  forming  large  noncovalent  structures  which 
attract cations and water molecules.  The resulting tissue is highly hydrated and 
thus  is  an  ideal  material  for  resisting  compression.    The  majority  of  mature 
articular  cartilage  is  poorly  vascularised,  consequently  if  damaged  it  has  a 
striking  inability  to  heal  (Newman,  1998).    However,  capillary  systems  are 
present in the cartilage at the ends of newly forming long bones; vascularisation 
of the chondro-osseous junctions of growth plates is essential for bone formation 
(Gerber et al., 1999). 
Sox9,  the  major  regulator  of  chondrogenic  differentiation,  initiates  the 
differentiation of chondrocytes from MSCs (Bi et al., 1999).  Sox5 and 6 are also 
thought  to  play  key  roles  in  the  differentiation  process;  investigations  have 
suggested  that  mutations  in  either  gene  can  result  in  severe  skeletal 
malformations  (Lefebvre  et  al.,  2001)  indicating  the  importance  of  proper 
cartilage formation in skeletal development. 
 
Osteoblasts 
The formation of the mineralised extracellular matrix that comprises bone is the 
responsibility of the osteoblast.  Early differentiation of osteoblasts from MSCs is 
governed by Runx2, the ‘master switch’ for osteoblast transcription (Schroeder et 
al., 2005), initiating the differentiation of osteoblasts from MSCs and activating 
osterix.    Osterix  is  the  transcription  factor  required  for  osteoblast  maturation 
(Nakashima et al., 2003); its activation stimulates the expression of a wide range 
of bone matrix genes (Kurata et al., 2007).   Chapter 1 Introduction 
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Mature osteoblasts are characterised by their high expression of alkaline 
phosphatase and their ability to secrete osteoid, the unmineralised bone matrix, 
and  matrix  vesicles.    The  osteoid  secreted  by  osteoblasts  consists  of  type  I 
collagen, the major organic component of bone comprising ~90% of the total 
bone  protein.    Osteoid  also  contains  osteocalcin  (a  bone-specific,  calcium- 
binding protein) and chondroitin sulphate which is thought to function to control 
the water content of bones and is likely to be involved in regulating the formation 
of  collagen  fibres  subsequent  to  mineralisation  (Young  et  al.,  2006).  
Maintenance of the bone water content at an appropriate level is essential to the 
structural integrity and elasticity of bone and for mineral homeostasis, allowing 
ion exchange on bone surfaces that are relatively removed from the circulation 
(Timmins et al., 1977). 
 
Osteocytes 
Osteocytes  are  the  most  abundant  cellular  component  of  mammalian  bone, 
making  up  95%  of  all  bone  cells  (Franz-Odendaal  et  al.,  2006).    Mature 
osteoblasts that become trapped in the mineralised matrix and cease forming 
bone  are  the  terminally  differentiated  osteocytes.    Osteocytes  have  long 
cytoplasmic extensions which cover a vast surface area allowing them to perform 
a multipurpose role in bone biology.  These cellular projections are located in thin 
canaliculi in the mineralised matrix and allow osteocytes to form connections via 
gap-junctions with neighbouring cells and with the bone surface (Aarden et al., 
1994; Doty, 1981).  These cytoplasmic extensions function for communication 
and nutrient exchange, in the early stages of the osteocyte development they are 
mainly directed towards the bone surface.  As the cell becomes more engulfed in 
the  mineralised  matrix  some  of  these  processes  are  directed  towards  blood 
vessels to maintain cellular nutrition (Palumbo, 1986).   Chapter 1 Introduction 
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Early  work  suggested  the  role  of  osteocytes  was  to  induce  osteolysis 
(Belanger, 1969), but more recent evidence points towards the role they play 
being  related  to  mineral  homeostasis  and  strain  detection  (Cullinane,  2002; 
Lanyon, 1993), essential for the mechanical adaptation of bone.   
 
Collagen 
Collagen is an insoluble fibrous protein secreted by connective tissue cells.  In 
humans there are at least 19 different gene products for collagen, each giving 
rise to a different type as a result of different amino acids being incorporated into 
the  helical  structure.    The  different  collagen  types  are  distinguished  by  their 
ability  to  associate  into  fibrils,  form  sheets  or  cross-link  with  other  collagen 
molecules  (Lodish  et  al.,  2000);  it  is  the  variation  in  size  and  orientation  of 
collagen  molecules  that  gives  rise  to  the  varied  morphologies  of  connective 
tissues.   
 
The structure of collagen 
The  basic  structural  unit  of  collagen  consists  of  three  amino  acid  chains  (α 
chains) characterised by the repeating ‘gly-X-Y’ triplet, where X and Y can be 
any amino acid but X is often proline and Y is often hydroxyproline (Berg et al., 
1973).    The  characteristics  of  these  amino  acids  are  responsible  for  the 
polypeptide chains spontaneously forming left-handed alpha helices.  The high 
prevalence of glycine is required in order for the chains to twist enough to form a 
helix.  The small hydrogen side chain of the glycine residues are accommodated 
in the interior of the helix, whereas the larger ring structures of the proline side 
chain are found protruding from the helix; their presence allows sharp turns in 
the  polypeptide  chains,  contributing  to  helical  aggregation.    The  polypeptide Chapter 1 Introduction 
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chain is subject to multiple post-translational modifications.  Certain prolyl and 
lysyl residues are hydroxylated, the extent of which depends on the species, cell 
and  tissue  type  and  may  be  subject  to  change  depending  on  developmental 
status, age or pathological conditions (Lehmann et al., 1995; Kowits et al., 1997). 
Hydroxyproline is believed to be the key to the stability of the triple helical 
structure; it was originally hypothesised that the -OH group allowed increased 
hydrogen bonding and thus conferred stability.  However, more recently it has 
been shown that the hydroxyl group confers stability through stereo-electronic 
effects and that its hydration provides little benefit in terms of structural stability 
(Kotch et al., 2008).  The hydroxylase enzymes require ferrous ions, ascorbic 
acid, α-ketoglutarate and molecular oxygen for activity (Hutton et al., 1967).  A 
lack of any one of these cofactors results in delays or reductions in the formation 
of the collagen molecule.  This is clearly exemplified by the prevalence of scurvy 
when the diet is low in vitamin C.  Lack of ascorbate results in reduced proline 
hydroxylation  and  consequently  reduced  collagen  biosynthesis which  leads to 
characteristically poor wound healing associated with the disease  (Chojkier et 
al., 1983).  The dependence of the hydroxylase enzymes on molecular oxygen is 
of particular relevance to this thesis; reduced oxygen levels result in a diminished 
activity of the proline and lysyl hydroxylases and as a result aggregation of the 
triple  helical  structure  is  impaired  (Towe,  1970).    The  role  of  oxygen  in 
connective tissue formation is investigated in Chapter 3.   
In  a  second  stage  of  post-translational  modifications  some  of  the 
hydroxylysyl residues are glycosylated, the exact function of this is unclear but it 
has  been  suggested  that  they  may  play  a  role  in  fibrillar  organisation 
(Brinckmann et al., 1999) and contribute to collagen stability (Bann et al., 2000b).    
Disulphide bond formation between alternative C- and N-terminal regions 
of the propeptide sequences aligns the three chains, forcing the central portions Chapter 1 Introduction 
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of the chains to associate and twist into the characteristic right handed triple helix 
of the procollagen molecule.  The procollagen molecule is transported out of the 
cell, into the extracellular space where it is subject to cleavage at the N- and C-
termini.  It is the cleavage of the C-terminal propeptide that is the stimulus for the 
initiation of fibril formation (Kadler et al., 1987); once cleaved the fully mature 
collagen  molecule  can  form.    Lysyl  oxidases  act  to  form  reactive  aldehydes 
which  allow  spontaneous  cross-linking  between  individual  fibrils  and  thus  the 
formation of strong, stable collagen fibres. 
Type I collagen is a fibrillar molecule that aggregates to form fibres found 
in skin, bone, dentin and tendon.  It is the most abundant protein in the body and 
the main constituent of the vertebrate endoskeleton.  The most usual molecular 
form of type I collagen is a heterotrimer of two α1 and one α2 chains wound 
around each other to form a right handed triple helix.  In the full collagenous 
structure  the  fibrils  in  adjacent  collagen  molecules  are  displaced  by 
approximately  one  quarter  of  their  length,  resulting  in  a  staggered  array  that 
appears striated when viewed by transmission electron microscopy after heavy 
metal staining (Figure 1.2). 
 
Mineralisation of the collagenous matrix 
Following  the  deposition  of  collagen  in  the  extracellular  space,  the 
mineralisation process begins.  The mineral deposits in bone are composed of 
calcium  and  phosphate  which  are  deposited  as  hydroxyapatite 
(Ca10(PO4)6(OH)2) crystals.  Matrix vesicles are found in the extracellular fluid of 
the mineralising tissues and form by budding and then ‘pinching off’ from the 
outer cell membranes of osteoblasts, chondrocytes, odontoblasts and tenocytes 
(Anderson, 2003).  They contain high levels of enzymes that can increase local 
concentrations  of  phosphate  ions,  including:  alkaline  phosphatase,  Chapter 1 Introduction 
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pyrophosphatase and ATPases  (Ali et al., 1970) and as such are capable of 
initiating  the  synthesis  and  deposition  of  the  mineral  component  of  skeletal  
tissues.    In  the  growth  plate  of  growing  animals  the  mineralisation  process 
begins within the matrix vesicles where mineral crystals begin to form, and is 
followed  by  their  penetration  of  the  vesicular membrane  and  exposure to the 
extracellular fluid.  The conditions (i.e.  pH, availability of calcium and phosphate 
ions) of the extracellular fluid govern further mineral crystal growth (Anderson, 
1995).  In mature bone the mineralisation process is somewhat different.  Here, 
the  staggered  array  of  the  collagen  fibres  forms  grooves  which  provide  the 
nucleation sites for calcium phosphate crystals (Mann, 1988).   
 
 
 
 
 
 
 
 
Figure 1.2.  Type I collagen fibres viewed by transmission electron microscopy. 
Collagen fibres formed by long bone osteoblasts after 28 days in culture in DMEM supplemented 
with 10nM dexamethasone and 50 µg/ml ascorbate.  See Chapter 2 for details of transmission 
electron microscopy procedure.   
Striated banding patterns can be clearly seen.  Collagen fibres that have been cut in transverse 
section appear as dots.  Scale bar = 500µm. Chapter 1 Introduction 
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Mineralisation of the extracellular matrix is regulated by the availability of 
substrates  required  for  the  formation  of  mineral  (i.e.    calcium  and  phosphate 
ions) and is inhibited by the accumulation of other local factors.  Pyrophosphate 
has long been known to be a physiochemical inhibitor of calcification (Fleisch et 
al.,  1962)  and  more  recent  in  vitro  studies  have  revealed  that  extracellular 
nucleotides  (Orriss  et  al.,  2007)  and  acidic  conditions  (Brandao-Burch  et  al., 
2005) also prevent mineral from being laid down.  These findings emphasise the 
importance of the vasculature in the removal of by-products of cellular functions 
in the formation and maintenance of bone. 
It has been suggested that the mineralisation process is regulated at a 
local  level  by  matrix  gla  protein  (MGP).    MGP  is  expressed  by  mature 
osteoblasts  and  chondrocytes  and  inhibits  mineralisation  of  the  extracellular 
matrix  around  these  cells  (Murshed  et  al.,  2004).    Although  MGP
-/-  mice  are 
normal at birth, severe, lethal arterial calcification occurs within weeks (Luo et al., 
1997),  suggesting  that  MGP  is  a  key  regulator  in  the  mineralisation  process.  
However, this does not appear to hold true in humans where a lack of functional 
MGP  results  in  Keutal  syndrome,  where  sufferers  experience  calcification  of 
cartilage but not arteries (Schinke et al., 2000), indicating that additional mineral-
binding proteins must play a role in the mineralisation process. 
 
Skin 
The skin is the body’s largest organ by weight and by covering the entire body 
surface provides a protective barrier against pathogen invasion.  The skin has a 
rich  vascular  supply;  a  microcirculatory  bed  feeds  the  dermis,  with  capillaries 
penetrating into the epidermal layer (Yen et al., 1976).  In addition to its oxygen 
and  nutrient  providing  roles,  this  highly  dense  capillary  network  functions  to Chapter 1 Introduction 
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control  body  temperature;  vasodilation  and  constriction  alter  the  blood  flow 
through  these  vessels  allowing  heat  loss  from  the  body  to  be  regulated 
(Charkoudian,  2003;  Fortney  et  al.,  1985).    Normally,  the  skin  receives 
approximately 5-10% of cardiac output in temperate conditions but this can be 
increased to up to 50-70% under severe heat stress (Rowell, 1977).  In very cold 
conditions blood flow to some body extremities including the finger tips, ears and 
nose, is almost entirely cut off in order to conserve heat.  The skin is capable of 
withstanding this severe reduction in blood supply for relatively long periods of 
time but eventually, if not restored, frostbite ensues as a result of both freezing 
tissue and depleted oxygen supply resulting in severe local hypoxia (Gage et al., 
1970). 
 
Bone 
Bone is a highly specialised, mineralised connective tissue, the main function of 
which is structural, whereby the skeleton supports and protects vital organs and 
tissues  and  acts  as  a  system  of  levers  for  muscles  to  work  from,  allowing 
movement.  However, the skeleton is more than just a supportive structure; bone 
is a dynamic tissue with a high metabolic rate, tightly regulated by a variety of 
hormones and by mechanical stresses placed upon it.  Bone is the predominant 
store of calcium and phosphate ions in the body.  It contains about 99% and 80-
90% of the body totals of calcium and phosphate ions respectively, providing a 
reservoir that is key to whole body chemical homeostasis  (Copp et al., 1963; 
Flynn,  2003).    Haematologically,  the  skeleton  is  of  importance  too; 
haematopoietic stem cell (HSC) differentiation and maturation takes place in the 
red marrow in the flat bones and at the ends of long bones.  The skeleton has 
also  recently  been  implicated  in  endocrine  regulation  and  thus  energy 
metabolism (Lee et al., 2007).   Chapter 1 Introduction 
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During development of the mammalian foetus bone can be formed in one 
of two ways.   
 
Intramembranous ossification 
The  flat  bones  of  the  skull,  the  mandible,  the  sternum  and  the  clavicle,  are 
formed by the de novo synthesis of bone.  MSCs in the mesenchyme condense 
and form vascularised layers of connective tissue.  Upon stimulation by Runx2, 
MSCs within these condensed ‘nodules’ differentiate directly into osteoblasts and 
begin  producing  collagen.    Mature  osteoblasts  secrete  osteoid  into  the 
extracellular space which undergoes mineralisation, forming bone.   
The exact vascularisation patterns of flat bones are still disputed but it is 
agreed that the blood supply is extensive.  The blood supply differs between thin 
and thick parts of the bone; bone thinner than 0.4mm is fed by the periosteum, 
whereas  thicker  areas  of  bones  develop  distinct  periosteal,  cortical  and bone 
marrow networks similar to that of long bones (Pannarale et al., 1997). 
 
Endochondral ossification 
The majority of bones in the body including the long bones of the limbs, small 
bones  with  marrow  cavities  and  the  vertebrae,  form  via  endochondral 
ossification.    In  this  case,  MSCs  differentiate  into  chondroblasts  forming  a 
cartilagous model of the skeleton which is later replaced by mineralised tissue.   
 In  the  early  development  of  endochondrally  formed  bones,  high 
expression  of  Sox9  induces  MSCs  to  differentiate  into  chondrocytes.    These 
chondrocytes form a hyaline cartilage model of the limb bud which is surrounded 
by a dense layer of fibrous connective tissue, the perichondrium.  Chondrocytes Chapter 1 Introduction 
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within the perichondrium undergo hypertrophy which induces cellular production 
and secretion of vascular endothelial growth factor (VEGF), triggering the onset 
of angiogenesis and vascular invasion of the model of bone (Karsenty, 2001).   
Runx2  stimulation  causes  terminal  differentiation  of  MSCs  into 
preosteoblasts  which  mature,  begin  producing  type  I  collagen  and  secrete 
osteoid.    Newly  synthesised  osteoid  matures  in  the  extracellular  space  for 
several days after which time mineral deposition begins.  Continuous mineral 
accumulation on the newly forming bone surface results in the formation of a ring 
of  bone around  the  cartilage  model.   The cavities  within  bone  are  generated 
when  cartilage  at  the  centre  of  the  diaphysis  (the  middle  section  of  the  long 
bone) begins to disintegrate as chondrocytes undergo apoptosis.  Disintegrating 
cartilage is replaced by trabecular bone.  This centre of primary ossification is the 
point from which bone growth extends outwards to the ends of bones (where, in 
long  bones  secondary  centres  of  ossification  are  established).    Long  bones 
continue to grow in this manner until their genetically predetermined length is 
reached and only a thin strip of cartilage remains at either end; this cartilage (the 
epiphyseal growth plate) persists until the bone reaches its full adult length and 
is then replaced with mineralised tissue.   
The  final  stage  in  the  bone  formation  sees  the  cessation  of  cartilage 
growth and fusion of the growth plate with the end of the bone.  Further growth 
occurs  at  a  much  reduced  rate  and  is  seen  appositionally,  whereby  bone 
thickness  is  increased  by  osteoblast  activity  on  the  surface  of  the  bone  and 
osteoclast activity inside the lumen, creating space for more marrow.   
The fully mature bone consists of two main types of osseous tissue.  The 
outer cortex of bone, the cortical bone, is mainly comprised of hydroxyapatite 
and is organised in osteons; concentric rings of tightly packed bone around a 
central canal (Haversian canal) which supplies the tissues blood flow and nerve Chapter 1 Introduction 
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supply  (Trias  et  al.,  1979).    The  spongy  interior  matrix  (the  trabecular  or 
cancellous  bone),  contains  the  organic  component  which  includes  the 
collagenous fibres, bone cells and the majority of blood vessels that supply bone 
and is filled with marrow.  As cortical bone contains most of the mineral in the 
skeleton it is much denser than trabecular bone, contributing significantly more to 
the total skeletal weight (Gong et al., 1964).   
 
Regulation of osteogenesis  
Indian hedgehog/parathyroid hormone related protein signalling 
Chondrocyte hypertrophy is controlled by indian hedgehog (Ihh) and parathyroid 
hormone related protein (PTHrP), a structurally similar but functionally different 
member  of  the  parathyroid  hormone  family.    Ihh  promotes  chondrocyte 
hypertrophy and as such is key to the endochondral bone formation process: 
Ihh-deficient mice have decreased chondrocyte proliferation and display severe 
abnormalities in long bone development (St-Jacques et al., 1999).  Conversely, 
PTHrP delays endochondral ossification.  This is achieved by its direct inhibitory 
effects on chondrocyte hypertrophy (Chung et al., 2001) and by inhibiting Runx2 
(Guo et al., 2006). 
 
Bone morphogenic proteins and fibroblast growth factor  
The  TGFβ  superfamily  consists  of  multifunctional  peptides  that  control 
proliferation, differentiation and other functions in many cell types.  The bone 
morphogenic protein (BMP) family is a member of this superfamily and plays a 
key role in the induction of growth in both bone and cartilage (Massague et al., 
2000).    The  BMPs  promote  mesenchymal  condensation  and  chondrocyte Chapter 1 Introduction 
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differentiation  by  maintaining  the  expression  of  the  Sox  transcription  factors 
(Yoon et al., 2004).  In addition to this, a positive feedback loop exists between 
BMPs  and  Ihh,  and  as  such  they  work  together  to  upregulate  chondrocyte 
proliferation  (Minina  et  al.,  2001).    Specific  BMPs  have  direct  effects  on 
osteoblasts, BMP2 has been reported to stimulate osteoblast precursor lineage 
commitment, increased alkaline phosphatase activity and osteocalcin production 
in vitro (Yamaguchi et al., 1996). 
  Fibroblast growth factor (FGF) acts antagonistically to the BMPs, inhibiting 
chondrocyte  proliferation  and  thus  the  balance  of  BMP  and  FGF  signalling 
dictates the rate of chondrocyte development (Minina et al., 2002). 
 
Wnt signalling  
The  canonical  Wnt  signalling  pathway  plays  a  central  role  in  controlling 
embryonic bone development and mass (Westendorf et al., 2004; Chen et al., 
2009).    Wnts  are  secreted  glycoproteins  that  bind  to  receptor  complexes 
composed of Lrp5/Lrp6 and the Frizzled protein.  Lrp5 is present in bone on the 
surface of osteoblasts in endosteal and trabecular bone (Koay et al., 2005) and 
is critical to proper bone formation; Lrp5
-/- mice are viable and fertile but exhibit 
low bone mass which often results in multiple fragility fractures and can lead to 
severely shortened life spans (Kato et al., 2002).   
Canonical Wnt signalling is also implicated in joint formation (Hartmann et 
al., 2001) and cartilage development.  It has been shown that β-catenin mediated 
wnt signalling is required for chondrocyte maturation, with misexpression of the 
Frizzled  protein  resulting  in  delayed  chondrogenesis  and  consequently,  long 
bone formation (Hartmann et al., 2000). 
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Sclerostin   
Naturally  occurring  inhibitors of Wnt  signalling  have  dramatic  effects  on bone 
formation, as exemplified by the osteocyte secreted protein sclerostin (SOST).  
SOST is present in high concentrations throughout the canalicular system and 
acts  to  inhibit  osteoblastic  bone  formation  (Winkler  et  al.,  2003).    SOST 
negatively regulates bone formation by binding to the Lrp5/Lrp6 coreceptor and 
antagonising the normal Wnt response (Semenov et al., 2005; ten Dijke et al., 
2008). 
SOST is almost exclusively expressed by osteocytes and has inhibitory 
effects  on  bone  by  preventing  the  differentiation  of  osteoblastic  cells  (van 
Bezooijen et al., 2004) and promoting their apoptosis (Sutherland et al., 2004), 
thus playing a key regulatory role in bone remodelling.  Loss of the sclerostin 
protein  results  in  sclerosteosis,  a  bone  remodelling  disorder  that  arises  from 
progressive  bone  thickening  and  overgrowth  but  has  little  or  no  effect  on 
resorption.  Sufferers experience increased bone density at multiple sites, but 
specifically  in  the  clavicles  and  the  skull  with  noticeable  effects  seen  in  the 
calvaria and mandible (Sugiura et al., 1975).  Sclerosteosis is inherited as an 
autosomal  recessive  trait,  which  results  from  mutations  arising  in  the  van 
Buchem  disease-gene  region  of  chromosome  21  (Balemans  et  al.,  1999).  
Heterozygous carriers of the disorder are clinically normal,
 although some may 
show age-related radiographic evidence of
 calvarial thickening (Gardner et al., 
2005).   
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Osteogenesis and angiogenesis  
Bone  receives  approximately  7-8%  of  cardiac  output  which  is  supplied  to 
developing  bones  by  the  rich  capillary  network  that  surrounds  bone  in  the 
periosteum.    Without  this  highly  vascular  environment  osteoblasts  do  not 
differentiate from MSCs and bone formation does not occur.  Fully formed bones 
have a rich vascular supply, nutrient arteries enter the diaphysis of long bones 
though canals which traverse the cortical bone.  After reaching the medullary 
cavity these arteries then divide, with arteriole branches feeding the epiphysis 
and metaphysis (Brookes, 1963; Wheeless, 2010).  Earlier in life, before these 
arteries have fully developed the blood is supplied to bone through small vessels 
that  penetrate  the  cortical  bone  connecting  the  marrow  space  and  the 
periosteum (as seen in Figure 1.3).  As bone ages medullary atherosclerosis 
results  in  a  return  to  the  reliance  on  periosteal blood  supply.    Consequently, 
medullary ischemia and reduced marrow arterial pressure result (Bridgeman et 
al., 1996). 
 
Vascular endothelial growth factor 
Vascular  endothelial  growth  factor  (VEGF)  is  thought  to  be  the  key  pro-
angiogenic stimulus in normal skeletal development and fracture repair.  VEGF 
and its receptor are expressed by both osteoblasts and osteoclasts, indicating 
that bone formation, remodelling and angiogenesis are tightly coupled processes 
(Wang et al., 2007; Towler, 2008; Street et al., 2002; Tombran-Tink et al., 2004).   
VEGF induces capillary  invasion of the perichondrium and plays a key 
role in skeletogenesis in both intramembranous and endochondral ossification in 
vivo.    Using  mice  lacking  some  of  the  allelic  variants  of  VEGF,  Zelzer  et  al.  
(2002)  have  shown  that  both  intramembranous  and  endochondral  bone Chapter 1 Introduction 
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formation require VEGF with reductions in mineralisation observed in both bone 
formation  processes  in  the  knockout  mice  compared  with  the  wild-types.  
However, they also found that the most notable differences displayed between 
the  transgenic  animals  and  the  wild-types  was  in  the  vascularity  of  the  long 
bones.    Mice  lacking  fully  functional  VEGF  displayed  delayed  recruitment  of 
blood  vessels  into  the  perichondrium  and  delayed  invasion  of  the  primary 
ossification centre (Zelzer et al., 2002).   
 
 
 
 
 
 
 
 
 
 
Figure 1.3.  Vascular channels in the shaft of a rat femur. 
Scanning  electron  microscope  image  of  vascular  channels  penetrating  the  inner  surface  of 
cortical bone.  Channels appear as pores within the bone.   
Reproduced with the kind permission of Professor Alan Boyde, QMUL, London. 
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Bone remodelling 
The  synchronised  activity  of  osteoblasts  and  osteoclasts  allows  bone  to  be 
modelled  and  remodelled,  enabling  the  skeleton  to  fulfil  its  structural  and 
homeostatic roles.  Bone remodelling serves to repair micro-cracks, maintaining 
strength and structural integrity and providing a continual reservoir of calcium 
and phosphorus for mineral homeostasis which is continuously adapting to the 
systemic  needs  of  the  body.    Under  normal  physiological  conditions  bone 
resorption and bone formation are balanced, allowing skeletal regeneration to 
take place.  Trabecular bone has a much higher rate of turnover than cortical 
bone, with 26% and 3% respectively being replaced annually (Sandhu, 2003). 
At  discrete  regions  in  the  skeleton,  termed  the  basic multicellular units 
(BMU), the remodelling process is initiated by stimulated osteoclasts binding to 
and  resorbing  the  bone  surface.    The  resorption  phase  is  followed  by 
proliferation  and  differentiation  of  MSCs  into  osteoblasts,  which  form  new 
osseous tissue in the excavated pit.  The formation of osteocytes completes the 
remodelling cycle and leaves the bone in a quiescent state (Figure 1.4).   
 
Osteoclasts 
Osteoclasts  are  usually  quite  large,  multinucleate  cells  which  contain  a  high 
number of mitochondria (Ch'uan, 1931).  Functionally, osteoclasts act to resorb 
bone by excavating pits or trails known as Howship’s lacunae.  They associate 
tightly  with  the  bone  surface,  forming  a  sealed  zone,  within  which  resorption 
takes place.  The osteoclast membrane in contact with the bone surface, known 
as the ruffled border, is the site from which the osteoclast secretes the bone 
degrading  components.    Hydrogen  ions  are  actively  pumped  across  the 
membrane  to  dissolve  the  crystallised  hydroxyapatite  which  makes  up  the 
mineral  phase of  the  bone  tissue.    Osteoclasts  actively  synthesise  lysosomal Chapter 1 Introduction 
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enzymes  that  are  capable  of  degrading  the  organic  component  of  bone,  the 
collagenous matrix.   The cysteine-rich protease, cathepsin K, is secreted from 
the  ruffled  border  and  is  collagenolytic  (Troen,  2004).    Tartrate  resistant 
isoenzyme of acid phosphatase (TRAP 5b) is also secreted by actively resorbing 
osteoclasts  and  is  thought  to  modulate  osteoclast  adhesion  by 
dephosphorylation  of  osteopontin  and  bone  sialoprotein  (Ek-Rylander  et  al., 
1994) 
Osteoclast formation is initiated by receptor activator of nuclear factor β 
(RANK) ligand and macrophage colony-stimulating factor (M-CSF), secreted by 
osteoblasts and MSCs, respectively.  These factors cause monocytic cell fusion, 
resulting in osteoclast formation and subsequent maturation (Teitelbaum, 2000).   
 
The RANKL / OPG system   
Receptor activator of nuclear factor κB ligand (RANKL) and its decoy receptor 
osteoprotegrin  (OPG)  are  cytokines  of  the  tumour  necrosis  factor  (TNFα) 
superfamily and play a key role in the regulation of bone turnover.  RANKL is 
expressed on the surface of preosteoblastic cells and its receptor, RANK, on the 
surface  of  preosteoclastic  cells;  upon  their  interaction,  the  differentiation  and 
activation of preosteoclasts are induced.  RANKL also has a positive role when it 
binds  to  RANK  expressed  on  mature  osteoclasts,  promoting  cellular  survival 
(Glantschnig et al., 2003).  OPG is a soluble protein also secreted by osteoblasts 
and is the natural decoy receptor for RANKL, preventing its interaction with the 
RANK receptor and potently inhibiting bone resorption in vivo (Hofbauer et al., 
2000; Khosla, 2001).  Further evidence for the pro-osteoclastogenic nature of 
RANKL has been shown in mice with disrupted copies of the RANKL gene; these 
mice  completely  lack  osteoclasts  as  a  result  of  an  inability  of  osteoblasts  to 
support  osteoclastogenesis.    Consequently  they  experience  severe Chapter 1 Introduction 
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osteopetrosis and a defect in tooth eruption (Kong et al., 1999).  The ratio of 
RANKL : OPG is therefore directly responsible for controlling the maturation and 
activation  of  osteoclasts  and  thus  bone  resorption.    The  majority  of  factors 
affecting the resorption rate mediate their effects by causing an alteration in one 
or both of these cytokines. 
 
Figure 1.4.  The bone remodelling cycle. 
The arrival of pre-osteoclasts at the bone surface from the marrow initiates the bone remodelling 
cycle,  their  maturation  and  activation  leads  to  resorption  of  the  mineralised  matrix.    In  the 
reversal phase, osteoblast precursors proliferate and differentiate into fully functional osteoblasts 
and deposit new bone matrix which is subsequently mineralised.  Maturation of the osteoblasts 
into osteocytes ends the cycle and restores bone to its resting state.  Adapted from (Hill, 1998). 
 
Factors affecting bone remodelling 
The balance between bone resorption and formation is maintained by a multitude 
of  factors  which  have  positive  and  negative  effects  on  the  differentiation, 
formation and growth of bone cells.  Some of the factors that are relevant to this 
thesis are discussed below.   Chapter 1 Introduction 
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Oestrogen and testosterone 
The sex steroids have huge effects on bone in both men and women.  The most 
significant sex hormone for bone is oestrogen whose anti-resorptive effects have 
been  long  known  (Riggs  et  al.,  1969).    Oestrogen  has a  protective  effect  on 
bone,  increasing  OPG  release  from  osteoblasts  and  inhibiting  osteoclast 
formation  (Riggs  et  al.,  2002),  thus  maintaining  the  strong  bone  matrix.  
Oestrogen inhibits osteoclast resorption even when only present at low levels but 
severely  depleted  levels  that  occur  in  post-menopausal  women  can  result  in 
increased bone resorption and osteoporosis commonly develops (Heshmati et 
al., 2002).   
Diminishing testosterone levels in aging men have been associated with 
bone  loss  by  similar  mechanisms;  when  these  men  were  treated  with 
testosterone, reductions in bone remodelling and increases in trabecular bone 
density  were  seen  (Katznelson  et  al.,  1996).    However,  as  the  age  related 
changes  in  sex  hormones  in  men  are  much  less  than  those  seen  in  post-
menopausal women, associated bone loss is much less. 
 
Parathyroid hormone (PTH)  
It has long been known that PTH is the major peptide regulator of calcium and 
phosphate  homeostasis  (Albright  et  al.,  1928).    PTH  is  synthesised  by  the 
parathyroid gland as a 115 amino acid precursor polypeptide, which is cleaved 
and secreted as an 84 amino acid polypeptide.  Small decreases in blood serum 
calcium levels are sensed by the calcium sensing receptors (CASR) on the chief 
cells  of  the  parathyroid  glands  and  PTH  1-84  is  released  into  the  circulation 
(Collip, 1924).   Chapter 1 Introduction 
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PTH is known to elicit its effects on bone in a number of different ways.  
PTH binds to its receptor (PTHR1) on osteoblastic and stromal cells, inducing 
RANKL and inhibiting OPG secretion.  This promotes the fusion of osteoclastic 
precursors  resulting  in  activated  cells  which  resorb  bone  and  consequently 
calcium is released, increasing the amount in the circulation (Lee et al., 1999).   
It was initially thought that PTH had no direct effect on bone resorption by 
acting on osteoclasts alone and significant changes in resorption were only seen 
when  osteoclasts  were  cultured  in  the  presence  of  osteoblast-like  cells 
(McSheehy  et  al.,  1986).    As  such,  it  was  a  long  held  belief  that  osteoblast 
mediated effects on osteoclast activity were responsible for the catabolic effects 
observed  in  vivo  (Ma  et  al.,  2001;  Lee  et  al.,  1999).    However,  more  recent 
reports have shown that direct stimulation of osteoclast activity  by PTH does 
occur; PTHR1 is expressed by activated, resorbing osteoclasts (Hoylans et al., 
1999) and upon PTH stimulation osteoclastic resorption has been seen to be 
increased by 2-3-fold in cultures where no osteoblasts were present (Dempster 
et al., 2005).   
PTHR1 receptors are also present in the kidney, where PTH has multiple 
effects.  Here, PTH enhances the active reabsorption of calcium and increases 
the secretion of phosphate (lowering the amount of calcium bound to phosphate 
in the circulation and increasing free calcium) (Agus et al., 1973).  The effect of 
PTH on the kidney is also essential for the hydroxylation of vitamin D, converting 
it from its inactive to its active form which then acts on the small intestine to 
increase calcium uptake from dietary sources (Dowdle et al., 1960) (Figure 1.5).   
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Figure 1.5 .  Whole body calcium regulation by PTH. 
Decreases  in  serum  blood  calcium  triggers  the  release  of  PTH  into  the  bloodstream  by  the 
parathyroid  glands.    PTH  modulates  calcium  activity  by  causing  increased  bone  resorption, 
increased reabsorption by the kidneys and the activation of vitamin D which can then act on the 
small intestine to increase calcium absorption.  As a result, blood calcium levels are raised.  The 
system self-regulates via negative feedback mechanisms.   
Images  taken  from  http://www.dorlingkindersley-uk.co.uk/,  http://www.fotosearch.com  and   
http://anatomy.med.umich.edu/. 
 
 
The  concentration  of  blood  serum  calcium  is  regulated  via  negative 
feedback  mechanisms  which  inhibit  the  secretion  of  PTH  by  the  parathyroid 
glands  when  blood  calcium  levels  are  raised,  thus  maintaining  blood  serum 
calcium within narrow limits.  The thyroid gland works synergistically  with the 
parathyroid gland to maintain tight regulation of blood calcium levels.  CASRs Chapter 1 Introduction 
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are  also  present  on  the  parafollicular  cells  of  the  thyroid  gland;  when  blood 
serum calcium is high, increased secretion of calcitonin is triggered (Foster et al., 
1964).  This has the opposite effects to those described above and results in a 
decrease in blood serum calcium. 
 
1,25-dihydroxyvitamin D3 and calcium 
1,25-dihydroxyvitamin D3, (1,25-(OH)2D3) the biologically active form of vitamin 
D, also plays a key role in mineral homeostasis.  Vitamin D can be obtained from 
a small range of foods in the diet with high levels of the vitamin found in liver and 
oily fish.  As these foods are not eaten in significant amounts, foods such as 
milk, breakfast cereal and margarine are often fortified  (Calvo et al., 2004) to 
increase dietary vitamin D intake.  However, the majority of vitamin D in the body 
is  produced  in  the  skin,  where  ultraviolet  light  from  the  sun  converts  the 
provitamin into the natural form of vitamin D (Loomis, 1967).  This form of vitamin 
D is transported to the liver where it is hydroxylated to its inactive precursor.  
Upon stimulation by PTH, 25-vitamin D3 is transported to the kidney where it is 
further hydroxylated to its hormonally active form, 1,25-(OH)2D3 (Jones et al., 
1975).   
Like PTH, vitamin D is essential to the regulation of calcium homeostasis 
in  the  body.    1,25-(OH)2D3  facilitates  intestinal  absorption  of  calcium  and 
regulates the transcription of osteocalcin (Skjodt et al., 1985) which is required 
for mineralisation by osteoblasts.  The importance of vitamin D is exemplified by 
the skeletal defects arising from a deficiency which include rickets in children and 
osteomalacia in adults. 
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‘Environmental’ factors and bone turnover 
The local environment surrounding tissue plays a key role in its function.  The 
vasculature  is responsible  for the  supply  of  nutrients  required for growth  and 
survival  as  well  as  the  removal  of  waste  products  produced  by  actively 
metabolising cells and as such is fundamental to cellular homeostasis. 
 
pH 
There are numerous potential causes for changes in the pH tissues are exposed 
to.  Acidic conditions may arise locally as a result of tissue hypoxia caused by 
infection, fractures, inflammation or tumours (Arnett, 2010); or systemically due 
to kidney failure, respiratory disease, diet (rich in protein or carbonated drinks), 
ageing and the menopause, to name a few. 
The skeleton acts as a reserve base for the body which is called upon to 
buffer systemic changes in pH if the kidneys and lungs are unable to excrete 
sufficient H
+ and CO2 (Arnett, 2008).  Alterations in the concentration of hydrogen 
ions in the local bone environment can have profound effects, with slightly acidic 
conditions inhibiting the mineralisation phase of bone formation (Brandao-Burch 
et  al.,  2005)  and  switching  on  osteoclastic  resorption  resulting  in  bone  loss 
(Arnett et al., 1986). 
 
Temperature 
Decreases in core body temperature have also been seen to have an effect on 
bone formation.  This commonly occurs in the elderly population, where core 
body temperatures of 35.5
oC are common as a result of the reduced ability of the 
body to produce heat and reductions in peripheral vasoconstriction (Collins et al., 
1977).    In  vitro  experiments  have  shown  that  mild  hypothermia  inhibits Chapter 1 Introduction 
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osteoblastic  bone  formation  and  promotes  osteoclastogenesis  (Patel  et  al., 
2009). 
 
Oxygen tension  
Bone is capable of sustaining a relatively high metabolic rate (e.g.  compared 
with  cartilage)  owing  to  its  rich  vasculature  supply.    The  blood  provides  a 
constant  source  of  nutrients  and  oxygen  which  allows  bone  to  remodel  and 
repair.  Physiologically, the pO2 in the majority of tissues is in the region of 5-
12% with arterial blood having a pO2 at the upper end of this range at ~ 12% and 
venous blood at the lower end, at ~ 5%.  The bone marrow cavity is sinusoidal 
and  thus  contains  a mixture  of  venous  and  arterial blood.   The  pO2  of  bone 
marrow aspirated from normal, healthy volunteers has been measured at ~ 6.8% 
(Harrison et al., 2002).   
Reduced  blood  supply  to  bone  can  occur  in  a  number  of  common 
situations including: ageing (Katschinski, 2006), trauma or fracture, inflammation 
or inflammatory disease such as rheumatoid arthritis (Firestein, 1999), smoking 
(Jensen  et  al.,  1991),  tumours  (either  a  primary  bone  tumour  or  secondary 
metastasis), diabetic ischemia, or due to prolonged corticosteroid/glucocorticoid 
use.   When  the  blood  supply  is  reduced  or  disrupted,  oxygen  levels  fall  and 
hypoxia can occur.   
 
Oxygen sensing 
It is critical that cells can sense and respond to alterations in the local oxygen 
concentration as it is essential for a wide range of developmental, physiological 
and pathological processes.  The effects of hypoxia are mediated by the hypoxia 
inducible  factor  1α  (HIF-1α),  a  transcriptional  activator  of  oxygen  responsive Chapter 1 Introduction 
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genes  (Figure  1.6).    In  normoxic  conditions  both  HIF1α  and  the  von  Hippel 
Lindau protein (pVHL) are hydroxylated by prolyl hydroxylases (PHD) allowing 
them to interact.  pVHL forms part of an E3 ubiquitin ligase: once the interaction 
between HIF1α and pVHL has taken place the complex is rapidly ubiquitinated 
and targeted for degradation by the cellular proteosome. 
The prolyl hydroxylase enzymes belong to a family of oxygen, iron and 2-
oxoglutarate-dependent dioxygenases and as such, their activity is significantly 
decreased in hypoxia (D'Angelo et al., 2003).  It has been suggested that the 
absolute requirement for oxygen by the HIF PDH enzymes directly implicates 
them in cellular oxygen sensing (Jaakkola et al., 2001).  The interaction between 
pVHL and the HIF-1α subunit is regulated through hydroxylation of a specific 
proline residue (HIF-1α P564); in the absence of oxygen, the HIF-1α subunit is 
stabilised  and  accumulates  in  the  cytoplasm.    HIF-1α  then  diffuses  into  the 
nucleus,  where  it  forms  a  complex  with  the  HIF-1β  subunit  and  recruits 
transcriptional  co-activators  such  as  p300/CBP  for  full  transcriptional  activity.  
This  complex  binds  to  the  hypoxia  response  element  (HRE)  in  the  promoter 
region of a wide range of target genes required for the cellular adaptation to 
oxidative stress and induces their transcription (Figure 1.6.).  These target genes 
include  genes  involved  in  angiogenesis  (in  particular  VEGF),  erythropoiesis, 
glucose metabolism, apoptosis, cell proliferation and survival, pH regulation and 
proteolysis  (Carroll  et  al.,  2005).    VEGF  is  involved  in  mediating  the  cellular 
response to hypoxia, with chronic hypoxia seen to induce angiogenesis in rat 
skeletal muscle in response to increased stabilisation of HIF1α (Deveci et al., 
2002).  Increased VEGF production in response to HIF1α is also believed to be a 
key factor in the coupling of osteogenesis to angiogenesis (Riddle et al., 2009; 
Wang et al., 2007). 
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Figure 1.6.  HIF-1α regulation by proline hydroxylation.   
In  normoxia  HIF-1α  is  hydroxylated,  polyubiquitinated,  recognised  by  the  proteosome  and 
subsequently degraded.  In response to hypoxia, proline hydroxylation is inhibited and thus HIF-
1α is stabilised and accumulates.  It translocates to the nucleus where it forms a complex and 
initiates transcription of oxygen responsive genes.  Abbreviations: pVHL = von Hippel Lindau 
protein, PHD = prolyl hydroxylase, Ub = ubiqutin, CBP = CREB-binding protein.  Figure adapted 
from (Ke et al., 2006). 
 
It is noteworthy to mention that although they belong to the same family, 
the  prolyl  hydroxylases  (PHDs)  involved  in  the  modification  of  HIF1α  are 
cytoplasmic  proteins  and  differ  from  the  collagen  modifying  PHDs.    HIF 
hydroxylation is carried out by PHDs 1-3, PHD2 is thought to be the key oxygen 
sensing  enzyme  (Berra  et  al.,  2003).    However,  collagen  modifications  are 
catalysed by a homologous family of PHDs which are found in the endoplasmic 
reticulum.  The difference in the nature of the protein surrounding the proline Chapter 1 Introduction 
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residues to be hydroxylated means that PHDs 1-3 recognise and bind to different 
substrates  to  collagen  modifying  PHDs  and  as  such  it  has  been  shown  that 
recombinant collagen PHD isoforms have no activity on HIF substrates (Bruick et 
al., 2001). 
 
The effect of hypoxia on bone  
It  is  well  documented  that  hypoxia  has  a  stimulatory  effect  on  bone  marrow 
derived cells of the monocyte-macrophage lineage (Roiniotis et al., 2009), which 
are very closely related to osteoclasts.  These cells appear to be well adapted to 
working in hostile conditions, a likely reflection of their physiological function and 
anatomical locations.  In vitro investigations have shown that hypoxia causes 
profound stimulation of osteoclast formation, resulting in resorption of significant 
amounts of bone before undergoing what would normally be considered to be a 
premature death (Arnett et al., 2003). 
This is in stark contrast to the effect of hypoxia on osteoblasts, whose 
proliferation and differentiation, including  collagen forming ability are severely 
inhibited in low oxygen conditions (Utting et al., 2006).  This is believed to be a 
result of the effect that hypoxia has on Runx2 whose expression is significantly 
decreased and consequently transcription of osteoblastogenic genes including: 
osteocalcin, osteopontin, bone sialoprotein, osteoprotegrin and collagenase, are 
reduced  (Park  et  al.,  2002).    Upon  reoxygenation,  bone  forming  ability  is 
restored, suggesting that the cells adopt a dormant state until more favourable 
conditions return (Utting et al., 2006). 
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Pathologies 
Soft tissue wounds 
Fibroblasts  are  essential  to  the  wound  healing  process  of  soft  tissues;  the 
mechanisms for their localisation to the site of damage are poorly understood but 
it has been proposed that chemokines and cytokines are upregulated at the site 
of injury and released into the circulation.  This causes MSCs to downregulate 
adhesion  molecules  that  keep  them  attached  at  their  niche  site  in  the  bone 
marrow (Liu et al., 2009).  Circulating MSCs are then ‘homed’ from the blood to 
the  target  tissue  and  undergo  in  situ  proliferation  and  maturation  into  fully 
functional cells that integrate into the injured tissue, contributing to the healing 
process.   
Damage to soft tissue often cannot be repaired perfectly by the body and 
as a result scars are formed.  The rapid deposition of new collagen fibres by 
connective tissue fibroblasts results in tissue that is thicker and denser than its 
surroundings.  Scar tissue has limited functionality compared to healthy tissue; it 
is poorly vascularised and consequently appears pale and its extreme density 
means that movement and sensation are restricted. 
 
Fractures 
The coupled relationship between osteogenesis and angiogenesis is highlighted 
at a fracture site, where a decrease in vascular supply is followed by an increase 
in  osteoclast  number  in  order  for  the  dead  and  necrotic  bone  tissue  to  be 
resorbed.  In these conditions bone can become severely hypoxic; early work 
performed on rabbit models of fracture healing showed oxygen levels as low as 
0.8% O2 in bone four days post fracture, rising to only 3.8% O2 in newly formed 
bone fourteen days post fracture (Brighton et al., 1972).  Platelets are some of Chapter 1 Introduction 
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the first cells to localise to a site of skeletal injury and play a key role in initiating 
the process.  Platelets secrete platelet-derived growth factor (PDGF) which is 
believed  to  act  additively  with  hypoxia  to  increase  VEGF  mRNA  expression 
(Bouletreau et al., 2002).  VEGF stimulates angiogenesis and thus restores the 
blood flow to the damaged bone.  PDGF also has potent mitogenic effect on cells 
of  MSC  origin  (Zhang  et  al.,  1991),  resulting  in  increases  in  osteoblast 
proliferation,  collagen  synthesis  and  bone  formation.    Newly  formed  bone  is 
subjected  to  extensive  remodelling,  when  osteoclast  activity  is  seen  to  peak 
again  (Schell  et  al.,  2006).    Should  the  blood  supply  to  the  fracture  not  be 
adequately restored non-union fractures can result. 
 
Metabolic diseases of bone 
When the balance between osteoblastic bone formation and osteoclastic bone 
resorption is upset due to impaired bone formation or enhanced resorption, bone 
loss results.   Two diseases in which bone cell activity is affected leading to 
potentially  detrimental  skeletal  effects  that  are  relevant  to  this  thesis  are 
described below. 
 
Osteoporosis  
Osteoporosis is the most common age-related disorder of bone.  It is estimated 
to affect 75 million people in Europe, the USA and Japan, with a lifetime risk of 
fracture estimated to be ~50% for women and ~20% for men over 50 suffering 
from the disease (van Staa et al., 2001).  Osteoporosis is characterised by low 
bone mass which occurs mainly as a result of increased osteoclastic activity.  
The reasons for the onset of osteoporosis are multifactorial: a family history of Chapter 1 Introduction 
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the  disease,  poor  diet  lacking  calcium  and  vitamin  D,  smoking,  age-related 
reductions  in  the  sex  hormones  (Aloia  et  al.,  1985),  lack  of  weight-bearing 
exercise (Giangregorio et al., 2002), glucocorticoid use and excessive alcohol 
consumption (Bilezikian, 1999) are all contributory factors.  As has already been 
discussed,  decreases  in  oestrogen  production  by  the  ovaries  of  post-
menopausal  women  and  age  related  losses  in  testicular  function  and  thus 
decreases in testosterone in men, both contribute significantly to loss of bone 
density.  Consequently, the protective roles the sex hormones have on bone are 
significantly  reduced  and  increases  in  bone  resorption  are  observed.    This 
results in the trabeculae within bone becoming very thin and deterioration of the 
microarchitectural structure, leaving the bone very susceptible to fracture. 
  Glucocorticoid use is a well known inducer of osteoporosis.  Although low 
levels are required for normal cell function and are essential for bone formation 
in vitro, raised levels often lead to osteopaenia and if treatment is prolonged, 
osteoporosis.    This  is  believed  to  be  a  result  of  glucocorticoid  treatment 
attenuating  osteoblast  differentiation,  promoting  apoptosis  of  osteoblasts  and 
osteocytes (Weinstein et al., 1998) and increasing the life span of osteoclasts 
(Jia et al., 2006). 
 
Hyperparathyroidism  
Over-secretion of PTH by the parathyroid glands is caused by overactivation or 
enlargement of one or more of the glands.  Primary hyperparathyroidism is a 
relatively common endocrine disease with an incidence of between 1 in 500 and 
1  in  1000,  the  majority  of  individuals  affected  are  older,  post-menopausal, 
women (Silverberg et al., 2008).   
In  primary  hyperparathyroidism,  increased  PTH  secretion  is  usually  a 
result  of  enlargement  of  one  of  the  glands  due  to  adenoma  formation.  Chapter 1 Introduction 
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Secondary hyperparathyroidism usually occurs as a result of renal failure, where 
decreased serum calcium causes increased PTH secretion by the parathyroid 
glands.  As a result, blood calcium levels are raised and hypercalcaemia results.  
Hyperparathyroidism is easily detectable by measuring blood serum calcium but 
if  undiagnosed  and  untreated  then  osteoporosis,  recurrent  kidney  stones  and 
osteitis and osteoclastic cysts (which can cause significant bone pain) can arise 
(Keating, 1961). 
 
 
Current therapies 
The majority of current therapies for the treatment of metabolic bone disease 
work by inhibiting osteoclast activity.  The front line therapies for the treatment of 
osteoporosis  are  the  nitrogen-containing  bisphosphonates:  Aledronate, 
Risedronate and Zoledronate.  These drugs reduce bone turnover by binding to 
the  mineralised  bone  surface  and  inhibiting  activity  of  mature  osteoclasts, 
resulting in increased BMD and reduced fracture risk (Russel, 2006).   
Other therapies that are becoming increasingly popular target key factors 
that modulate bone cell activity.  Denosumab, a monoclonal human antibody that 
specifically targets RANK ligand, has recently been approved by the U.S.  food 
and  drug  administration  (FDA)  for  treatment  of  postmenopausal  women  with 
osteoporosis  who  are  at  increased  risk  of  fracture  (Rizzoli  et  al.,  2010).  
Denosumab  effectively  mimics  the  function  of  OPG,  binding  to  RANKL  and 
results  in  decreased  osteoclast  formation  (Kostenuik,  2005).    Clinical  studies 
have shown significantly greater increases in hip BMD in patients treated for 12 
months with Denosumab compared to those treated with Aledronate (Brown et 
al., 2009).   Chapter 1 Introduction 
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Targeting naturally occurring inhibitors of bone formation also results in 
increased  bone mass.    The  inhibition  of  the  production  of  sclerostin  leads  to 
enhanced canonical Wnt signalling and thus increase bone formation (Baron et 
al.,  2007).    A  sclerostin  monoclonal  antibody  (Scl-Ab)  has  recently  been 
generated  and  has  been  shown  to  increase  bone  mass  and  strength  by 
stimulating new bone formation in an ovariectomy-induced bone loss rat model 
(Li et al., 2009). 
As bone formation and resorption are interconnected processes, inhibition 
of  resorption  is  accompanied  by  decreases  in  bone  formation.    Bone  loss 
diseases result when the balance between these two processes is upset.  Anti-
resorptive therapies prevent further bone loss and thus aid in fracture prevention 
but  do  not  rebuild  bone  that  was  lost  before  the  onset  of  treatment.  
Consequently,  the  most  effective  treatments  for  bone  disease  must  inhibit 
excess resorption and increase bone formation. 
 
Anabolic effects of PTH on bone  
PTH has been developed as a drug for the anabolic treatment of metabolic bone 
disease.    The  naturally  occurring  hormone  has  been  generated  as  a 
recombinant, containing the 34 amino acids present at the N-terminal end of the 
naturally occurring protein, PTH 1-34.  All the structural elements required for 
binding to PTHR1 are present in this fragment and thus the drug binds with high 
affinity. 
The effects of using PTH as an anabolic drug were recognised over three 
decades  ago  (Reeve  et  al.,  1980).    However,  the  understanding  that  this 
anabolic action, i.e.  promoting bone growth and turnover, is dependent on the 
duration and pattern of exposure had not been well documented until relatively Chapter 1 Introduction 
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recently  (Frolick  et  al.,  2003;  Ishizuya  et  al.,  1997;  Poole  et  al.,  2005).  
Continuous exposure to PTH in vivo results in catabolic effects on bone, with 
increases  in  bone  resorption  and  concomitant  raised  serum  calcium.  
Conversely, when administered intermittently profound anabolic effects are seen; 
recombinant human PTH (hPTH) (Teriparatide, Forteo™) is widely used as a 
drug for the treatment of osteoporosis, preventing fractures by increasing BMD 
(Neer et al., 2001; Dempster et al., 2001; Alexander et al., 2001; Brommage et 
al., 1999).  Initial increases in bone formation by intermittent PTH treatment are 
followed by increases in remodelling, thus, this treatment is most effective when 
used in combination with an anti-resorptive therapy.  In addition to its use as a 
preventative measure for fractures, intermittent PTH treatment has recently been 
shown to improve bone volume and mechanical properties of healing fractures 
and in bones subjected to distraction osteogenesis (Aleksyniene et al., 2009).   
Despite the use of intermittent PTH as an anabolic treatment for low bone 
mass, the mechanism by which this occurs remains elusive.  Furthermore, an 
explanation  for  the  differential  effects  of  intermittent  and  continuous  PTH 
exposure has yet to be proposed.   
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Thesis aims 
The aim of this thesis was to explore some of the fundamental regulators of cells 
of  MSC origin  and  to  critically  examine factors which  have  an  effect on their 
ability to produce and excrete extracellular matrix.  The emphasis has been on 
the effects of these regulators on collagen and bone formation with a particular 
focus  on  the  role  of  oxygen  and,  by  implication,  the  vasculature  in  these 
processes.   
The  work  started  with  investigations  into  the  effects  of  hypoxia  on 
osteoblasts  and  dermal  fibroblasts,  examining  their  differentiation,  growth, 
collagen  forming  ability  and  adhesive  properties  in  normoxia  and  hypoxia 
(Chapter 3).  This study and the majority of in vitro research in this field have 
been carried out on primary cells using osteoblasts derived from the calvaria of 
neonatal rats.  Given the differences between the bone formation processes and 
blood supply to bones in these discrete anatomical locations, the relevance of 
using calvarial-derived cells as a representative model of in vivo bone formation 
was questioned.  To address this, a new method for isolating osteoblasts using 
cells derived from the long bones of neonatal rats was developed and these cells 
were characterised alongside analogous calvarial cells (Chapter 4).  Using these 
long-bone-derived  cells,  the  direct  effect  of  PTH  on  osteoblasts  in  vitro  was 
investigated.  The relationship between PTH treatment and sclerostin was also 
examined and the direct effect of endogenous sclerostin on the activity and bone 
forming ability of osteoblasts was observed (Chapter 5).  Using the findings from 
these studies, a general theory that could help to explain the actions of some of 
the major bone regulatory factors is proposed (Chapter 6).    
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Chapter 2 
Materials and methods 
 
Reagents 
Tissue culture media, sera and buffers were purchased from Invitrogen (Paisley, 
UK).  The main buffer used was 1X Dulbecco’s phosphate buffered saline (PBS) 
which  contained:  200mg/L  potassium  chloride  (KCl),  200mg/L  potassium 
phosphate  monobasic  (KH2PO4),  8000mg/L  sodium  chloride  (NaCl)  and 
2160mg/L sodium phosphate dibasic (Na2HPO4-7H2O).  1X Hanks’ balanced salt 
solution  (HBSS)  which  contained:  400mg/L  KCl,  60mg/L  KH2PO4,  350mg/L 
sodium  bicarbonate  (NaHCO3),  8000mg/L  NaCl,  48mg/L  sodium  phosphate 
dibasic (Na2HPO4) anhydrous, 1000mg/L D-glucose and 10mg/L phenol red was 
used for making up enzyme solutions. 
Bulk  liquids  (organic  solvents,  acids  and  bases)  were  purchased  from 
VWR International Ltd (Leighton Buzzard, UK).  Molecular biology reagents were 
purchased from Promega, UK (Hampshire, UK), and all primers were from MWG 
Biotech  (Ebersberg,  Germany).    All  other  chemicals  were  purchased  from 
Sigma-Aldrich (Dorset, UK) unless otherwise stated.  The Melinex used was a 
kind donation from Dupont Teijin Films (HiFi Industrial Film Ltd, Stevenage, UK).  
A  sample  of  the  sclerostin  protein  was  generously  supplied  by  Dr.    Christine 
Halleux (Novartis AG, Basel, Switzerland). 
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Cell culture 
Osteoblast calvarial bone formation assay 
Osteoblasts were obtained by sequential enzyme digestion of calvarial bones 
excised  from  2-day-old  Sprague-Dawley  rats.  The  enzyme  digest  involved  a 
three step process; 1% trypsin in PBS for 10 minutes to digest the outer protein 
layer; 0.2% collagenase type II in Hanks balanced salt solution (HBSS) for 30 
minutes  to  weaken  the  collagen  structure  and  removed  the  unwanted 
collagenous matrix; 0.2% collagenase type II in HBBS for 60 minutes to release 
osteoblasts  from  the  bone.    The  first  two  digests  were  discarded  and  cells 
liberated  by  the  third  digest  were  washed  and  plated  into  a  75cm
2  flask  in 
Dulbecco’s modified essential medium (Gibco, Paisley, UK) supplemented with 
10%  foetal  calf  serum,  2  mM  l-glutamine,  100  U/ml  penicillin,  100  μg/ml 
streptomycin  and  0.25  μg/ml  amphotericin  (complete  mixture  abbreviated  to 
‘DMEM’).  Cells were cultured for 3 days in a humidified atmosphere of 5% CO2 - 
95% air at 37°C, until confluent.  Upon confluency, cells were sub-cultured into 6, 
12 or 24-well trays in DMEM supplemented with 10nM dexamethasone, 50 μg/ml 
ascorbate  and  2  mM  β-glycerophosphate  (complete  mixture  abbreviated  to 
‘supplemented  DMEM’).    Dexamethasone  is  required  for  osteoblastic 
differentiation from mesenchymal stem cell precursors; ascorbate as an enzyme 
cofactor for collagen synthesis and β-glycerophosphate as a phosphate source, 
enabling osteoblasts to deposit hydroxyapatite mineral.  Cells were cultured for 
up to 28 days with half media changes performed every 3-4 days.  Mineralised 
bony  structures  typically  developed  from  day  10,  giving  rise  to  a  dense, 
organised, trabecular-shaped network by days 21-28.  Further details of in vitro 
bone formation assays are given in Chapter 4. 
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Fibroblast collagen formation assay 
Fibroblasts  were  isolated  from  the  dermis  of  2-day-old  Sprague-Dawley  rats.  
Skin flaps (~1cm
2) were removed from the flanks of neonatal Sprague-Dawley 
rats  killed  by  cervical  dislocation  and  washed  in  PBS.   The  keratinised outer 
layer of the skin was removed and discarded and the dermis was subjected to a 
single collagenase digest (0.2% collagenase type II in HBSS for 60 minutes at 
37°C).  The cells were washed and plated into a 75cm
2 flask in DMEM.  Cells 
were cultured for 3 days in a humidified atmosphere of 5% CO2 - 95% air at 
37°C, until confluent.  Upon confluency, cells were sub-cultured into 6 or 24-well 
trays in DMEM containing 5% FCS and supplemented with 50 μg/ml ascorbate. 
 
Generation of a hypoxic environment 
Isolated cells were allowed to settle in tissue culture plates for 24 hours before 
being  exposed  to  hypoxic  conditions.    Tissue  culture  plates  were  placed  in 
humidified  air-tight  polycarbonate  enclosures  (Fibox  Ltd,  Cleveland,  UK)  and 
exposed to 2%, 5%, 12% or 20% O2 / 5% CO2 / N2 balance (BOC, London, UK) 
through openings drilled in the lid for 2 minutes.  Holes were sealed with PVC 
electrical tape (Temflex™ 1500, 3M, Bracknell, UK) and boxes placed in a 37°C 
incubator  (Figure  2.1.).    Daily  gassing  of  the  cells  in  these  air-tight  boxes 
ensured  culture  medium  was  maintained  at,  or  around  the  desired  oxygen 
concentration (Figure 2.2.).   
As hypoxia can cause acidification of cell cultures, an excess of medium 
was used to provide additional buffering capacity and half media changes were 
performed every 3-4 days.  Culture medium pH was regularly monitored using a 
blood-gas analyser (see later) but was not found to differ significantly between 
cultures exposed to different oxygen tensions.   Chapter 2 Materials and methods 
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Figure 2.1.  Experimental set up for generating a hypoxic environment. 
a.  24-well trays were placed in humidified, air-tight polycarbonate enclosures and gassed for 2 
minutes through openings drilled in the lid with 2%, 5%, 12% or 20% O2 / 5% CO2 / N2 balance 
custom gas mixtures. 
b.    Gassing  inlet  and  outlets  were  then  sealed  with  vinyl  tape  and  boxes  placed  in  a  37°C 
incubator. 
 
 
 
 
 
 
 
 
 
Figure  2.2.    Oxygen  concentration  of  the  medium  measured  24  hours  post-gassing 
indicates maintenance of a hypoxic environment over the course of the experiment. 
Flasks containing DMEM were gassed at 20%, 12%, 5%, 2% or 0.2% O2 / 5% CO2 / balance N2 
and  culture  medium  oxygen  concentrations  were  measured  24  hours  later  using  the  FOXY 
probe.    Readings  were  taken  every  minute  after  insertion  of  the  probe.    After  six  minutes 
readings remained unchanged, suggesting equilibrium between the probe and culture medium 
had been reached.  Adapted from (Utting, 2006). 
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Staining  
Alizarin red staining 
Osteoblast cultures were terminated after 14 – 21 days in culture by fixing cell 
monolayers in 2.5% glutaraldehyde for 5 minutes.  Mineralised structures were 
visualised  by  staining  with  1%  w/v  alizarin  red  S  in  PBS  for  5  minutes.  
Monolayers were washed three times in 50% ethanol to remove excess stain 
and air-dried before quantification of bone area.  The plates were imaged at 800 
dpi  using  a  high-resolution  flat-bed  scanner  (Epson  Perfection  Photo  3200, 
Epson) in reflected light mode.  Images of individual wells  were converted to 
greyscale then digitised, before being subjected to automated analysis (Scion 
Image  software,  Scion  Corporation;  http://www.scioncorp.com), using  constant 
‘threshold’  and  ‘minimum  particle’  levels  to  determine  the  number  and  plan 
surface area of mineralised bony structures (Figure 2.3.). 
Figure 2.3.  Stages of the image analysis process. 
Alizarin red stained cell well monolayers were imaged using a high-resolution flat-bed scanner.  
Images  were  converted  to  greyscale  and  standard  threshold  values  applied  to  create  digital 
images from which extracted data can be analysed. 
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Masson’s trichrome stain for deposited collagen 
After 14 days of culture in 6-well trays, cell layers were washed in PBS and fixed 
in Bouin’s solution overnight at room temperature.  Monolayers were washed in 
running  water  and  then  stained  in  Weigert’s  hematoxylin  A  solution  for  10 
minutes.  Cells were thoroughly washed in tap water and stained in 0.5% acid 
fushin / 5% glacial acetic acid (0.5 grams acid fushin, 5ml glacial acetic acid and 
100ml  dH2O)  for  5  minutes,  rinsed  in  distilled  water  and  treated  with 
phosphomolybidic acid solution for 5 minutes.  This solution was then removed 
and cells stained for 5 minutes with 2% methyl blue / 2.5% glacial acetic acid (2 
grams methyl blue, 2.5ml glacial acetic acid and 100ml dH2O).  After rinsing with 
distilled  water  cells  were  treated  with  1%  acetic  acid  for  2  minutes  before 
dehydration  in  a  graded  ethanol-water  series  and  air  drying.    Plates  were 
visualised under an Olympus IMT-2 inverted microscope and images taken using 
a Zeiss AxioCam MRc5 digital camera. 
 
Assays 
Alkaline phosphatase assay 
Osteoblasts  were  cultured  for  7  or  14  days  in  24  well  trays  as  previously 
described.    Culture  medium  was  removed  and  monolayers  washed  in  PBS.  
Cells were scraped into 500µl of distilled water (dH2O) and lysates transferred to 
1.5ml Eppendorfs which were sonicated on ice for 10 minutes.  Cell debris was 
pelleted by centrifugation at 2500g, 4°C for 10 minutes.  100µl of supernatant 
was removed from each sample and added to a 96 well tray along with 100µl of 
alkaline phosphatase reagent (Biotron Diagnostics, Inc., CA, USA).  Absorbance 
at 405nm was measured immediately and after 1, 3 and 5 minutes incubation at Chapter 2 Materials and methods 
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37°C  in  the  dark.    Enzyme  activity  was  determined  by  the  rate  of  product 
formation relative to total protein (see Bradford assay, below). 
 
Soluble collagen assay 
Cells were grown for 7 or 14 days in 24 well trays with test substances present.  
24 hours prior to performing the assay, media was removed from the wells and 
replaced  with  500µl  of  supplemented  DMEM  (5%  FCS),  200µM  β-
aminoproprionitrile (βAPN) and test substances.  After 24 hours of incubation (at 
37°C 5% CO2 - 95% air), the Sircol soluble collagen assay (Biocolor Ltd, County 
Antrim,  UK)  was  performed  as  per  manufacturer’s  instructions.    This  assay 
measures  the  amount  of  soluble  collagen  released  into  the  culture  medium 
during cell growth and maintenance by exploiting the binding of the sirius red dye 
to the [Gly-X-Y]n motif found in collagen fibrils.  A standard curve was prepared 
using known concentrations of collagen and 100µl of unused culture media from 
which values of collagen in solution were obtained colorimetrically by measuring 
absorbance at 570nm.  Amounts of collagen produced were normalised for total 
protein which was assessed using the Bradford assay (with collagen production 
expressed as a percentage of total protein). 
 
Bradford assay for determination of total protein 
A standard curve was prepared using bovine serum albumin (BSA) (0-8µg) with 
50µl  dH2O  and  200µl  Bradford  reagent.    The  same  quantities  of  dH2O  and 
Bradford reagent were also added to 3µl of test samples.  After 5 minutes at 
room temperature samples were read at 450nm and 570nm and protein levels 
established. 
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Cell number and viability assay 
Cells were cultured in 24-well trays and cell number was measured after 4, 7, 10 
and 14 days of culture using the CytoTox 96® non-radioactive cytotoxicity assay 
(Promega UK, Southampton UK).  This assay quantitatively measures cellular 
lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released on cell 
lysis  and  shows  good  agreement  with  non-viable  cell  number  (Racher  et  al., 
1990).  LDH oxidises lactate into pyruvate, generating NADH, which is then used 
to convert a tetrazolium salt into a red formazan product.  The amount of colour 
formed is proportional to the number of lysed cells.  One hour prior to assaying, 
osteoblasts  were  switched  to  serum  free  DMEM  containing  lysis  buffer  (1% 
Triton X-100 in water); following sample collection the assay was performed as 
per  manufacturer’s  instructions.    A  standard  curve  for  determination  of  cell 
numbers was constructed using cells seeded at 10
3 to 10
6 per well.  Manual cell 
counts were performed in parallel for assay validation. 
To investigate cell viability the same assay  was performed.  One hour 
prior to assaying, osteoblasts were switched to serum free DMEM and following 
sample collection the assay was performed as per manufacturer’s instructions.  
To determine the viability of the cells the following equation was used: 
 
 
(sample absorbance - blank)
% loss in cell viability =   x 100
 (lysed sample absorbance - blank)
 
 
Cellular ATP release 
Cells were cultured in 12-well trays and ATP release was measured after 7 and 
14  days  using  CellTiter-Glo®  Luminescent Cell Viability  Assay  (Promega  UK, 
Southampton, UK).  Low concentrations of ATP inhibits in vitro bone formation 
(Hoebertz  et  al.,  2002);  measuring  the  amount  of  ATP  released  by  cells  in Chapter 2 Materials and methods 
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response to a specific condition/treatment provides an insight as to whether this 
is  the  mechanism  by  which  bone  formation  is  being  inhibited.    The  reagent 
inhibits  endogenous  ATPases  and  provides  luciferase/luciferin  for  ATP 
measurement.  Luciferase catalyses the reactions: 
   Luciferin + ATP   Luciferyl Adenylate + PPi  
And 
 Luciferyl Adenylate + Oxygen   Oxyluciferin + AMP (with the production of light)
 
The high efficiency of this reaction and the long half-life (generally greater 
than 5 hours) of the luminescent signal allows this assay to be based on the 
assumption that the luminescent signal generated in proportional to the amount 
of ATP present. 
To perform the assay, 50μl of culture media was removed from each well 
in the tissue culture plate and added to 50μl of CellTiter-Glo® Luminescent Cell 
Viability  reagent  and  allowed  to  stand  for  10  minutes  at  room  temperature.  
Samples were then read using the GloMax® 20/20 luminometer (Promega UK 
Ltd).    A  standard  curve  for  determination  of  amount  of  ATP  released  was 
constructed using ATP from 100pM to 1μM diluted in serum free media.  The 
remaining  cell  monolayers  were  assayed  for  cell  number  and  viability  as 
described previously. Chapter 2 Materials and methods 
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Microscopy 
Transmission electron microscopy (performed with the help of Mark Turmaine, 
Dept of Cell & Developmental Biology, UCL) 
Osteoblasts were cultured on Melinex film (Dupont Teijin Films, UK), cut into 1x1 
cm discs in 12-well trays.  After 28 days of culture, cell layers were fixed in 2.5% 
glutaraldehyde for 48 hours.  Monolayers were washed in 0.1M phosphate buffer 
for 10 minutes and then post-fixed in 1% osmium tetroxide / 0.1M cacodylate 
buffer (pH 7.3) for 1 hour at 4°C in the dark.  This was followed by staining with 
0.5%  uranyl acetate  /  dH2O  at  4°C for 30  minutes.    After rinsing  with  dH2O, 
specimens were dehydrated in a graded ethanol-water series and infiltrated with 
Agar 100 resin mix overnight.  Ultra thin sections were cut at 70-80nm using a 
diamond knife on a Reichert Ultracut E microtome.  Sections were collected on 
Formvar® coated slot grids (Agar Scientific, Essex, UK) and stained with uranyl 
acetate  and  lead  citrate.    Imaging  was  performed  using  a  JEOL  JEM-1010 
transmission electron microscope (JEOL (UK) Ltd., Herts, UK) and photographs 
taken using an 11 megapixel SC1000 Orius® TEM CCD camera (Gatan UK, 
Abingdon, UK). 
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Molecular biology 
Total RNA extraction and complementary DNA strand synthesis 
Cells were cultured in 6-well trays for up to 14 days in supplemented DMEM; 
monolayers were washed briefly in PBS and the total RNA was extracted at days 
7  and  14  using  TRIzol®  reagent  (Invitrogen,  Paisley,  UK)  according  to  the 
manufacturer’s  instructions.    Before  first  strand  complementary  DNA  (cDNA) 
synthesis, extracted RNA was treated with RNase-free DNase I (35 U/ml) for 30 
minutes at 37°C.  The reaction was terminated by heat inactivation at 65°C for 10 
minutes.    Total  RNA  was  quantified  spectrophotometrically  by  measuring 
absorbance  at  260nM  (NanoDrop™  ND1000  Spectrophotometer,  Thermo 
Fischer Scientific, Epsom, Surrey, UK).  For each sample, 1μg of DNase-treated 
total RNA was used as a template for first strand synthesis in a 20μl reaction 
also containing 0.5μg oligo dT, 3mM MgCl2, 0.5mM dNTPs, 20U recombinant 
RNasin®  ribonuclease  inhibitor,  ImProm-II®  5x  reaction  buffer  and  200U 
ImProm-II reverse transcriptase.  The reaction mix was annealed for 5 minutes at 
65°C followed by extension at 50°C for 60 minutes and inactivation at 70°C for 
15 minutes.  cDNA was stored at -20°C until amplification by the polymerase 
chain reaction (PCR). 
 
Polymerase chain reaction 
cDNA  derived  from  cultured  cells  was  amplified  by  PCR  in  25μl  reactions 
containing 0.5μg cDNA, 0.2mM dNTP, 1.5mM MgCl2, 0.2μM of both sense and 
antisense primers and 1U Taq DNA polymerase in thermophilic DNA polymerase 
10x  buffer.    PCR  was  performed  in  accordance  with  the  manufacturer’s 
instructions, with cycles of denaturation at 95°C for 30 seconds, annealing for 30 
seconds (see Appendix I, Table 1 for annealing temperatures), extension at 72°C Chapter 2 Materials and methods 
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for 45 seconds and reaction termination at 72°C for 5 minutes.  For analysis, 
PCR  products  were  fractionated  on  a  1%  agarose  gel  labelled  with  0.3μg/ml 
ethidium  bromide  run  at  100mA  for  ~30  minutes  and  visualised  by  UV 
transillumination.  cDNA levels were normalised to β-actin expression. 
 
Quantitative real-time PCR (qRT-PCR) 
Calvarial and long bone osteoblast cDNA (25ng/μl) was amplified by qRT-PCR 
using SYBR® Green Jumpstart™ Taq ReadyMix™ (Sigma, Poole, Dorset, UK).  
qRT-PCR was performed using a Bio-Rad Chromo4 PTC-400 real-time detector 
according to manufacturer’s instructions with initiation of the reaction (94°C for 2 
minutes)  being  followed  by  40  cycles  of  denaturation  (94C for 15  seconds), 
annealing  (55  or  60°C  for  1  minute),  elongation  (72°C  for  1  minute)  and 
detection.    Data  was  analysed  by  relative  quantification  of  the  target  gene 
transcript in comparison with a reference gene transcript using the Pfaffl method 
(Pfaffl, 2001).  The reference gene used for the experiments performed in this 
thesis  was  β-actin.    All  reactions  were  carried  out  in  triplicate  using  cDNAs 
derived  from  3  different  osteoblast  cultures.    Primer  pairs  are  displayed  in 
Appendix I, Table 2. 
 
Enzyme-linked immunosorbent assays (ELISAs)  
Detection of apoptosis 
Apoptosis was assessed using an ELISAPLUS cell death detection kit (Roche 
Diagnostics  Ltd,  East  Sussex,  UK)  according  to  the  manufacturer’s  protocol.  
Apoptosis  is  characterised  by  membrane  blebbing,  cytoplasmic  condensation 
and  the  activation  of  endogenous  Ca
2+  and  Mg
2+  dependent  endonucleases Chapter 2 Materials and methods 
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which  cleave  double  stranded  DNA  at  internucleosomal  linker  regions, 
generating  mono-  and  oligonucleosomes.    During  apoptosis,  this  DNA 
degradation occurs several hours before breakdown of the plasma membrane 
and histone DNA fragments (i.e.  the mono- and oligonucleosomes) accumulate 
in the cytoplasm.  This assay uses mouse monoclonal antibodies to measure 
histone DNA accumulation which is assumed to be proportional to apoptotic cell 
death. 
Briefly, cells were cultured for 14 days in the presence of test substances.  
They were then lysed and mononucleosomes and oligonucleosomes released 
into the cytoplasm were detected by measuring the absorbance at 405nm and 
490nm.  The specific enrichment of mononucleosomes and oligonucleosomes 
released into the cytoplasm was calculated using the following formula: 
 
mU of sample (treated cells)
Enrichment Factor (EF) = 
mU of corresponding negative control (untreated cells)
 
Where mU = absorbance x 10
-3 
 
Quantitative determination of VEGF 
Cellular VEGF release was examined using a rat VEGF ELISA kit (Invitrogen, 
CA, USA) and was performed as per manufacturer’s instructions.  This assay 
measures the amount of both natural and recombinant rat VEGF protein that has 
been released into the tissue culture medium.  Cells were cultured for 14 days in 
the  presence  of  test  substances  after which  time  the  media  was  collected  in 
pyrogen/endotoxin-free  tubes  and  stored  at  -20°C  until  required  for  analysis.  
This assay uses a highly purified rat anti-VEGF antibody which binds the VEGF 
protein present in the sample and thus the intensity of the final coloured product Chapter 2 Materials and methods 
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is directly proportional to the concentration of rat VEGF present in the original 
sample.   
 
Monitoring cell culture homeostasis 
Blood gas analyser 
Culture medium pH, pCO2 and pO2 were monitored using a blood gas analyser 
(ABL  705,  Radiometer,  Crawley,  UK).    The  blood  gas  analyser  automatically 
equilibrates two buffer solutions (high and low pH) by means of pure air and pure 
CO2,  these  solutions  are  used  for  electrode  calibration,  set  to  occur  every  2 
hours.  The blood gas analyser also performs an internal calibration and thus a 
high degree of accuracy is achieved.   
 
Oxygen measurement using fibre optic oxygen (FOXY) probe 
Oxygen levels in the hypoxic range in media were measured using a FOXY-R 
stainless-steel 1/16” OD fibre probe with FOXY-AF silicone overcoat and LS-450 
blue  LED  light  source  connected  to  a  USB2000-FL  spectrometer  (all  from 
OceanOptics, Duiven, Netherlands).  A pulsed blue LED sends light at ~475nm 
to  an  optical  fibre  which  carries  it  to  the  tip  of  the  probe  which  contains  a 
ruthenium complex immobilised in a hydrophobic gel.  The light from the LED 
causes  the  ruthenium  compound  to  fluoresce  and  emit  light  at  approximately 
600nm.  The excitation of the ruthenium compound is quenched by non-radiative 
transfer of energy to oxygen molecules; the degree of quenching is proportional 
to the partial pressure of oxygen in the gel, which is in dynamic equilibrium with 
the sample.  The energy released is detected and converted to a digital signal by Chapter 2 Materials and methods 
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the  spectrometer  and  analysed  using  software  that  was  provided  with  the 
spectrometer on a PC. 
The system was calibrated using 0% O2 (7.5% w/v sodium hydrosulphite 
(Na2S2O4)  in  PBS)  and  20%  O2  (PBS)  solutions.    The  probe  was  left  to 
equilibrate for a few minutes until a stable reading was attained and then washed 
briefly before measuring experimental samples.  Due to difficulties with sterilising 
the  probe,  oxygen  measurements  could  only  be  taken  at  the  end  point  of 
experiments. 
 
Statistics 
Multiple comparisons were performed by one-way analysis of variance (ANOVA) 
using  GraphPad  InStat  (version  3.06,  GraphPad  software  Inc.),  using  the 
Bonferroni  correction.    Unless  otherwise  stated,  representative  data  are 
presented as means  one standard deviation (SD) for 5 or 6 replicates.  All 
experiments were performed in at least triplicate.  Significance was assumed to 
be P<0.05, where P<0.05 = *, P<0.01 = ** and P<0.001 = ***. 
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Chapter 3 
Hypoxia inhibits collagen producing cells 
Introduction 
The biosynthesis of the collagen triple helix is dependent upon the availability of 
an adequate oxygen supply (Hunt et al., 1969).  One obvious explanation for this 
is that the prolyl hydroxylase enzymes involved in the conversion of proline to 
hydroxyproline  are  oxygen  dependant  (Yen  et  al.,  1979).    Hydroxylation  of 
proline  residues  provides  increased  stability  by  serving  as  glycosylation  and 
cross linking sites which allow individual polypeptides to associate and form the 
basic collagen  unit,  the  triple helix  (Bann et  al., 2000a;  Mizuno  et  al., 2003).  
Thus de novo collagen synthesis has an absolute requirement for oxygen.   
As  has  already  been  described  (Chapter  1),  in  normal,  healthy  tissue, 
both  bone  and  skin  have  extensive  blood  supplies  which  serve  the  local 
environment with nutrients and oxygen, and remove the by-products of cellular 
respiration.    In  osseous  tissue,  capillary  networks  penetrate  throughout 
trabecular bone and the osteons of cortical bone carry the blood vessels that 
feed more densely packed areas.  The skin has a dense capillary supply; the 
majority of these blood vessels are concentrated within the dermal layer of the 
skin and play an important role in thermoregulation.  However, disruption to the 
capillaries feeding these tissues, as is seen following a fracture or wound, can 
result in local hypoxia.   
The  oxygen  tension  in  a  wound  reflects  a  balance  between  oxygen 
delivery and oxygen consumption; this drops to its lowest in the first day post 
trauma (Chang et al., 1983), when the cells in the wound have an increased Chapter 3 Hypoxia inhibits collagen producing cells 
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metabolic demand and the blood supply to the injured area is reduced to prevent 
excessive  bleeding.    The  oxygen  tension  in  the  centre  of  soft  tissue  wounds 
remains low during the healing process; restoration of normal oxygen levels does 
not begin until at least 8 days post-trauma and is still not complete 14 days post-
trauma (Remensenyder et al., 1968).  In order for successful wound healing to 
occur, the blood flow to the affected area must be restored so that the amount of 
oxygen available to the cells is sufficient for collagen synthesis.  Progression of 
wound  healing  in  vivo  suggests  collagen  deposition  is  related  to  the  oxygen 
tension  of  the  wound  (Tandara  et  al.,  2004)  and  thus  the  effects  of  chronic 
hypoxia on the ability of osteoblasts and fibroblasts to differentiate, proliferate 
and form collagen in low oxygen environments merits further investigation. 
The  majority  of  studies  on  the  effects  of  hypoxia  on  osteoblasts  have 
focused  on  the  gene  expression  profiles  of  these  cells  when  exposed  to  low 
oxygen tensions for relatively short periods of time (up to 96 hours).  In these 
conditions  mRNA  has  been  shown  to  be  decreased  for  a  wide  range  of 
osteogenic markers including: Runx2, type I collagen, alkaline phosphatase and 
osteocalcin  (Warren  et  al.,  2001;  Park  et  al.,  2002;  Liu  et  al.,  2007),  with 
concomitant increases in mRNA expression of VEGF (Steinbrech et al., 1999b; 
Akeno et al., 2001).  It has been proposed that this response is mediated by the 
hypoxia inducible factor (HIF), whose upregulation in hypoxia is known to initiate 
transcription of a wide range of genes mediating adaptation and survival (Ke et 
al., 2006; Schipani et al., 2008).   
Similar, short-term exposure studies have been carried out with dermal 
fibroblasts  and  hypoxia  but  the  results  are  less  conclusive.    Increases  in  the 
expression  of  stress-responsive  proteins  have  been  observed  in  response  to 
hypoxia on human dermal fibroblasts, but the same study found no effects of 
hypoxia on proliferation (Boraldi et al., 2007).  As was seen in osteoblast studies, Chapter 3 Hypoxia inhibits collagen producing cells 
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short  term  cultures  in  hypoxia  resulted  in  notable  increases  in  VEGF  mRNA 
expression  and  concomitant  downregulation  of  Col1α1  mRNA  expression  by 
human  dermal  fibroblast-like  cells  (Steinbrech  et  al.,  1999a),  suggesting  that 
hypoxia mediates angiogenesis required for tissue repair.  Others have found 
that hypoxia causes increases in collagen synthesis in renal fibroblast-like cells 
resulting in fibrogenesis (Norman et al., 2000).  As such, further work is clearly 
needed in order to clarify the exact response of fibroblasts to hypoxic insult. 
The effects of long term hypoxia on cells producing type I collagen have 
been somewhat more neglected.  Previous work done by our group has begun to 
examine  the  long  term  effects  of  hypoxia  on  osteoblasts  showing  dramatic 
inhibition of bone formation by cells grown in low oxygen tensions for 7 or 14 
days  (Utting  et  al.,  2006).    The  authors  suggested  that  hypoxia  induces  a 
dormant  state  of  ‘suspended  animation’  on  osteoblasts,  resulting  in  gradual 
decreases in cellular activity and bone forming ability with decreasing oxygen 
tension, which is relieved upon reoxygenation.  However, there has been little 
work on  the  effects  of  chronic hypoxia  on  the  ability  of  the fibroblasts  of  the 
dermis to differentiate, proliferate and form collagen.   
Given  the  similarities  in  the  behaviour  displayed  by  fibroblasts  and 
osteoblasts to short term hypoxia, it is plausible that fibroblasts would behave in 
a similar manner to osteoblasts when exposed to long term hypoxia.  One study 
has shown that long term hypoxia suppresses de novo elastin production by rat 
lung fibroblasts (Berk et al., 2005), indicating an inhibitory mechanism similar to 
that  displayed  by  osteoblasts.    However,  overgrowth  of  connective  tissue,  as 
occurs  in  tissue  fibrosis,  is  associated  with  pathological  and  disease  states 
where the oxygen tension in the local area is low.  Chronic progression of fibrosis 
results  in  excessive  deposition  of  extracellular  matrix  components  without 
resolution  (Mutsaers  et  al.,  1997),  indicating  that  even  in  the  lowest  oxygen Chapter 3 Hypoxia inhibits collagen producing cells 
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tensions  where  collagen  formation  is  likely  to  be  severely  inhibited,  over-
production can still occur.  It has been suggested that hypoxia may cause an 
upregulation of connective tissue growth factor (CTGF), the trigger for fibroblastic 
differentiation  from  MSCs,  resulting  in  skin  fibrosis.    CTGF  upregulation  has 
been associated with fibrotic lesions in skin scleroderma and renal fibrosis (Hong 
et al., 2006; Higgins et al., 2004).  This paradox raises questions relating to the 
behaviour  of  fibroblasts  exposed  to  long  term  hypoxia  and  their  ability  to 
differentiate  from  MSCs,  proliferate  into  fully  functional  cells  and  produce 
collagen.   
In this chapter I investigate further the effect of hypoxia on osteoblasts, in 
particular the effect of low oxygen tension on the expression of some previously 
unstudied genes, including sclerostin.  I then explore the effects of long term 
hypoxia on collagen production by rat dermal fibroblasts and examine the effects 
of low oxygen on the adhesive properties and proliferation of these different cell 
types.   Chapter 3 Hypoxia inhibits collagen producing cells 
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Methods 
Materials  and  methods  specific  to  this  chapter  are  described  here,  all  other 
methods used are described in Chapter 2. 
 
Adhesion studies 
To examine the effect of hypoxia on the adhesion of fibroblasts and osteoblasts 
to plastic, cells were seeded at 1x10
5 cells per well in 6-well plates and allowed 
to settle for 6 or 96 hours.  After this time period had elapsed the medium was 
removed from the tissue culture plates and the cells were gently washed in PBS.  
The  osteoblasts  and  fibroblasts  were  then  trypsinised  (0.25%  trypsin  for  10 
minutes at 37°C) and blinded manual cell counts were performed.  Manual cell 
counts had to be performed rather than using the LDH assay; the LDH assay 
measures the amount of LDH released by the cell upon cell lysis.  In hypoxic 
conditions  increased  anaerobic  respiration  results  in  upregulation  of  LDH 
enzyme activity (Robin et al., 1984) and mRNA expression (Firth et al., 1994) 
and as such, would give inaccurate results in low oxygen conditions.   
These experiments were designed based on the principle that in the first 6 
hours after plating, cells would attach to the tissue culture plate and a cell count 
would allow the effect of hypoxia on cellular adhesion to be assessed.  After this 
time, the cells would begin proliferating and thus a cell count performed 96 hours 
after plating would allow the extent of proliferation under hypoxic conditions to be 
examined. 
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Results 
Osteoblasts and hypoxia   
Hypoxia  exerted  dramatic  inhibitory  action  on  the  bone  forming  ability  of 
osteoblasts.  Eight-fold decreases in the amount of bone formed by osteoblasts 
grown in long-term hypoxia (2% O2) were observed when compared with those 
grown in normoxia (20% O2) (Figure 3.1).  Gene expression studies using RNA 
isolated after 7 and 14 days of culture revealed that exposure to hypoxia caused 
retardation  in  the  differentiation  of  osteoblasts,  with  delays  in  the  onset  of 
expression of osteocalcin (OCN), a key marker of late osteoblast differentiation.  
Expression  of  RANKL  mRNA  was  also  delayed  in  osteoblasts  exposed  to 
hypoxia.    The  expression  of  OPG,  the  natural  decoy  receptor  for  RANKL, 
appeared to be relatively unaffected by hypoxia (Figure 3.2). 
As a key factor in the inhibition of osteoblast function in vivo, the potential 
role  of  sclerostin  in  mediating  the  osteoblastic  response  to  hypoxia  was 
investigated.  Sclerostin (SOST) expression appeared to be downregulated by 
hypoxia,  a  likely  consequence  of  its  increased  expression  with  increasing 
osteoblastic differentiation.  Dentine matrix protein 1 (DMP1), a marker not only 
for  odontoblasts  (George  et  al.,  1995),  but  also  for  osteocyte  formation 
(Toyosawa  et  al.,  2001)  was  run  alongside  SOST  and  showed  clear 
downregulation (Figure 3.2.), indicating that hypoxia slows the differentiation and 
maturation of osteoblasts. 
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Figure 3.1.  Hypoxia inhibits osteoblast bone forming ability. 
Calvarial osteoblasts from neonatal rats were cultured in supplemented DMEM in 2% or 20% 
oxygen for 14 days.   
a.  Scanned images of alizarin red stained mineralised structures formed by osteoblasts revealed 
strong inhibition of bone formation in hypoxic conditions.  Scale bar = 1mm. 
b.    Alizarin  red  stained  bony  structures  viewed  by  phase  contrast  microscopy  showed  that 
hypoxia affects the size, as well as number of trabecular structures formed.  Scale bar = 0.2mm.   
c.  Quantification of bone formation in these cultures by image analysis of alizarin red stained 
monolayers,  revealed  that  long  term  exposure  to  hypoxia  causes  a  8-fold  decrease  in  bone 
formation.  ***, significantly different from 20% O2 control, P<0.001. 
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Dermal fibroblasts and hypoxia 
To investigate whether the inhibitory effect of hypoxia on osteoblasts was cell-
specific or a general trait common to other collagen producing connective tissue 
cells, fibroblasts isolated from the dermis of neonatal rat pups were cultured in a 
gradation  of  oxygen  tensions.    Increasing  inhibition  of  growth  and  collagen 
forming  ability  were  apparent  with  decreasing  oxygen  tension  (Figure  3.3).  
Closer examination in hypoxia (2% O2) and normoxia (20% O2) revealed that 
collagen production by these fibroblasts was affected by hypoxia in a similar way 
to bone formation by osteoblasts; hypoxia caused severe inhibition of collagen 
deposition  over  the  course  of  the  culture  (Figure  3.4.a.  and  3.4.b.)  and  a 
significant, 4-fold decrease in production of soluble collagen (Figure 3.5.). 
Figure  3.2.    Hypoxia  causes 
changes  in  gene  expression  by 
osteoblasts. 
Osteoblast  RNA  was  extracted  after  7 
and 14 days of culture in supplemented 
DMEM in 2% or 20% oxygen and mRNA 
expression  levels  assessed  using  RT-
PCR.    Hypoxia  (2%  O2)  caused 
retardation of osteoblastic differentiation, 
as  displayed  by  the  late  expression  of 
mRNA  for  OCN  and  RANKL.  
Expression  of  OPG  was  relatively 
unaffected  by  hypoxia.    DMP1  and 
SOST  (osteocyte  markers)  were  also 
downregulated by hypoxia suggesting a 
delay  in  osteoblast  maturation  in  these 
conditions.  OCN = osteocalcin; RANKL 
= RANK  ligand; OPG  = osteoprotegrin; 
DMP1 = dentine matrix protein 1; SOST 
= sclerostin. 
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Previous  work  by  this  research  group  has  shown  osteoblastic  expression  of 
VEGF to be strongly upregulated by exposure to long term hypoxia and mRNA 
for  Col1α1  to  be  relatively  unaffected  (Utting,  2006).    Similar  trends  were 
observed when expression of these genes by dermal fibroblasts exposed to the 
same conditions was examined (Figure 3.6).  The expression of Col1α1 mRNA 
showed a possible mild downregulation in hypoxic condition, while VEGF was 
strongly upregulated by low oxygen conditions. 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  Decreasing oxygen tension inhibits fibroblast collagen production. 
Scanned images of Masson’s trichrome-stained dermal fibroblasts cultured for 14 days in DMEM 
supplemented with 5% FCS and 50 µg/ml ascorbate in 20%, 12%, 5% and 2% oxygen.  Images 
display a general overview of the inhibitory effects of hypoxia on collagen production by dermal 
fibroblasts, with the darker purple areas indicating more collagen deposition.  Scale bar = 2mm. 
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Figure 3.4.a.  Hypoxia inhibits collagen deposition by dermal fibroblasts. 
Rat dermal fibroblasts were grown for 7 and 14 days in DMEM supplemented with 5% FCS and 
50 µg/ml ascorbate in 20% and 2% oxygen.  Collagen deposits were stained using Masson’s 
trichrome and viewed by reflected light microscopy.  Scale bar = 0.5mm. 
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Figure  3.5.    Hypoxia  inhibits 
soluble  collagen  production  by 
dermal fibroblasts. 
Rat dermal fibroblasts were grown for 
14 days in DMEM supplemented with 
5%  FCS  and  50  µg/ml  ascorbate  in 
20% and 2% oxygen.   Production of 
soluble  collagen  was  measured 
relative  to  the  total  cell  protein  and 
was seen to be significantly inhibited 
by  low  oxygen.    **,  significantly 
different from 20% O2 control, P<0.01. 
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Figure  3.4.b.    Quantification  of 
deposited collagen formation. 
Rat  dermal  fibroblasts  were  cultured 
for  7  and  14  days  in  DMEM 
supplemented  with  5%  FCS  and  50 
µg/ml  ascorbate  in  20%  and  2% 
oxygen.  Masson’s trichrome stained 
monolayers were quantified by image 
analysis. 
**,  significantly  different  from  day  7 
20% control, P<0.01.  ***, significantly 
different  from  day  14  control, 
P<0.001. 
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Figure 3.6.  Exposure of fibroblasts to hypoxia strongly upregulates VEGF mRNA but 
does not affect Col 11. 
RNA was extracted from dermal fibroblasts grown for 10 days in DMEM supplemented with 5% 
FCS and 50 µg/ml ascorbate in 20% and 2% oxygen.  mRNA expression for type I collagen 
(Col1α1) was relatively unaffected by hypoxia but expression of mRNA for vascular endothelial 
growth factor (VEGF) was strongly upregulated.  The three bands present represent three mRNA 
splice variants for VEGF. 
 
Hypoxia does not affect adhesion of osteoblasts or fibroblasts to plastic 
Unpublished data from our laboratory suggest hypoxic conditions may promote 
formation of increased numbers of small colonies in culture from osteoblasts and 
fibroblasts (K.  W.  Colston, personal communication), and it was hypothesised 
that this may be related to the ability of these cells to adhere.  To investigate this 
further,  suspended  rat  calvarial  osteoblasts  and  rat  dermal  fibroblasts  were 
allowed to sediment onto plastic surfaces in hypoxic and normoxic conditions for 
6 hours (the time for initial adhesion of cells to the plastic tissue culture plates to 
occur).    Parallel  cultures  were  maintained  for  96  hours  by  which  time  cell 
proliferation would be expected to have commenced.  There was no significant 
difference in cell number after 6 hours of exposure to hypoxia for either cell type 
when compared to normoxic controls, suggesting hypoxia does not affect the 
ability of these cells to adhere to plastic.  However, hypoxia caused significant Chapter 3 Hypoxia inhibits collagen producing cells 
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decreases in cell number in both fibroblastic and osteoblastic cultures after 96 
hours of exposure to hypoxia (Figure 3.7.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  Hypoxia inhibits proliferation but not adhesion of collagen producing cells. 
Dermal  fibroblasts  were  allowed  to  adhere  and  proliferate  for  6  and  96  hours  in  DMEM 
supplemented  with  5%  FCS  and  50  µg/ml  ascorbate  in  20%  and  2%  oxygen  before  blinded 
manual cell counts were performed. 
a.  Dermal fibroblasts.  b.  Calvarial osteoblasts.  ***, significantly different from 20% O2 control, 
P<0.001. 
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Discussion 
The work presented in this chapter shows that hypoxia inhibits the function of 
osteoblasts and fibroblasts.  The production of collagen by both cell type was 
particularly affected, with strong inhibition of both bone formation by osteoblasts 
and collagen deposition by fibroblasts observed.   As these cell types are key to 
the reparative processes in both fracture and wound healing respectively, their 
adaptation to low oxygen environments is essential to the restoration of healthy 
tissue.  These data provide evidence that both osteoblasts and fibroblasts adapt 
to low oxygen tensions by regulating cellular differentiation and proliferation. 
Before growth, differentiation and collagen formation can occur, cells must 
adhere to the surface on which they will develop and proliferate, yet the effects 
hypoxia has on cellular adherence have been paid little attention.  In vivo studies 
of low oxygen environments suggest that adherence would be reduced in low 
oxygen tensions; decreased cell-cell and cell-extracellular matrix interactions as 
a result of hypoxia are regarded to be the first steps in the progression of tumour 
metastasis (Kunz et al., 2003).  The findings presented in this chapter suggest 
that hypoxia has little to no effect on adhesion of either osteoblasts or fibroblasts 
to plastic but does have an inhibitory effect on subsequent proliferation of these 
cells.  However, although decreased, both fibroblasts and osteoblasts retained 
some ability to proliferative when cultured for 96 hours in hypoxia.  While the 
studies  presented  here  cannot  draw  conclusions  relating  to  the  fate  of  cells, 
previous  studies  indicate  that  osteoblasts  do  not  undergo  apoptosis  when 
cultured in long term hypoxia (Utting et al., 2006).  Due to the similar behaviour 
that is exhibited by fibroblasts and osteoblasts, it is hypothesised that fibroblasts 
would not undergo apoptosis either, rather, like osteoblasts, fibroblasts display 
decreased  differentiation  and  adopt  a  state  of  cellular quiescence  in  order to 
survive.   Chapter 3 Hypoxia inhibits collagen producing cells 
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The method used to generate the hypoxic environment may provide some 
answers to the reason for this.  While cultures were maintained at the desired 
oxygen tension by gassing the boxes daily (Figure 2.2.), cells were exposed to 
atmospheric  oxygen  for  a  short  period  of  time  when  media  changes  were 
performed.    While  this  short  ‘burst’  of  oxygen  exposure  was  not  sufficient  to 
induce collagen formation, it may be sufficient to allow cellular proliferation and 
prevent cell death.  However, as the in vivo environment is unlikely to remain at 
very low oxygen tensions for prolonged periods, even in pathological situations, 
the system used provides a more accurate reflection of the in vivo environment 
than one where cells would be continuously exposed to hypoxia.   
  The production of extracellular matrix by osteoblast and fibroblasts was 
significantly  decreased  by  hypoxia.    Despite  collagen  protein  production  by 
dermal  fibroblasts  being  severely  inhibited  by  long  term  hypoxia,  mRNA 
expression revealed only marginal decreases when cells were cultured in low 
oxygen.  This unexpected result could be explained by the oxygen dependence 
of the collagen modifying enzymes.  The prolyl hydroxylases (PHDs), which post-
translationally modify the collagen polypeptide chains have decreased activity in 
hypoxia (D'Angelo et al., 2003; Nakayama, 2009).  PHD2 (which is involved in 
the HIF pathway) is believed to act as the cellular oxygen sensor (Berra et al., 
2003).    The  findings  presented  in  this  chapter  indicate  that  the  collagen 
modifying PHDs may also act as cellular oxygen sensors by modulating cellular 
activity, i.e.  collagen production, in response to changing oxygen levels.  While 
collagen mRNA is still synthesised in hypoxic conditions, the PHD enzymes have 
limited functionality.  As such, formation of the stable collagen triple helix does 
not  occur  and  reduced  collagen  protein  production  is  observed.    This  would 
suggest that collagen synthesis is governed at the translational, rather than the 
transcriptional level in low oxygen environments.  These findings are redolent of 
the  effects  of  ascorbate  deficiency  (an  additional  cofactor  required  for  PHD Chapter 3 Hypoxia inhibits collagen producing cells 
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activity), which are exemplified by scurvy where decreased collagen synthesis 
and secretion occur (Kipp et al., 1996; Peterkofsky, 1991).  However, it has been 
reported  that  ascorbate  deficiency  also  results  in  significant  reductions  in 
collagen  mRNA  expression  which  is  restored  upon  ascorbate  replenishment 
(Spanheimer et al., 1986). 
Previous  reports  have  suggested  that  short  term  hypoxia  results  in 
increased collagen formation in the early stages of wound healing due to dermal 
fibroblasts upregulating TGFβ (Falanga et al., 1991).  However, the experiments 
described in this chapter suggest that collagen production by dermal fibroblasts 
is inhibited in long term hypoxia and thus it is possible that the effects seen in the 
early  stages  of  wound  healing  are  produced  by  cells  migrating  to  the  site  of 
injury.  Evidence supporting this hypothesis has been published, suggesting that 
pericytes,  relatively  undifferentiated  cells  associated  with  the  walls  of  blood 
vessels,  migrate  from  the  vessel  wall  to  hypoxic  areas  (Gonul  et  al.,  2002).  
Pericyte proliferation is stimulated by hypoxia (Yamagashi et al., 1999) and the 
increased  production  of  type  I  collagen  by  these  cells  is  known  to  result  in 
fibrosis (Lin et al., 2008).   
Cells migrating from other parts of the vessel wall may also play a role in 
the increased production of collagen in the dermis in hypoxic conditions.  While 
pericytes  are  located in  the basement membrane  of  the  vessel  (Joyce  et al., 
1985),  adventitial  fibroblasts  surround  the  outer  walls  of  blood  vessels.  
Adventitial fibroblasts, like pericytes, are activated by both short term and long 
term  hypoxia  (Das  et  al.,  2001).    Both  adventitial  fibroblasts  and  circulating 
fibrocytes have been seen to play a role in the vascular remodelling process in 
hypoxic  conditions  (Stenmark  et  al.,  2002;  Frid  et  al.,  2006).    However,  the 
collagen producing ability of these cells is not discussed in the aforementioned 
reports.  Based on the ideas described above relating to the role of oxygen in 
collagen formation by these cells it would seem likely that hypoxia would also Chapter 3 Hypoxia inhibits collagen producing cells 
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inhibit  collagen  formation  by  adventitial  fibroblasts.    As  such,  attempts  were 
made to isolate and culture cells from the adventitia of rat arteries in order to 
examine  their  behaviour  when  exposed  to  hypoxia  in  vitro,  however,  these 
endeavours proved unsuccessful.  Further work examining the collagen forming 
ability  of  adventitial  fibroblasts  would  be  useful  in  ascertaining  whether  their 
migration to the dermis is responsible for the stimulation of collagen synthesis 
that is seen in response to short term hypoxia and if fibroblast migration could be 
linked to fibrosis. 
One  of  the  key  genes  that  is  upregulated  in  hypoxia  is  vascular 
endothelial  growth  factor  (VEGF),  which  is  secreted  by  a  variety  of  cells  to 
increase angiogenesis and thus blood flow to the hypoxic area (Shweiki et al., 
1992).  It  has  been  shown  that  osteoblasts  are  one  of  the  cell  types  which 
secrete  and  upregulate  VEGF  in  response  to  low  oxygen  (Steinbrech  et  al., 
1999b).  Investigations described in this chapter reveal that dermal fibroblasts 
also upregulate VEGF mRNA in response to hypoxia.  Taken together these data 
suggest  that  in  vivo  the  hypoxic  area  that  develops  in  and  around  a  wound 
causes  dramatic  upregulation  of  VEGF  expression  by  cells  in  the  locality, 
resulting in vascular remodelling and ultimately leading to reoxygenation of the 
area.  This increase in oxygen relieves the inhibition of collagen formation by 
fibroblasts and allows wound healing to progress. 
The  effects  of  long  term  hypoxia  on  the  expression  of  selected 
osteoblastic genes was also examined.  Increases in sclerostin (SOST) mRNA 
have been seen to follow VEGF expression in healing fractures (Genetos et al., 
2008)  implying  that  hypoxia-induced  VEGF  expression  may  be  regulating 
sclerostin.  Thus, it is possible that sclerostin could be involved in mediating the 
inhibitory effect of hypoxia on osteoblasts.  Decreased SOST mRNA expression 
by osteoblasts exposed to hypoxia was observed in this study, which is in good 
agreement  with  a  report  published  since  these  experiments  were  performed Chapter 3 Hypoxia inhibits collagen producing cells 
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(Genetos et al., 2010).  However, further investigations by Genetos et al.  led 
them to conclude that this is mediated through enhanced antagonism of BMP 
signalling,  independent  of  VEGF,  suggesting  that  the  parallel  expression  of 
VEGF and SOST seen in healing fractures is coincidental.  The results in this 
chapter suggest SOST expression by osteoblasts is inhibited in hypoxia.  It is 
likely  this  is  a  result  of  decreased  differentiation  of  osteoblasts  in  hypoxia,  a 
hypothesis  supported  by  the  decreased  expression  of  OCN  and  RANKL  in 
hypoxic  conditions.    In  a  normoxic  environment,  RANKL  is  expressed  by 
maturing  osteoblasts  (Atkins  et  al.,  2003),  and  osteocalcin  by  mineralising 
osteoblasts (Desbois et al., 1995), thus their downregulation in hypoxia indicates 
delayed differentiation. 
The experiments described here suggest that dermal fibroblasts respond 
to hypoxia in a similar way to other mesenchymal stem cell progenitors such as 
osteoblasts in vitro (Utting et al., 2006).  These findings strongly reinforce the 
idea  that  collagen  production  is  an  oxygen  dependent  process  and  help  to 
explain the relationship between the highly vascular nature of connective tissues 
such as the dermis, bone and periodontal ligament, which have high rates of 
turnover and repair, compared with poorly vascularised tissues, including tendon 
and cartilage, which show limited regenerative capabilities.  Further investigation 
of  the  mechanisms  underlying  the  response  to  hypoxia  of  collagen-producing 
cells  is  certainly  warranted,  in  particular  quantitative  analysis  of  fibroblastic 
collagen  mRNA  expression  of  cells  grown  in  hypoxia  compared  to  normoxia.   
However,  the  present  results  provide  strong  evidence  for  the  oxygen 
dependence of the wound healing processes in skin and bone. 
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Chapter 4 
A novel method for the isolation of rat long bone 
osteoblasts 
 
Introduction 
In vitro, osteoblast cell culture systems are used to investigate the aetiology of 
bone  diseases  and  compare  the  behaviour  of  bone  cells  in  normal  and 
pathophysiological states.  The in vitro system provides controlled environments 
and thus allows direct examination of the effects of test substances or factors on 
cell growth, proliferation and bone forming ability in an environment that is free 
from the influence of other cell types which would normally be present in bone.   
The classical method for the isolation of osteoblasts for in vitro studies 
uses cells derived from rodent calvarial bones (Yagiela et al., 1977).  Several 
other  methods  for  the  isolation  of  osteoblasts  have  been  developed  as 
alternatives to the calvarial model but none have proved as successful.  Attempts 
have been made to isolate osteoblasts from human trabecular bone (Robey et 
al., 1985).  Although using cells derived from a human source would seem more 
physiologically  relevant  than  using  cells  from  rodents,  the  methods  used  to 
obtain these cells often have limitations.  Human trabecular bone samples can 
be obtained from surgical waste, however, these samples are regularly sourced 
from older patients where the number of mesenchymal stem cells (MSCs) with 
osteogenic  potential  is  decreased  (D'Ippolito  et  al.,  1999)  and  the  total  cell 
number achieved at confluency is reduced (Evans et al., 1990).  Consequently, 
in vitro cultures using these cells proceed slowly and yield relatively little bone 
growth when compared with cells obtained from young rats.  A bone formation Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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assay using osteoblasts derived from avian tibia has also been developed (Gay 
et  al.,  1993),  however,  these  cells  were  seen  to  differentiate  and  grow  more 
rapidly than those derived from rodent calvaria.  This is a likely reflection of the 
faster  bone  turnover  (and  thus  more  rapid  fracture  healing)  seen  in  birds 
compared to mammals (Bennett et al., 1992) and as such differences exist, it 
may be wise not to use cells from avian sources as a model for a mammalian 
system.   
The  rat  provides  a  convenient  animal  model  for  the  study  of  bone 
formation and function.  Neonatal pups are readily available to the majority of 
scientists  and  are  convenient  to  work  with  as  the  rat  has  a  relatively  short 
gestation period (approximately 3 weeks) and produces large litters (on average 
8-10 pups).  Fragments of rat tibia have been used in attempts to culture long-
bone-derived cells but this method of outgrowth is slow with bone formation not 
evident until 48 days  after isolation  (Stringa et al., 1995).  Consequently, the 
protocol using the neonatal rat calvaria seems to provide the best model for the 
study of primary osteoblastic cells to date.  The calvariae from these animals 
provide a plentiful source of young, vigorous, osteoblast precursors which are 
relatively  easy  to  harvest  and  culture.    Furthermore,  these  cells  exhibit 
osteoblastic  behaviour  and  produce  mineralised  bone-like  structures  after  15 
days of growth in supplemented media  (Bellows et al., 1986), indicating their 
suitability for a study model.  However, this method is not without its drawbacks; 
in vivo formation of the flat bones, including the skull, mandible, scapula and 
clavicle, differs from the majority of the other bones in the body.  As described in 
the  introduction  to  this  thesis,  the  flat  bones  of  the  body  form  via 
intramembranous  ossification;  MSCs differentiate  directly  into  osteoblasts  and 
bone  is  synthesised  de  novo.    The  majority  of  the  other  bones  in  the  body 
including those of the long bones and the vertebrae, form by endochondral (or 
intracartilaginous) ossification.  MSCs differentiate into chondroblasts which form Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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a  cartilaginous  model  of  the  skeleton  which  is  replaced  by  bone  after  blood 
vessel  invasion  and  osteoblast  proliferation.    In  addition  to  these  discrete 
formation mechanisms, the blood supplies to the long bones and flat bones are 
different; during formation  long  bones  develop  their own  vascular  supply  with 
arteries penetrating the bone (Shim et al., 1968), whereas the flat bones of the 
skull are, in the most part, reliant on the vascular networks of the periosteum 
(Pannarale et al., 1997). 
Osteoporosis, one of the main focus diseases for bone research, often 
manifests with fractures in the hip (femoral head) or vertebrae  (Center et al., 
1999), both bones which form by endochondral ossification.  Furthermore, the 
flat  bones,  unlike  the  long  bones,  do  not  require  a  daily  input  of  mechanical 
loading or strain to maintain their integrity (Lanyon et al., 1984; Carter, 1984).  
Diseases  of  malnutrition  which  result  in  skeletal  abnormalities  also  exhibit 
predominant effects in the long bones (Nakamoto et al., 1979).  Rickets, which 
arises due to limited vitamin D / calcium in the diet, results in a failure or delay in 
calcification  of  newly  forming  bone  at  long  bone  physes  and  is  often 
accompanied  by  osteomalacia  in  adulthood  (Alman  et  al.,  2006).    The  most 
apparent effects of rickets are observed in the lower limbs where bowing of the 
legs is observed resulting in a ‘waddling-gait’. 
The  pronounced  differences  in  the  mechanisms  of  bone  formation 
between the skull (where cells are often obtained from for in vitro study) and the 
long  bones  (where  some  of  the  most  profound  effects  of  bone  diseases  are 
observed) raise questions relating to the pathophysiological relevance of using a 
primary  in  vitro  culture  system  of  cells  derived  from  the  calvaria.    While  the 
studies described here have gone some way in providing alternative models for 
investigation, none has gone so far as to comparatively analyse their findings 
with those from calvarial cells cultured in a similar manner to validate findings Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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from  previous  in  vitro  calvarial  studies.    To  address  this,  I  developed  a  new 
method  for  the  isolation  and  culture  of  rat  osteoblasts  derived  from  the  long 
bones of neonatal animals.  In this chapter, I describe the method used for the 
successful  harvesting  and  culture  of  these  cells.    These  long-bone-derived 
osteoblasts  are  then  characterised  alongside  analogous  calvarial  cells,  with 
critical  examination  of  their  histology,  bone  forming  ability,  gene  expression 
profiles and responses to exogenous hormones.   Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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Methods 
Materials  and  methods  specific  to  this  chapter  are  described  here;  all  other 
methods used are described in Chapter 2. 
 
Long bone osteoblast isolation 
Primary  osteoblasts  were  isolated  from  the  long  bones  of  2-day-old  neonatal 
Sprague-Dawley  rats  killed  by  cervical  dislocation.    The  animals’  limbs  were 
removed and the long bones excised.  The paws were cut off and the skin and 
flesh  scraped  away  using  a  scalpel.    The  bones  were  washed  in  PBS  and 
cleaned further to  ensure  all  unwanted  connective  tissue  had been  removed.  
The epiphyses were cut away to remove the growth plate and chondrocytic cells, 
and the diaphyses was fragmented.  These fragments were vortexed in PBS and 
then allowed to settle before removing the supernatant containing the marrow 
and  remnants  of  connective  tissue.    The  washed  bone  fragments  were  then 
subjected to sequential enzyme digestion using a three step process (1% trypsin 
in PBS for 10 minutes; 0.2% collagenase type II in Hanks balanced salt solution 
(HBSS) for 30 minutes; 0.2% collagenase type II in HBSS for 60 minutes), with 
the first two digests being discarded.  The cells released from the final digest 
(~5x10
6 / animal), were washed and plated into a 75cm
2 flask in DMEM (see 
Chapter 2 for media details).  Cells were pre-cultured for 3-4 days in a humidified 
atmosphere of 5% CO2 - 95% air at 37°C, until confluent.  Upon confluency, cells 
were sub-cultured into 6, 12 or 24-well trays in supplemented DMEM, this was 
regarded as day 1 of culture.  Mineralised bony structures typically developed 
from day 10, giving rise to dense, organised trabecular-shaped networks by days 
21-28.  Half media changes were performed every 3-4 days.   Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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Results 
Long bone and calvarial osteoblasts form similar bony structures in vitro 
Growth of osteoblasts isolated from both the calvaria and long bones of neonatal 
rat pups proceeded over a similar time scale; bony structures formed were of a 
similar size, shape and exhibited similar trabecular-like structures when grown 
for up to 21 days in media supplemented with 10nM dexamethasone, 50 µg/ml 
ascorbate and 2mM β-glycerophosphate (Figure 4.1.). 
Closer examination by electron microscopy revealed cells of comparable 
size  and  shape  depositing  collagen  and  forming  extracellular  mineralised 
structures after 28 days in culture (Figure 4.2). 
 
Osteoblasts from autologous calvaria and long bones display similar  
characteristics in culture 
Cell number was estimated using lactate dehydrogenase release by osteoblasts; 
both calvarial and long bone cells showed comparable increases in cell number 
over the course of the culture (assessed after 4, 7, 10 and 14 days of growth), 
indicating  the  rate  of  cell  proliferation  is  similar  for  both  cell  types,  with  cell 
number peaking at day 10 for both types of osteoblast (Figure 4.3).  Increases in 
cell number were accompanied by increases in collagen deposition and bone 
formation.  Progression through the stages of differentiation, proliferation, growth 
and bone formation by long bone osteoblasts are displayed in Figure 4.4. 
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Figure 4.1.  Bone formation by calvarial and long bone osteoblasts. 
Osteoblasts were grown in supplemented DMEM for 21 days. 
a.  Unstained images of bone formed by osteoblasts viewed by reflected light.  Bony structures 
appear as white features.  Well width = 3.5cm. 
b.    Phase  contrast  microscopy  of  unstained  trabecular  like  structures  viewed  by  at  x4 
magnification.  Trabecular-like structures appear grey against confluent cell background.  Scale 
bar = 1mm.   Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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Figure 4.2.  TEMs of the extracellular matrix produced by long bone osteoblasts.   
Osteoblasts were grown in supplemented DMEM for 28 days and then viewed by transmission 
electron microscopy (TEM).  Collagen fibres can be seen longitudinally and in transverse section 
(appear as dots) indicated by C.  Specific mineralisation of the collagenous extracellular matrix is 
indicated by M.  Magnification at x20k and x30k scale bar = 1μm, x60k scale bar = 500nm. Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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Figure  4.3.    Calvarial  and  long  bone  osteoblasts  showed  parallel  increases  in  cell 
number over the course of the culture. 
Osteoblasts were grown in supplemented DMEM and cell number assessed by osteoblastic LDH 
release.  At the four time points examined both calvarial and long bone osteoblasts displayed 
similar cell number suggesting equivalent proliferation rates.  **, significantly different from cell 
number at day 4, P<0.01.  *** = P<0.001. 
 
To assess the dependence of osteoblast differentiation, proliferation and 
growth on the different supplements in the media, cells were cultured in media 
with  each  of  the  key  supplements  needed  for  osteogenesis  removed  in  turn.  
Removal of any one of these components resulted in a loss of bone forming 
ability  for  both  calvarial  and  long  bone  osteoblasts  (Figure  4.5.a.).    Alkaline 
phosphatase (ALP) activity also showed similar trends for both cell types upon 
removal of culture medium additives.  ALP activity was significantly decreased in 
the  absence  of  dexamethasone  or  in  the  absence  ascorbate.    The  role  of 
dexamethasone  in  osteoblast  differentiation  is  well  known  and  as  such 
decreases  in  ALP  activity  would  be  expected  in  its  absence.    However, 
decreases  in  ALP  activity  in  response  to  the  removal  of  ascorbate1  would 
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suggest  that  ascorbate  may  also  be  playing  a  role  in  the  differentiation  of 
osteoblasts in addition to it being a cofactor for collagen formation.  The removal 
of  β-glycerophosphate  resulted  in  an  approximate  1.5-fold  increase  in  ALP 
activity for both calvarial and long bone osteoblasts, it is likely that the removal of 
the phosphate source required for mineralisation causes enzyme upregulation in 
order for phosphate groups to be cleaved from other intracellular sources (Figure 
4.5.b.). 
 
β-glycerophosphate concentration 
Rat calvarial and long bone osteoblasts were cultured for 14 days before 
staining  with  alizarin  red  to  demonstrate  mineral  deposition.    For  further 
assessment of the cellular effects of this deposition, long bone osteoblasts were 
cultured  for  28  days  and  then  prepared  for  transmission  electron  microscopy 
(TEM).  In the absence of β-glycerophosphate (β-GP) bone mineralisation failed 
to occur due to insufficient inorganic phosphate with widespread, unmineralised 
collagenous matrix evident in the phase contrast and TEM images.  Bone formed 
in  the  presence  of  2mM  β-GP  displayed  typical  ‘trabecular’  morphology  and 
mineralisation was confined to these structures.  In the presence of 10mM β-GP, 
widespread,  non-specific  deposition  of  bone  mineral  occurred  across  the  cell 
monolayer, with inhibition of normal matrix deposition.  Intracellular deposition of 
mineral that appeared to be causing damage to cell membranes and organelles 
was also evident (Figure 4.6.). 
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Figure  4.4.    Collagen  deposition  and  bone  formation  by  long  bone  osteoblasts  at 
selected time points.   
Osteoblasts  were  grown  for  the  indicated  time  period  in  supplemented  DMEM.    Unstained 
structures were scanned and viewed by phase contrast microscopy at x4 magnification.   
Cell well scan scale bar = 50mm.  Phase contrast scale bar = 100μm. Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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Figure 4.5.   Requirement  of  calvarial and long bone osteoblasts  for key osteogenic 
culture medium supplements. 
Osteoblasts  were  grown  for  14  days  in  control  media  supplemented  with  2mM  β-
glycerophosphate (β-GP), 50µg/ml ascorbate (ASC) and 10nM dexamethasone (Dexa).  Cells 
were also cultured alongside in media with each of these additives removed in turn. 
a.  Full supplementation of the culture media is required for bone formation by both calvarial and 
long bone osteoblasts.   
b.    Alkaline  phosphatase  (ALP)  activity  is  significantly  increased  in  the  absence  of  β-
glycerophosphate but significantly decreased upon removal of ascorbate or dexamethasone from 
the media.  ***, significantly different from control, P<0.001.   
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Figure 4.6.a.   The effect of β-glycerophosphate concentration on bone mineralisation. 
Osteoblasts  were  cultured  for  14  days  then  stained  with  alizarin  red  to  demonstrate  mineral 
deposition  and  cultured  for  28  days  before  visualisation  by  transmission  electron  microscopy 
(TEM).    In  the  absence  of  β-glycerophosphate  (β-GP),  bone  formation  failed  to  occur; 
widespread, unmineralised collagenous matrix is evident in the phase contrast and TEM images 
(Figure 4.6.b.  overleaf).  Bony structures formed in the presence of 2mM β-GP show specific 
mineralisation of the collagenous matrix.  In the presence of 10mM β-GP non-specific deposition 
of bone mineral occurs.  Intracellular mineral  deposition causing damage  to membranes and 
internal organelles is also evident in the TEM images. Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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Figure 4.6.b.   TEMs showing the effect of β-glycerophosphate concentration on bone 
mineralisation. 
Scale bar = 1µm. Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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Collagen formation 
Calvarial  and  long  bone  osteoblasts  were  cultured  for  7  or  14  days  in 
supplemented DMEM.  Cell monolayers were stained with Masson’s trichrome.  
Clear increases in collagen fibre formation and deposition by osteoblasts in both 
culture types was observed over the culture period (Figure 4.7.).   Measurement 
of soluble collagen using the Sirius red assay, revealed increases in the amount 
produced by the cells and released into the media followed the same trend for 
both osteoblast type, steadily increasing in parallel over the course of the culture 
(Figure 4.8.).   
 
 
 
 
 
 
 
 
 
 
Figure 4.7.  Collagen deposition by calvarial and long bone osteoblasts.   
Cells were grown for 7 and 14 days in supplemented DMEM before monolayers were stained 
with Masson’s trichrome.  Dense collagen deposits can be seen as dark purple structures.  Scale 
bar = 0.5cm. 
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Figure 4.8.   Soluble collagen production by osteoblasts. 
Production of soluble collagen (as a percentage of total protein) measured at days 7, 10 and 14 
of culture showed comparable increases for calvarial and long bone osteoblasts.  Significance 
levels were assessed by comparing the test group to the day 7 control.  ***, significantly different 
from day 7 control, P<0.001. 
 
Gene expression profiles 
Calvarial  and  long  bone  osteoblasts  displayed  comparable  expression  of 
osteogenic marker genes at days 7 and 14.  Osteocalcin (OCN), a marker of 
osteoblast  differentiation,  was  barely  detectable  at  day  7  but  was  strongly 
expressed by day 14.  Increases in mRNA expression were also seen for other 
markers  of  osteoblastic  differentiation  including;  osterix  (OSX),  RANK  ligand 
(RANKL) and collagen type 1 (Col1α1).  Expression of the additional osteoblast 
maturity  markers  alkaline  phosphatase  (ALP),  osteopontin  (OPN),  matrix  gla 
protein (MGP) and osteoprotegrin (OPG) (Figure 4.9.), remained constant over 
time. 
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Figure 4.9.  Parallel expression of mRNA for a range of osteogenic markers by calvarial 
and long bone osteoblasts. 
mRNA  assessment  using  RNA  extracted  from  osteoblasts  after  7  and  14  days  of  culture  in 
supplemented DMEM revealed comparable expression profiles for osteoblastic gene markers for 
calvarial and long bone osteoblasts at day 7 and day 14.   
ALP = alkaline phosphatase; Col1α1 = collagen type I, alpha I; MGP = matrix gla protein; OCN = 
osteocalcin; OPN = osteopontin; OPG = osteoprotegrin; OSX = osterix; RANKL = RANK ligand. 
 
Osteocalcin mRNA expression was also assessed by qRT-PCR in order 
to measure the magnitude of the upregulation at day 14 relative to day 7.  36- 
and  32-fold  increases  in  calvarial  and  long  bone  osteoblast  OCN  mRNA 
expression, respectively, were observed.  Expression of key transcription factors 
involved  in  differentiation  along  other  MSC  pathways  was  also  quantitatively 
examined.   The  ‘master regulator’  of  adipogenesis,  PPARγ,  showed  marginal 
decreases over the time period of 0.6 and 0.8 fold in calvarial and long bone 
osteoblasts, and expression of Sox9, a key transcription factor in chondrocyte 
differentiation, increased by 1.4 and 2.3 fold respectively (Figure 4.10). Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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Figure  4.10.    Calvarial  and  long  bone  osteoblasts  showed  dramatic  upregulation  of 
osteocalcin but not PPARɣ and Sox9 at day 14 relative to day 7. 
mRNA was extracted from osteoblasts after 7 and 14 days of culture in supplemented DMEM.  
Quantification of gene expression by qRT-PCR revealed dramatic upregulation of OCN at day 14 
relative to day 7 but only marginal changes in the expression of PPARɣ and Sox9. 
 
Response to sex hormones 
Both  17-β-oestradiol,  the  major  oestrogen  secreted  by  the  pre-menopausal 
ovary,  and  5α-androstan-17β-ol-3-one  (dihydrotestosterone  (DHT)),  the  active 
form of testosterone elicited dose-dependent decreases in bone formation.  Total 
inhibition  of  bone  formation  was  seen  at  the  highest  concentrations  (100nm) 
tested of both hormones (Figure 4.11.). 
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Figure  4.11.    Dose-dependent  inhibition  of  bone  formation  by  gonadal  steroids  in 
cultures of calvarial and long bone osteoblasts.   
Osteoblasts were grown in for 14 days supplemented DMEM in the presence of: 
a.  17β-oestradiol.   
b.  5α-androstan-17β-ol-3-one. 
*, significantly different from control, P<0.05.  ** = P<0.01, *** = P<0.001. 
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Discussion 
In vitro models for the study of osteoblast behaviour are required for the direct 
examination  of  cellular  response  to  exogenous  stimuli  and  thus  provide  an 
insight to the in vivo behaviour of these cells.  It is essential that the cells used in 
these models behave as closely as possible to the cells in bone tissue, providing 
robust, reproducible results that can be relied upon. 
  The experiments described in this chapter indicate that calvarial and long 
bone  osteoblasts  exhibit  the  same  behaviour  in  vitro,  displaying  no  clear 
differences in genotype, phenotype or cellular activity for the parameters tested.   
The  structures  formed  by  calvarial  and  long-bone-derived  osteoblasts 
form an  extracellular matrix  that  contains  significant  amounts  of collagen  and 
undergoes selective mineralisation in the presence of a phosphate source.  Over 
the  course  of  the  culture  trabecular-like  structures  develop  which  are 
approximately  the  same  size  and  shape  as  those  seen  in  vivo.    The  spatial 
arrangement of these structures is similar to that of trabecular bone, with the 
appearance  of  spaces  that  are  not  dissimilar  to  those  that  accommodate 
vascular  channels  and  bone  marrow  in  vivo  (Figure  4.12.).    These  findings 
indicate that the extracellular matrix formed by these osteoblasts is osseous and 
are  supported  by  the  gene  expression  studies  which  revealed  dramatic 
upregulation  of  osteocalcin  in  these  cells.    In  addition  to  this  the  negligible 
changes  in  markers  for  adipogenesis  (PPARγ)  and  chondrogenesis  (Sox9) 
confirm that the isolated cells are not differentiating along other MSC pathways.  
Therefore, it can be said with a great deal of confidence that these cells are 
osteoblasts and the mineralised extracellular structures formed are bone. 
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Figure 4.12.  Bone formation by rat long bone osteoblasts and human trabecular bone. 
TOP:  Scanned  image  of  bone  formed  by  long  bone  osteoblasts  grown  for  28  days  in 
supplemented  DMEM.    MIDDLE:  The  same  section  viewed  by  phase  contrast  microscopy.  
BOTTOM LEFT: Human trabecular bone imaged using scanning electron microscopy (courtesy 
of Professor Tim Arnett, UCL).  BOTTOM RIGHT: Mouse trabecular bone viewed by micro-CT 
(courtesy of Dr.  Isabel Orriss, UCL).  Note trabeculae in bottom panels are of approximately 
similar scale to trabecular   features formed in vitro.  All scale bars = 0.5mm. 
 
The  rate  of  bone  formation  in  these  cultures  is  directly  related  to  the 
proliferation and maturation rates of the osteoblasts.  For both calvarial and long 
bone osteoblasts, the cellular population approximately doubles between day 4 
and day 7, and then again between day 7 and day 10.  The images in Figure 4.4. 
show that the cells are confluent by day 5 and after this time point cell density, 
and thus cell number, continue to increase.  As the culture progresses collagen 
is deposited by the osteoblasts and mineralisation takes place.  The decrease in 
cell number observed at day 14 (relative to day 10) is a likely consequence of the 
increased bone formation in the cultures, trapping cells in the mineralised matrix Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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and rendering them less accessible to the assay reagents.  While a decline in 
replicative capacity of the cells would be predicted to have occurred by day 14 
(Rubin, 2002), the total cell number is likely to be higher than that at day 10 if all 
cells were accessible to the assay reagents and could be counted. 
Bone  formation  by  these  cells  is  dependent  upon  the  medium  being 
supplemented  with  the  appropriate  additives  to  facilitate  osteogenesis:  
dexamethasone  is  required  for  osteoblastic  differentiation  from  mesenchymal 
stem cell precursors, ascorbate is an enzyme cofactor for collagen synthesis and 
β-glycerophosphate  provides  the  phosphate  source.    While  the  effect  of 
removing any one of these supplements resulted in almost total abolition of bone 
formation,  the  effects  on  alkaline  phosphatase  activity  were  somewhat  more 
varied.    Omission  of  ascorbate  from  the  culture  medium  caused  significant 
decreases  in  alkaline  phosphatase  activity,  suggesting  that  the  effects  of 
ascorbate on bone formation go beyond that of being a cofactor for the collagen 
forming enzymes.  It has been suggested that ascorbate has inhibitory effects on 
kidney alkaline phosphatase which are diminished in the presence of an enzyme 
substrate (Miggiano et al., 1983).  Other reports indicate that ascorbate may be 
involved  in  the  differentiation  and  proliferation  of  osteoblasts  from  their  MSC 
precursor cells (Franceschi, 1992).  Based on the data presented in here, it is not 
possible to say which role ascorbate is playing in these cultures; further work 
assessing the differentiation of cells grown in medium lacking ascorbate would 
required in order for conclusions to be drawn. 
The  presence  of  a  phosphate  source  in  osteogenic  culture  medium  is 
essential  for  mineralisation  of  the  extracellular  matrix;  β-glycerophosphate  is 
widely  used  as  it  provides  a  stable  source  of  phosphate  that  is  cleaved  by 
alkaline  phosphatase  when  it  is  required.    The  concentration  of  β-
glycerophosphate  in  the  medium  must  be  sufficient  for  selective  matrix 
mineralisation to occur but not in such excess that mineral deposition occurs in Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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an  uncontrolled  manner.    A  review  of  the  available  literature  on  the  subject 
revealed  that  many  studies  are  performed  using  10mM  β-glycerophosphate, 
based on the methodological reports that have been published (Jonsson et al., 
1999;  Nefussi  et  al.,  1985);  one  study  used  β-glycerophosphate  as  high  as 
50mM (Buttery et al., 2001).  The experiments described here suggest that these 
concentrations are far too high and would result in non-specific mineralisation of 
the  cell  monolayers.    As  bone  formation  is  used  as  the  end-point  for  these 
cultures, this is likely to result in inaccurate quantification of such formation.  In 
addition to this, the electron micrographs shown in this chapter reveal damaged 
cell  membranes  and  intracellular  mineral  deposition;  it  would  appear  that  a 
concentration  of  such  magnitude  leads  to  an  effective  ‘fossilisation’  of  cells.  
Thus,  for  successful  cell  growth  and  selective  mineralisation  of  the  collagen 
structures produced by the osteoblasts, a concentration of β-glycerophosphate 
of, or around, 2mM should be used.   
When  β-glycerophosphate  was  removed  from  the  medium  altogether, 
approximately 1.5-fold increases in alkaline phosphatase activity were observed 
by both calvarial and long bone osteoblasts.  This phenomenon has also been 
observed in microbes, where increased alkaline phosphatase activity was seen 
in response to growth in phosphate limited environments (Nakamoto et al., 1979; 
Raheb  et  al.,  2006).    It  is  likely  that  upon  removal  of  the  phosphate  source 
alkaline  phosphatase  activity  is  upregulated  as  a  compensatory  mechanism; 
cleaving  phosphate  groups  off  other  molecules  in  an  attempt  to  maintain 
homeostasis and retain the mineralisation capacity of these cells.   
Assessment of the response to both calvarial and long bone osteoblasts 
to  the  physiological  concentrations  of  gonadal  hormones  (Roddam,  2008) 
revealed dramatic inhibition of bone formation.  While previous reports suggest 
that  sex  hormones  increase  osteoblast differentiation  and proliferation  in  vitro Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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(Ernst et al., 1988; Gray et al., 1992; Scheven et al., 1992) the ability of these 
osteoblasts  to  form  bone  was  not  assessed.    In  vivo  the  sex  hormones, 
particularly oestrogen, are essential to the maintenance of bone, exemplified by 
the onset of osteoporosis in post-menopausal women (Turner et al., 1994).  The 
inhibition of bone formation that is observed when osteoblasts are exposed to 
both oestradiol and DHT indicate that the primary role of these hormones is not 
anabolic.    Consequently,  the  in  vivo  association  between  sex  steroids  and 
increased BMD (Greendale et al., 1997) is likely to be related to the effect of sex 
hormones on other cell types.  In addition to the protective effect oestradiol has 
on  bone,  one  possible  explanation  could  be  related  to  the  effect  of  gonadal 
steroids  on  endothelial  cells.    Sex  hormones  have  been  associated  with 
vasodilation/vasorelaxation (Orshal et al., 2004; Khalil, 2005) and as such may 
influence bone formation by increasing its vascular supply. 
The data presented in this chapter indicate that although osteoblasts from 
the calvaria and long bones form bone via different mechanisms in vivo, when in 
culture,  bone  is  formed  de  novo  by  all  cells.    A  recent  report  has  described 
differences in expression of the developmental Hox genes between cells derived 
from the skull and the limb both  in vivo and in cell culture (Rawlinson et al., 
2009).  However, given that no clear differences are observed in bone formation 
by calvarial and long bone osteoblasts described in this chapter, it would appear 
that osteoblasts have an intrinsic program for the in vitro formation of bone which 
is independent of their anatomical site of origin.  The absence of cartilaginous 
differentiation  factors  in  the  in  vitro  environment  and  the  presence  of 
dexamethasone, which rapidly induces osteoblastic differentiation (Rickard et al., 
1994), is likely to be the reason for the direct formation of bone in these cultures.  
Therefore, it would appear difficult to recapitulate endochondral ossification  in 
vitro as in essence one would have to recreate the exact timings and sequence 
of chondrogenic and osteogenic stimuli.  Recently, Scotti et al, claim to have Chapter 4 A novel method for the isolation of rat long bone osteoblasts 
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achieved  this  feat.    By  culturing  human  MSCs  in  vitro  with  the  appropriate 
chondrogenic stimuli they argue that it is possible to form endochondral bone in 
vitro and then use bone formed in this manner for successful bone grafts (Scotti 
et al., 2010).   
The novel method for the isolation of long bone osteoblasts that has been 
described here can be used in addition to the pre-existing calvarial osteoblast 
assay  to  obtain  osteoblasts,  allowing  more  cells  to  be  yielded  from  a  single 
animal and providing an alternative method for the study of osteoblast behaviour. 
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Chapter 5 
PTH inhibits bone formation by osteoblasts in vitro 
Introduction 
The  use  of  ‘intermittent’  parathyroid  hormone  (rhPTH  1-34)  to  induce  bone 
growth is becoming increasingly widespread (Tashjian et al., 2006).  Intermittent 
PTH treatment was the first anabolic bone therapy approved in the UK by the 
National Institute of Clinical Excellence (NICE) and by the US Food and Drug 
Administration (FDA) for the treatment of low bone mass (Mauck et al., 2006).  It 
is prescribed to women with post-menopausal osteoporosis, men with primary or 
hypogonadal  osteoporosis  or  men  and  women  with  glucocorticoid  induced 
osteoporosis (Kurland et al., 2000; Saag et al., 2007).  For all these groups the 
recommended  dosage  is  20µg  by  daily  subcutaneous  injection.    Peak  serum 
concentrations of 4.86µM (Satterwhite et al., 2010) are reached approximately 
30 minutes after administration and decline to almost undetectable levels within 
3 hours, due the relatively short half life of the drug.  The 20µg dose causes 
transient  increases  in  the  serum  calcium  concentration,  beginning  after 
approximately 2 hours and peaking between 4 and 6 hours post administration.  
Serum calcium levels return to baseline between 16 to 24 hours after each dose 
(Eli Lilly - Forteo prescription information, 2002; Hodsman et al., 2005).  As such, 
once  daily  injections  provide  fluctuations  in  the  blood  serum  concentration  of 
PTH resulting  in an  ‘intermittent’  dosing  pattern,  reflecting  the  natural  cyclical 
variations  of  the  amount  of  PTH  circulating  in  healthy,  hormone  balanced 
individuals. 
Despite  much  investigation  over  the  past  few  decades  the  precise 
biochemical mechanisms mediating the anabolic effects of PTH and the reasons Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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for the phenotypic differences arising due to variations in dosage and exposure 
patterns remain elusive (Jilka, 2007).  Several suggestions as to how intermittent 
PTH treatment results in bone formation have been proposed.  As described in 
Chapter  1  and  reviewed  by  (Hock,  2001),  treatment  with  PTH  is  thought  to 
increase bone turnover resulting in a net gain in trabecular bone volume.  The 
increased bone mineral density (BMD) is a result of improved structure in both 
cortical and cancellous bone (Jiang et al., 2003) and it has been suggested that 
the  number  and  thickness  of  trabeculae  are  also  increased  (Seeman  et  al., 
2001).  Intermittent PTH treatment has also been reported to increase osteoblast 
differentiation  (Ishizuya  et  al.,  1997)  and  have  anti-apoptotic  effect  on 
osteoblasts, increasing cell survival and thus bone forming potential (Jilka et al., 
1999). 
More recent findings have implicated the Wnt signalling pathway in the 
osteoblastic response to PTH; key molecular components of the pathway have 
been shown to be regulated by PTH (Kulkarni et al., 2005; Kakar et al., 2007; 
Chen  et  al., 2009).   Of particular  interest  is  sclerostin  (SOST),  the  osteocyte 
secreted inhibitor of bone formation (Winkler et al., 2003); it has been suggested 
that SOST is a target gene for PTH, whereby PTH inhibits the secretion of SOST 
from osteocytes (Keller et al., 2005; Bellido et al., 2005).  These findings have 
been furthered by studies using transgenic animals where SOST gain-of-function 
and  loss-of-function  mutants  were  seen  to  display  attenuated  responses  to 
intermittent PTH treatment, implying that SOST contributes to the PTH-induced 
bone gain in vivo (Kramer et al., 2010).  These studies have provided important 
insights into the mechanism of PTH action and the interaction between different 
cells in the bone environment, however, it would seem unlikely that relief of the 
inhibitory action that SOST has on osteoblasts would be sufficient to induce the 
anabolic effect observed in response to intermittent PTH treatment.   Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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In addition to its effects on bone formation PTH has also been implicated 
in angiogenesis.  Both VEGF and its receptors are expressed by osteoblasts 
(Tombran-Tink  et  al.,  2004).    Upregulation  of  VEGF  (as  occurs  in  hypoxia) 
results in increased blood vessel formation and thus greater vascularisation of 
the environment.  PTH (1-34) has been shown to stimulate VEGF expression up 
to 5-fold when administered in combination with vitamin D in osteoblast-like cells 
(Schlaeppi  et  al.,  1997).    Furthermore,  the  C-terminal  PTHrP  peptide  (PTHrP 
(107-139)) has been seen to stimulate rapid and transient increases in VEGF 
expression  at  both  the  transcriptional and protein  level in  human  osteoblastic 
cells  (Esbrit  et  al.,  2000).    Taken  together,  these  findings  suggest  PTH  may 
cause  an  upregulation  in  VEGF  production  by  osteoblasts  and  as  such,  the 
anabolic effects may be mediated by neovascularisation. 
To  fully  comprehend  how  PTH  mediates  bone  anabolism  an 
understanding of its direct effects on osteoblast function is vital; however, this 
area has been neglected.  Some in vitro studies have been performed;  among 
the most notable findings are that: PTH stimulated the proliferation of human 
trabecular  bone  cells  (Macdonald  et  al.,  1986);  PTH  decreased  osteocalcin 
production by human bone cells (Beresford et al., 1984) and that PTH had an 
inhibitory effect on the differentiation and bone formation of cells derived from rat 
calvaria  (Bellows  et  al.,  1990).    These  reports  suggest  that  PTH  exerts  an 
inhibitory effect on formation and function, despite promoting early proliferation.  
However, all of these data were published before the true anabolic effects of 
PTH  were  widely  recognised  and,  as  such  were  not  considered  in  the  same 
context as they may be today.   
More recently is has been suggested that the anabolic affect that is seen 
in vivo can be replicated in vitro (Kondo et al., 2009); the authors propose PTH 
acts primarily on immature osteoblasts, stimulating their differentiation and thus Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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leading to increased bone formation.  However, the dosing pattern used was not 
reflective of PTH treatment that results in anabolism in vivo and as such it is 
difficult  to  conclude  that  this  effect  alone  accounts  for  the  increased  bone 
formation. 
Given the importance of PTH as a bone anabolic therapy it is essential 
that the controversy surrounding its possible mechanism of action be resolved.  
In this chapter I explore the direct effects of PTH on bone formation using the 
long  bone  osteoblast  culture  system  developed  and  described  in  Chapter  4.  
Osteoblasts exposed to PTH in continuous and intermittent doses are examined 
and  the  effects  on  the  activity  and  bone  forming  potential  of  these  cells  are 
assessed.  The direct effect of sclerostin on osteoblasts is also examined.  The 
potential upregulation of angiogenesis is explored and the role of the vasculature 
in mediating the anabolic response to intermittent PTH treatment is discussed.   
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Methods 
Long bone osteoblasts were isolated and cultured as described in Chapter 4.  All 
other materials and methods used in this chapter are described in Chapter 2.   
To examine the  response of  osteoblasts  to  PTH (Parathyroid  hormone 
fragment 1-34 rat, CAS number 98614-76-7, Sigma Aldrich, Poole, Dorset, UK), 
cells were cultured with continuous or intermittent doses of PTH.  In continuously 
treated cultures, 0, 1, 10 or 100nM PTH (diluted in DMEM) was present for the 
duration of the experiment.  Intermittently treated cultures were exposed to PTH 
in  a  dosing  pattern  in  line  with  previously  published  reports  where  anabolic 
effects were seen in response to treatment (Ishizuya et al., 1997; Locklin et al., 
2003), and as such, osteoblasts were subject to 100nM PTH for 6 hours every 3 
days.  Cells were cultured for an average of 14-17 days. 
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Results 
PTH is a potent inhibitor of osteoblastic bone formation 
Continuous exposure to PTH inhibited bone formation by both calvarial and long 
bone osteoblasts in a dose-dependent manner, with complete abolition of bone 
formation at the highest concentration tested (Figure 5.1).  These findings were 
the stimulus for the rest of the work carried out in this chapter as they raised 
questions relating to the mechanism of action of PTH in vivo.  The direct effects 
of PTH on the number and size of trabeculae formed by long bone osteoblasts 
are shown in Figure 5.2. 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.1.    PTH  potently  inhibits  bone  formation  by  both  calvarial  and  long  bone 
osteoblasts. 
Osteoblasts  were  grown  for  14  days  in  media  supplemented  with  2mM  β-glycerophosphate, 
50µg/ml ascorbate, 10nM dexamethasone and continuous exposure to the relevant concentration 
of PTH.  To analyse the amount of bone formed, cell monolayers were stained with alizarin red 
and bone formation quantified by image analysis.  ***, significantly different to control, P<0.001. 
[PTH] (nM)
0 1 10 100
Bone 
f
orm
at
ion (
mm
2
)
0
2
4
6
Calvarial OB
Long bone OB
***
***
***
***
***
***
[0] [0]Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.  Exposure to PTH caused dose-dependent reductions in both the number 
and size of trabeculae formed by long bone osteoblasts. 
Cell wells and phase contrast images of structures formed after osteoblasts were grown for 14 
days in supplemented DMEM with the relevant concentration of PTH.   
Well width = 1.6cm.  Scale bar = 0.5 cm.   Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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Intermittent PTH treatment causes dose-dependent decreases in bone formation 
When treated with intermittent doses of PTH, bone formation by osteoblasts was 
inhibited  in  the  same  manner as  when  cells  were  treated  continuously.    The 
inhibition was less marked in the intermittently treated group when compared to 
the continuously treated group but the observed effect was directly proportional 
to the duration of PTH exposure, highlighting the direct inhibitory action of PTH 
on osteoblasts (Figure 5.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.  Intermittent PTH treatment inhibits long bone osteoblast activity. 
Osteoblasts were grown for 14 days in supplemented DMEM with PTH treatment as described 
below.  After this time period cell monolayers were stained with alizarin red and bone formation 
quantified by image analysis.  ***, significantly different to control, P<0.001. 
INT = Intermittent - 100nM PTH for 6 hours every 3 days.  CONT = Continuous - 100nM PTH 
throughout. 
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PTH causes decreases in cell number  
Continuous exposure to PTH caused dose-dependent decreases in osteoblast 
number.    Apoptosis,  estimated  by  measurement  of  the  specific  mono-  and 
oligonucleosomal  enrichment  of  the  cytoplasm  also  decreased,  however,  the 
general trend would suggest that this decrease probably reflects the decrease in 
cell  number (Figure  5.4).    The dramatic decrease  in  apoptosis at  10nM  PTH 
suggests that PTH may be having an anti-apoptotic effect at this concentration. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.  PTH treatment decreases osteoblast cell number and apoptosis. 
Osteoblasts were grown for 14 days in supplemented DMEM and in the presence of PTH.  Cell 
number was assessed using the lactate dehydrogenase assay.  Apoptosis was estimated using 
the cell death detection ELISAPLUS (Roche Diagnostics).  The apoptosis index is a measure of 
the mono- and oligonucleosomes released into the cytoplasm from the nucleus upon initiation of 
the apoptotic cell death.  *, significantly different from control, P<0.05.  *** = P<0.001. 
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PTH decreases osteoblastic alkaline phosphatase activity 
Decreases in alkaline phosphatase activity were observed upon treatment with 
PTH at 10 and 100nM; a 29% reduction in enzyme activity occurred as a result 
of treatment with 10nM PTH and a significant, 60% decrease when osteoblasts 
were treated with 100nM PTH.  The effect on cells treated with 1nM PTH was 
negligible.  This indicates that PTH reduces the ability of osteoblasts to generate 
free phosphate and as such, the quantities of phosphate present are not likely to 
be sufficient to allow mineralisation of the collagenous matrix (Figure 5.5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.  PTH inhibits alkaline phosphatase activity. 
Osteoblasts cultured for 14 days in supplemented DMEM and the indicated concentration of PTH 
were assayed for alkaline phosphatase (ALP) activity, which was measured relative to the total 
cell protein present.  Amount of ALP* = Amount of alkaline phosphatase measured as enzyme 
activity (U / min / µg cell protein). 
**, significantly different from control, P<0.01. 
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PTH does not affect extracellular ATP levels 
As nucleotides inhibit osteoblast mineralisation (Orriss et al., 2007), cellular ATP 
release was measured to ascertain if the inhibition of bone formation observed in 
response to PTH treatment was a consequence of increased release of ATP 
from osteoblasts.  At the higher concentrations of PTH tested, slight increases in 
ATP release were observed at day 7, but these were much less pronounced by 
day 14.  However, all observed increases in ATP release were accompanied by 
losses in cellular viability.  Dead or dying cells release ATP and as such it is 
likely that this is the cause of the increases seen, rather than a controlled release 
in response to PTH treatment (Figure 5.6.).   
 
PTH decreases expression of mRNA for osteogenic markers 
RT-PCR revealed marginal decreases in mRNA expression for type I collagen 
(Col1α1)  at  the  highest  concentration  of  PTH  tested.    However,  strong 
downregulation of osteocalcin (OCN) in the presence of 10nM and 100nM PTH 
was observed; additionally osterix (OSX) expression was notably decreased in 
cells cultured with 100nM PTH.  Expression of the PTH receptor (PTHR1) was 
also  dose-dependently  decreased.    The  expression  of  sclerostin  (SOST),  a 
known  inhibitor  of  bone  formation,  was  examined  and  showed  dramatic 
decreases  across  the  test  concentration  range  but  its  receptor,  Lrp5,  was 
relatively unaffected  (Figure 5.7).    Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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Figure 5.6.  PTH does not cause increases in ATP release by osteoblasts. 
Osteoblasts were grown in supplemented DMEM with PTH.  ATP release measurements taken 
at day 7 and day 14 were normalised for cell number.  The percentage loss in cell viability was 
assessed alongside to ascertain whether ATP released was due to PTH treatment or increased 
cell death; losses in cell viability suggest increases in ATP release are a result of increased cell 
death.  *, significant difference to control, P<0.05.  *** = P<0.001. 
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Figure 5.7.  mRNA expression by long bone osteoblasts treated continuously with PTH. 
RNA was extracted from osteoblasts grown for 14 days in supplemented DMEM and PTH as 
indicated.  mRNA expression for all osteogenic gene markers examined was decreased at the 
highest concentration of PTH tested.  Sclerostin (SOST) also showed strong downregulation but 
the expression of the sclerostin co-receptor Lrp5, appeared unaffected. 
Col1α1 = Collagen type 1 alpha 1; OCN = Osteocalcin; OSX = Osterix; PTHR1 = PTH Receptor 
1; Lrp5 = Low-density lipoprotein receptor-related protein 5; SOST = Sclerostin. 
 
The effect of sclerostin on osteoblasts 
To investigate the effects of sclerostin on osteoblastic bone forming potential a 
baseline characterisation was performed using a sample of the sclerostin protein 
(kindly donated by Novartis).  Over the concentration range tested (0, 0.1, 1, 10 
µg/ml),  only  small  inhibitory  effects  were  seen  on  bone  formation,  alkaline 
phosphatase activity and production of soluble collagen (Figure 5.8.); the only 
statistically significant inhibition observed was on soluble collagen production at 
the highest dose of sclerostin tested. Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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Figure 5.8.  Mild inhibition of osteoblast function by exogenous sclerostin. 
Calvarial osteoblasts were cultured for 14 days in supplemented DMEM and in the presence of 
increasing concentrations of sclerostin.  Modest inhibition of osteoblast activity was observed at 
the highest concentration tested.   
a.  Bone formation.  b.  Soluble collagen production.  *, significantly different to control, P<0.05.  
c.  Alkaline phosphatase (ALP) activity. 
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The effect of PTH on VEGF expression 
As discussed in the introduction to this chapter, PTH has been reported to have 
effects on aspects of the vascular supply, causing vasodilation of vascular beds 
and PTHrP has been implicated in increased angiogenesis via upregulation of 
VEGF.  Thus, the expression of VEGF mRNA by PTH treated osteoblasts was 
examined.    No  significant  effects  on  the  expression  of  VEGF  mRNA  were 
observed  over  the  concentration  range  tested.    Decreases  in  osteocalcin 
expression reinforce the findings of the RT-PCR studies and further indicate PTH 
may be inhibiting the differentiation of these cells into mature osteoblasts. 
Examination  of  the  amount  of  VEGF  protein  secreted  by  long  bone 
osteoblasts indicated that treatment with PTH caused this to be decreased in a 
dose-dependent manner (Figure 5.9.). 
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Figure 5.9.  VEGF expression by PTH treated osteoblasts 
Osteoblasts were grown for 14 days in supplemented DMEM and PTH as indicated.   
a.  RNA was extracted from osteoblasts and qPCR performed to examine mRNA expression of 
VEGF and OCN in PTH treated osteoblasts.  OCN expression decreased over the test range but 
the fluctuations in VEGF expression suggest PTH is having little effect on its expression. 
b.  The supernatant from PTH treated cells was removed and analysed for the presence of VEGF 
protein using a rat VEGF ELISA kit from Invitrogen.  Decreases across the test range suggest 
VEGF is downregulated upon exposure to PTH.   **, significantly different from control, P<0.01.  
*** = P<0.001. 
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Discussion  
The  results  presented  in  this  chapter  provide  strong  evidence  that  the  direct 
effect  of  PTH  on  osteoblasts  is  to  potently  inhibit  their  activity.    The  data 
presented demonstrate clear inhibition of bone formation when osteoblasts are 
subject to either treatment pattern in a time- or dose-dependent manner, with 
increased exposure  leading  to  increased  inhibition  of  bone formation.   These 
findings suggest that the in vivo anabolic response to PTH must be mediated via 
indirect mechanisms acting on cells other than the osteoblast. 
Osteoblast cell number was decreased across the concentration range of 
PTH  tested,  this  suggests  PTH  is  inhibiting  the  ability  of  the  isolated  pre-
osteoblasts to differentiate and then proliferate into fully functional cells.  The 
reduced cell number appeared to be accompanied by decreases in apoptosis, 
however, apoptosis was measured by examining the oligonucleosome content of 
cytoplasmic proteins that were released upon cell lysis.  The assay used did not 
account for the reduction in cell number, thus the observed decrease is likely to 
be a consequence of the decreased cell number.  However, at 10nM PTH the 
decrease in apoptosis was not in line with decreasing cell number; it is possible 
that at this concentration PTH is suppressing apoptosis, as has been previously 
described (Schnoke et al., 2009). 
The activity of the cells was also reduced by PTH treatment.  ALP activity 
was decreased by approximately one third upon treatment with 10nM PTH and 
two  thirds  when  treated  with  100nM  PTH.    This  suggests  that  higher 
concentrations of PTH may be inhibiting the ability of cells to mineralise newly 
formed  collagenous  structures.    These  findings  are  supported  by  those  from 
mRNA  expression  studies;  reductions  in  osteocalcin  and  osterix  expression 
indicate  an  inhibition  of  differentiation  by  cells  exposed  to  increasing 
concentrations of PTH.  Interestingly, there is little effect on the expression of Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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mRNA for type I collagen, supporting the idea that the inhibitory effects of PTH 
may be more related to the inhibition of mineralisation, rather that the inhibition of 
collagen formation.  The dose-dependent downregulation of the PTH receptor, 
PTHR1, is also consistent with decreased differentiation.  PTHR1 is expressed 
by lineage committed, maturing osteoblasts (Datta et al., 2009);  if PTH inhibits 
the  early  differentiation  of  these  cells,  the  receptor  expression  would  be 
decreased.  It is possible that PTH could be specifically downregulating its own 
receptor via negative feedback mechanisms, however, given the downregulation 
of  the  other  markers  of  osteoblastic  differentiation  this  would  seem  a  more 
plausible explanation. 
Expression of sclerostin mRNA was also subject to strong downregulation 
by PTH treatment, however, expression of Lrp5, a protein that forms of part of 
the  sclerostin  receptor  complex,  appeared  to  be  relatively  unaffected  by  the 
treatment.  These data support previous findings that suggest PTH may relieve 
the inhibitory actions of sclerostin on bone formation (Keller et al., 2005; Kramer 
et al., 2010).  To further this work, and examine the extent of the inhibition of 
sclerostin on osteoblast function, a sample of the sclerostin protein (donated by 
Novartis)  was  tested.    Osteocyte  secreted  sclerostin  is  believed  to  act  on 
osteoblasts by binding to the Lrp5/Lrp6 receptor complex and inhibiting Wnt/β-
catenin signalling (reviewed by (Kneissel, 2010)).  As this signalling pathway is 
implicated  in  bone  mass  regulation,  inhibition  by  sclerostin  has  an  inhibitory 
effect on bone formation in vivo.  As such, similar effects were expected in in 
vitro studies.  To examine this hypothesis, osteoblasts treated with increasing 
concentrations of sclerostin were cultured and their bone forming ability, soluble 
collagen production and alkaline phosphatase activity were assessed.  For all 
parameters examined, the inhibitory effects of sclerostin were limited.  A possible 
explanation for these modest inhibitory effects observed could be explained by 
the differences that may exist between the in vivo concentration of sclerostin and Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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those tested here.  As the sclerostin producing osteocytes are buried deep within 
the bone matrix it is difficult to know the local, in vivo concentration of sclerostin 
and as such there are no detailed reports which discuss it.  However, diffusion 
along canaliculi has been reported to be somewhat restricted (Wang et al., 2005) 
and as a result it is possible that the local concentration of sclerostin could reach 
relatively  high  levels.    Consequently,  the  concentration  of  sclerostin  that 
osteoblasts are exposed to in vivo could be much higher than has been tested 
and  the  inhibitory  effects  much  more  potent  than  those  seen  in  the  in  vitro 
experiments performed in this study.   
The strong direct inhibitory action of PTH on bone formation taken with 
the weak direct inhibitory effect of sclerostin suggests that the in vivo anabolic 
response to PTH is mediated by the interaction of the osteoblast with other local 
or systemic factors.   The requirement of osteogenesis for an adequate vascular 
supply is becoming increasingly recognised; the findings presented in Chapter 3 
show the necessity for oxygen in order for collagen and bone formation to take 
place and it follows that an increase in local blood flow or supply is essential for 
significant  new  bone  formation.    Thus,  it  would  seem  likely  that  the  anabolic 
effect that PTH treatment has on bone could be linked to an increase in vascular 
supply.  As VEGF is a key factor mediating angiogenesis, its expression by PTH 
treated osteoblasts was examined.  However, the results presented here do not 
support  the  idea  that  PTH  stimulates  angiogenesis;  qPCR  investigations 
revealed  no  significant  change  in  VEGF  mRNA  expression  with  increasing 
exposure  to  PTH  and  analysis  of  the  VEGF  protein  showed  dose-dependent 
decreases in production indicating that the anabolic response to PTH is unlikely 
to be a result of neoangiogenesis.  It has been suggested that PTH could cause 
increases in blood flow to vascular beds by increasing vasodilation (Musso et al., 
1989; Wang et al., 1984) and cardiac output (Crass et al., 1987).  The extent of 
vasodilation in different vascular bed varies (Wang et al., 1984), but when the Chapter 5 PTH inhibits bone formation by osteoblasts in vitro 
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effects  were  examined  on  rat  kidney,  both  PTH  and  PTHrP  induced  similar 
concentration-related  increases  in  glomerular  blood  flow  and  diameters  of 
preglomerular vessels (Endlich et al., 1995).  One report has suggested that PTH 
induced  vasodilation  does  not  affect  the  vascular  beds  of  osseous  tissue 
(Rambausek et al., 1982) but this has not been clarified; more recently published 
reports indicate that the vasodilatory effects of PTH are widespread  (Laroche, 
2002;  Rashid et  al., 2007).    Although  this  has  not  been  examined  directly,  it 
would seem a distinct possibility.   
The  direct  effect  of  PTH  on  osteoblasts  is  potent  inhibition  of 
differentiation and bone forming ability.  However, given the profound inhibition of 
bone formation by osteoblasts in culture, these results strongly suggest that the 
in vivo anabolic action of PTH on bone must involve other systemic pathways.  
The previously published work on the effects of PTH on vasodilation, taken with 
the findings presented in this chapter, suggest that in vivo the anabolic effects 
seen may be a result of PTH increasing the blood flow to bone and consequently 
increasing  bone  formation.    PTH  works  quickly  in  the  body  and  so  this  is  a 
preferable  suggestion  to  that  of  angiogenesis,  which  with  the  requirement for 
new blood vessel formation, would take place over a much longer time period.  In 
addition, the short in vivo bioavailability of PTH results in the inhibitory effects on 
osteoblasts  being  limited  and  are  overcome  by  the  positive  effects  of  local 
vasodilation on bone.  Consequently, anabolism results.  The differential effect of 
continuous  PTH  treatment  can  also  be  explained  by  this  theory.    Chronic 
exposure  to  PTH  is  inhibitory  to  osteoblasts,  as  is  demonstrated  by  the 
experiments performed in this chapter and although continuous PTH may also 
cause vasodilation, this is not sufficient to overcome the direct inhibitory effect of 
PTH on osteoblasts.  Consequently, bone formation is inhibited.  This hypothesis 
will be further discussed in Chapter 6.    
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Chapter 6 
General discussion 
 
The relationship between cells that produce type I collagen and oxygen has been 
examined  in  this  thesis.    In  vivo,  oxygen  is  supplied  to  these  cells  by  the 
vasculature and as such the influence of vascular supply on cellular function has 
been considered.  Further, a potential role of the vasculature in mediating the 
response of bone to exogenous stimuli has been proposed. 
Hypoxia is one of the most profound effects of reduced vascular perfusion 
as all cells have an absolute requirement for oxygen for the aerobic generation of 
ATP.  In Chapter 3 the effect of chronic hypoxia on collagen producing cells 
derived from the mesenchymal stem cell lineage was investigated.  Exposure to 
hypoxia was found to cause a significant, 80% decrease in collagen deposition 
by fibroblasts and 88% inhibition of bone formation by osteoblasts.  The scale of 
the inhibitory effect of hypoxia is similar for these closely related cell types and 
when considered with the other experiments performed suggests that the same 
mechanisms  are  likely  to  be  mediating  the  response  to  low  oxygen  in  both 
osteoblasts  and  fibroblasts.    These  results  indicate  that  successful  wound 
healing in soft tissues and fracture repair are both dependent on an adequate 
vascular oxygen supply. 
There are a number of possible mechanisms by which hypoxia may cause 
inhibition  of  the  function  of  these  cells.    The  data  presented  in  Chapter  3 
indicates that hypoxia slows the growth and differentiation of these cells, with 
reduced proliferation of both cell types seen after culture in hypoxia for 96 hours 
and delayed expression of markers of osteoblast maturity revealed by the mRNA 
expression studies.  It is possible that the reduced cell number seen in hypoxia Chapter 6 General discussion 
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may be a result of apoptosis.  Previous work carried out by this research group 
has  suggested  that  hypoxia  does  not  result  in  osteoblast  apoptosis  in  vitro 
(Utting et al., 2006) and as such apoptosis of calvarial osteoblasts and dermal 
fibroblasts cultured in hypoxia were not examined in this study.  However, others 
have  reported  that  hypoxia  does  induce  apoptosis  when  mesenchymal  stem 
cells are grown in serum deprived media (Zhu et al., 2006), indicating that while 
hypoxia may not directly induce apoptosis, it may be a consequence of in vivo 
ischemia.   
Hypoxia also causes significant inhibition of collagen formation by these 
cells.  As discussed in Chapter 3 collagen production is dramatically inhibited in 
low  oxygen  conditions,  a  likely  consequence  of  the  requirement  of  the  prolyl 
hydroxylase (PHD) enzymes for oxygen.  The striking oxygen dependence of the 
PHD enzymes makes them ideal candidates for cellular oxygen sensing, as such 
the  PHDs  involved  in  the  hydroxylation  of  HIF  have  been  implicated  in  the 
cellular response to changing oxygen tensions (Schofield et al., 2004).  Reduced 
activity of the PHDs has been observed in oxygen tensions as high as 10%, with 
progressive  reduction  in  enzyme  activity  as  the  oxygen  tension  was  reduced 
further (Epstein et al., 2001).  As the collagen modifying PHD enzymes share the 
requirement for oxygen as a cofactor, their activity is also significantly reduced in 
low oxygen conditions and as such collagen production is inhibited.  The findings 
presented indicate that low oxygen would significantly slow the wound healing 
process, decreasing cellular proliferation and inhibiting collagen biosynthesis.   
The  upregulation  of  VEGF  mRNA  has  been  seen  previously  by 
osteoblasts exposed to long-term hypoxia (Utting, 2006) and the mRNA study in 
Chapter 3 demonstrates that VEGF is also upregulated by fibroblasts grown in 
hypoxia.  This indicates that the cellular adaptation to low oxygen is to improve 
the vascular supply via the induction of VEGF signalling.  When considered with Chapter 6 General discussion 
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the  inhibitory  effects  of  hypoxia  on  collagen  formation  by  these  cells  this 
indicates that increased vascularisation in response to hypoxia is a fundamental 
adaptation to low oxygen for these cells.   
Vascularisation  is  essential  for  bone  formation,  exemplified  by  the 
knockout studies that showed HIF1α mediated VEGF expression is required for 
the proper formation of rodent long bones (Wang et al., 2007).  As such, it is a 
commonly held view that  osteogenesis and angiogenesis are coupled (Riddle et 
al., 2009).  In addition, the restoration of an adequate oxygen supply to the site 
of soft tissue injury is essential in the final stages of wound healing (Braiman-
Wiksman et al., 2007).  When considered together, the findings presented in this 
thesis and the published literature on the subject indicate that an oxygen supply 
sufficient  for  the  proper  function  and  collagen  production  by  these  cells  is 
essential  to  the  formation,  function  and  repair  of  skin  and  bone.    This  is 
exemplified by the successful use of hyperbaric oxygen treatment  to decrease 
healing  time  in  bone  (Ueng  et  al.,  1998)  and  non-diabetic  leg  ulcers 
(Hammarlund et al., 1994).   
The adhesion studies performed on osteoblasts and fibroblasts showed 
limited  effects.    As  hypoxia  reduces  the  activity  of  the  majority  of  cellular 
functions  by  osteoblasts  and  fibroblasts,  reduction  in  the  ability  to  adhere  in 
hypoxia  was  expected.    However,  the  experiments  performed  in  Chapter  3 
revealed  that  growth  in  hypoxia  resulted  in  only  marginal  decreases  in  the 
adhesion of these cells to plastic.  A likely explanation for this behaviour can be 
proposed when the in vivo situations in which adhesion is likely to take place are 
considered.  In the early stages of wound healing MSCs  home to the site of 
injury in response to the release of inflammatory cytokines (Sordi, 2009; Fong et 
al., 2011).  The first phase of wound healing involves vasoconstriction, slowing 
the blood flow to the tissue in order to minimise blood loss and is followed by Chapter 6 General discussion 
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vasodilation  (Irvin,  1985).    If  truly  unaffected  by  hypoxia,  the  findings  of  the 
adhesions  studies  would  suggest  that  both  fibroblasts  and  osteoblasts  can 
adhere to the injured soft tissue or bone surface in preparation for proliferation 
and regeneration of the tissue once the vascular supply has been restored.   
A  novel  method  for  the  isolation  and  culture  of  long  bone  osteoblasts 
derived from neonatal rats is described in Chapter 4.  The characterisation of 
these bones alongside their analogous calvarial counterparts showed no clear 
differences  between  the  cells  derived  from  these  anatomical  locations  when 
cultured in vitro.  Recently published findings by Rawlinson et al.  indicate there 
is differential expression of the Hox genes between these two different sources 
of  osteoblasts  (Rawlinson  et  al.,  2009).    This  was  to  be  expected  given  the 
different  in  vivo  locations  and  thus  different  developmental  patterning  which 
would occur.  However, the data presented in this thesis suggest that this does 
not affect the in vitro behaviour of osteoblasts.  Consequently, once removed 
from  their  native  environments  and  cultured  in  osteogenic  medium  both  cell 
types  form  bone  de  novo,  with  no  evidence  of  endochondral  bone  formation 
occurring in long bone osteoblast cultures.   
As has already been discussed in Chapter 4, Scotti et al.  (2010) have 
proposed that it is possible to recapitulate endochondral ossification in vitro using 
marrow  derived  human  adult  MSCs.    By  engineering  human  hypertrophic 
cartilaginous tissue, the authors show it is possible to engineer tissue that has 
the potential to undergo developmental changes similar to those that take place 
during  limb  formation.    If  these  findings  hold  true,  it  holds  huge  promise  for 
therapeutic treatments. 
The bone formation assay developed and described in Chapter 4 provides 
an additional model for the study of osteoblasts that overcomes some of the 
shortcomings associated with other in vitro models, however, it is not without its Chapter 6 General discussion 
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limitations.  As is the case with all in vitro models, the study of one cell type in 
isolation allows the exact effects of the test substances to be examined, but this 
is  not  reflective  of  the  in  vivo  environment  where  cells  are  in  contact  and 
interacting with each other and the extracellular matrix (Abbott, 2002).   This is 
exemplified by the work performed examining the osteoblastic response to PTH 
(Chapter 5).  Further, the assay developed has not provided a model for the 
study of endochondral bone formation, but it has expanded the possibilities for 
the in vitro culture of osteoblasts.  By adopting this method the whole animal can 
be  used  in  a  reliable,  robust  bone  formation  assay  and  thus  the  number  of 
animals  required  for experiments  will  be  reduced.    This  is  beneficial  on  both 
ethical and economical grounds. 
Using this method for osteoblast isolation the effects of PTH on osteoblast 
function and bone formation were examined in Chapter 5.  The in vitro results 
presented  and  discussed  indicate  that  PTH  had  a  direct,  inhibitory  effect  on 
osteoblasts  when  cells  were  treated  with  the  hormone.    The  same  inhibitory 
effects  were  observed  when  cells  were  treated  with  PTH  in  intermittent  or 
continuous doses, with the level of inhibition observed being directly related to 
the duration of exposure to PTH.  This indicates that the differences between the 
anabolic and catabolic effects of intermittent and continuous PTH treatment seen 
in vivo (Uzawa et al., 1995) do not occur as a result of the direct action of PTH 
on osteoblasts and must involve other local or systemic factors.   
It  has  been  proposed  that  cell  types  other  than  the  osteoblast  and 
osteoclast could be involved in mediating the anabolic effects of PTH in vivo.  
Pacifici et al. have reported that T cells play an essential role in the anabolic 
response to PTH.  Experiments performed using T cell deficient mice revealed 
that  continuous  infusion  with  PTH failed  to  induce osteoclast formation,  bone 
resorption and bone loss (Gao et al., 2008).  In addition, when these mice were Chapter 6 General discussion 
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treated with intermittent PTH a blunted increase in bone formation and trabecular 
bone volume was observed.  The normal anabolic response to intermittent PTH 
treatment  was  restored  upon  adoptive  transfer  of  T  cells  into  deficient  mice 
(Pacifici,  2010).    As  the  response  to  intermittent  PTH  is  blunted  but  not 
completely abolished in T cell deficient mice, this cannot be the only mechanism 
involved in the anabolic response but it is certainly playing a key role.   
Other  findings  have  shown  that  PTH  has  dramatic  effects  on  vascular 
tone, resulting in vasodilation (the key references are discussed in Chapter 5).  It 
is plausible that the vasodilation and concomitant increased blood supply to bone 
could be playing a role in mediating the anabolic response of intermittent PTH 
treatment.    Thus,  it  is  hypothesised  that  when  administered  intermittently  the 
level of PTH in the blood is sufficient to cause vasodilation of arteries, increasing 
the  blood  supply  to  bone  and  resulting  in  bone  formation.    Experiments 
performed  on  the  rat  mesenteric  artery  have  shown  that  the  vasodilation  is 
stimulated  by  concentrations  of  PTH  in  the  low  nanomolar  range  (maximal 
effects were observed in the presence of 30nM PTH and half maximal effects at 
4nM  PTH)  (Nickols  et  al.,  1985).    These  concentrations  are  in  line  with  the 
reported  concentration  of  PTH  present  in  blood  serum  after  subcutaneous 
injection  with  teriparatide  (Satterwhite  et  al.,  2010).    Elevated  PTH  levels  in 
response to teriparatide administration are only present for a limited time period 
(approximately 2-3 hours post injection) (Frolik et al., 2003) and as such minute 
to minute changes in vascular tone result.  The lack of angiogenic involvement, 
as suggested by the reduction in VEGF protein described in Chapter 5, supports 
this hypothesis.  The formation of new blood vessels would take place over a 
much longer time period; if PTH was having a positive effect on angiogenesis, it 
would  have  to  be  bioavailable  for  much  longer  than  the  2-3  hours  after 
administration.    However,  when  PTH  is  present  for  longer  time  periods,  i.e.  
when it is administered continuously, the effect of PTH is no longer anabolic.   Chapter 6 General discussion 
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Continuous  exposure  to  PTH  causes  hypertension  in  normal  subjects 
(Hulter  et  al.,  1986)  suggesting  that  the  vasodilatory  effect  of  PTH  are 
diminished.    Further,  it  has  been  reported  that  prolonged  exposure  to  PTH 
causes  desensitisation  of  vascular  smooth  muscle  cells  (Nyby  et  al.,  1995).  
Therefore, it would seem reasonable to hypothesise that the anabolic effects of 
intermittent PTH may be mediated, at least in part, by the vasodilation of the 
blood  vessels  in  and  around  bone,  resulting  in  increased  blood  flow  and 
concomitant  osteogenesis.    In  addition  to  this  PTH  also  acts  directly  on 
osteoclasts, stimulating their activity (Dempster et al., 2005) and as such, bone 
resorption  occurs.    The  relative  amount  of  osteogenesis  associated  with 
intermittent  PTH  treatment  is  much  greater  than  the  osteoclastic  resorption 
taking place and consequently is anabolic.  As osteogenesis is not stimulated by 
continuous treatment, the relative osteoclastic activity is much greater and bone 
loss results.   
Nitric oxide (NO), is another known signalling molecule with vasodilatory 
actions (Ignarro et al., 1987).  While high levels of NO (as are seen in cases of 
severe  inflammation)  inhibit  bone  formation,  normal  physiological  levels  are 
required for bone formation (Van't Hof et al., 2001).  NO has been linked to the 
anabolic  effects  of  oestrogen  in  vivo,  with  inhibitors  of  nitric  oxide  synthase 
(NOS) causing decreases in oestrogen-induced bone formation (Samuels et al., 
2001).    In  addition,  oestrogen  has  been  seen  to  increase  the  synthesis  and 
release of NO by endothelial cells (Hayashi et al., 1995).  Thus it is possible that 
in addition to its direct anabolic effects on bone, NO mediated vasodilation may 
also contribute to the in vivo anabolic effect of oestrogen.   
This is not the only situation in which vasodilators are also seen to have 
bone anabolic effects.  The prostaglandins, particularly prostaglandin 2 (PGE2), 
is a known vasodilator of vascular beds at multiple sites (Lumley et al., 1982).   Chapter 6 General discussion 
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PGE2 is also implicated in increased bone formation (Chyun et al., 1984).  PGE2 
cannot be used as a bone anabolic therapy due to the associated side effects 
but PGE2 receptor selective agonists have been seen to induce bone healing 
(Paralkar et al., 2003).   
A similar mechanism may also be mediating the effects on bone of other 
factors.  Glucocorticoids are known to inhibit vasodilation, therefore preventing 
increased blood flow to vascular beds (Perretti et al., 2000).  Restriction of bone 
perfusion  is  known  to  impair  bone  metabolism  and  consequently  may  be 
associated with a reduction in bone mass (Vogt et al., 1997).  The association of 
glucocorticoid use with bone loss and resulting osteoporosis and fracture is well 
known (Reid, 1999) and is a likely consequence, at least in part, of the reduction 
in  vascular  supply  induced  by  steroid  use.    Therefore,  it  is  possible  that 
glucocorticoids act in a converse manner to PTH, restricting blood flow to bone 
and consequently resulting in bone loss. 
Even though the relationship between osteogenesis and angiogenesis is 
well documented, the role of the vasculature in mediating the response to bone 
anabolic  therapies  has  not  been  widely  considered  by  the  literature.    The 
mechanism  proposed  here  suggests  that  PTH  increases  bone  formation  by 
increasing vasodilation of the vascular network, increasing blood flow to bone.   
The relationship between vasodilation and bone formation is not limited to 
PTH,  with  other  bone  anabolic  agents  also  known  to  increase  blood  flow.  
Further, the reciprocal effects that result from glucocorticoid treatment indicate 
that this hypothesis may provide a link between the actions of these factors on 
bone and its vascular supply.  While the vasodilation hypothesis proposed here 
is unlikely to be the sole mechanism mediating the anabolic response to PTH, 
the  evidence  presented  strongly  suggests  that  it  is likely  to  be a  contributing 
factor.   Chapter 6 Future work 
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Future work 
The results presented in this thesis and suggestions made in the general 
discussion  point  towards  a  clearer,  more  descriptive  explanation  of  why 
intermittent and continuously administered PTH elicit different effects on bone in 
vivo.  Whilst this thesis has provided the initial proposition, to achieve a better 
understanding, the suggested hypothesis needs to be tested so that it can be 
definitely confirmed if the proposed mechanism for the action of PTH is true.   
Although upregulation of VEGF is not involved in the anabolic response, it 
is  possible  that  other  vascular  stimuli  may  be  upregulated  in  osteoblasts  in 
response to intermittent PTH treatment, and these factors may  play a role in 
mediating the changes in vascular tone.  Platelet derived growth factor (PDGF) is 
a  stimulator  of  angiogenesis  but  also  has  effects  on  vasoconstriction  and 
vasodilation  (Sakagami  et  al.,  2001).    PDGF-A,  an  isoform  of  PDGF,  is 
expressed by osteoblasts (Zhang et al., 1991; Yu et al., 1997), but its expression 
in PTH treated cells has not been investigated.  mRNA and protein expression 
studies could easily shed light on this and indicate whether or not PDGF plays a 
role in mediating the vascular response to PTH treatment.   
Using a basic organ culture of slices of rat artery and subjecting them to 
intermittent and continuous PTH treatment, the effects on vascular tone could be 
assessed.  However, in vivo studies would provide the most useful data, but this 
would be difficult to measure.  As PTHR1 null mice display chondroplaysia and 
die before birth (Clemens et al., 2001), knockouts cannot be used but targeted 
knock  down  or deletion  of  the  receptor  in VSMCs could  provide  a  system  in 
which  the  effects  of  PTH  on  bone  could  be  assessed  in  the  absence  of  the 
influence from the vasculature. Chapter 6 Conclusion 
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Conclusion 
An  adequate  vascular  supply  is  essential  for  the  proper  function  of  collagen 
producing  cells.    The  oxygen  requirement  for  collagen  synthesis  is  absolute:  
failure to establish or maintain a good vascular network has severe effects on the 
function  of  cells  producing  type  I  collagen  and  their  ability  to  produce  an 
extracellular matrix. 
This  thesis  has  consolidated  and  furthered  previous  findings  on  the 
response of osteoblasts and fibroblasts to hypoxia.  Furthermore, it has provided 
a novel method for the study of osteoblast in vitro and proposed explanations 
involving the vasculature in the varied responses to intermittent and continuous 
PTH treatment.  Put in a wider context, the suggested hypothesis could hold true 
for other factors that affect both bone mass and vascular tone.   
The relationship between the vasculature and collagen producing cells is 
tightly  coupled  and  offers  wide  ranging  possibilities  for  intervention  and  thus 
potential therapeutic targets.  
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Appendix I 
Primer sequences 
Table 1.  Primer pairs used for RT cDNA amplification 
Gene product  Primer sequence (5’-3’)  bp  ta (°C) 
Alkaline 
phosphatase 
S - CTCATTTGTGCCAGAGAA 
AS - GTTGTACGYCTTGGAGAC 
238  50 
Beta actin  S - GTTCGCCATGGATGACGAT 
AS - TCTGGGTCATCTTTTCACGG 
332  53 
Collagen 1α1  S – GGCTATGATGAGAAATCAGC 
AS - ACCACTGAAACCTCTGTGTC 
318  53 
DMP1  S - GAAAACAGTGCCCAAGATAC 
AS - CTGTCGTCTTCCTCAGAGAC 
371  53 
Lrp5  S- GTACCCGGAAGATCATTGTA 
AS - GAATGTCCATGGGTGAATAC 
303  53 
Matrix gla protein  S – CCCTGTGCTATGAATCTC 
AS - GACTCCGTAACAAAGCGA 
297  50 
Osteocalcin  S – GCAGACACCATGAGGACCCT 
AS - GCAGCTGTGCCGTCCATAC 
418  59.8 
Osteoprotegrin  S – GAGTGTTCTGGTGGACAGTT 
AS - ACAAGCTCACTAGCTTCAGG 
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Gene product  Primer sequence (5’-3’)  bp  ta (°C) 
Osteopontin  S – CGGTGAAAGTGGCTGAGT 
AS - GACTCGGGATACTGTTCA 
333  50 
Osterix  S – GAGGAAGAAGCTCACTATGG 
AS - GTAGACACTAGGCAGGCAGT 
351  55 
PTHR1  S - TGGGATACTCCATGTCTCTC 
AS - TTGGTAGCCAGGAAGTAGAG 
307  53 
RANK ligand  S – CGAGCGCAGATGGATCCTAAC 
AS – GACTTTATGGGAACCCGATGG 
330  57 
Sclerostin  S -  CACCATGCAGCTCTCACTA 
AS -  ACGTCTTTGGTGTCATAAGG 
228  53 
VEGF 
 
S -  TCCAGAGAGAAGTCAAGGAA 
AS -  AGAGAGAAGAGCCCAGAAGT 
359  65 
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Table 2.  Primer pairs used for cDNA amplification by qRT-PCR 
Gene product  Primer sequence (5’-3’) 
Beta actin  S – GCCTTCCTTCCTGGGTATGG   
AS – GAGGTGTTTACGGATGTCAACG 
Osteocalcin   S – CCAAGCCCAGCGACTCTGAG   
AS – TCCAAGTCCATTGTTGAGGTAGC 
PPARγ    S – TGCCTATGAGCACTTCACAA   
AS - ATCCATCACAGAGAGGTCCA 
Sox9  S – CAGAGAACGCACATCAAGAC 
AS – GGGCTGTAGGAGATCTGTTG 
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Abbreviations 
 
ABAM  Antibiotic-antimycotic  
ALP  Alkaline phosphatase 
ANOVA  One way analysis of variance 
ASC  Ascorbic acid 
ATP  Adenosine triphosphate 
BMD  Bone mineral density 
BMP  Bone morphogenic protein   
BMU  Basic multicellular unit 
BSA  Bovine serum albumin 
C/EBP  CCAAT/ enhancer binding protein 
CASR  Calcium sensing receptor 
CB 
CBP 
Calvarial bone osteoblasts 
CREB-binding protein 
cDNA  Complementary deoxyribonucleic acid 
CO2  Carbon dioxide 
Col1α1  Collagen type 1, alpha 1 
CTGF  Connective tissue growth factor 
Dexa  Dexamethasone Appendix II Abbreviations 
177 
 
dH2O  Distilled water 
DHT  Dihydrotestosterone   
DMEM  Dulbecco’s modified eagle medium 
DMP1  Dentine matrix protein 1 
DNA  Deoxyribonucleic acid 
DNase  Deoxyribonuclease 
dNTP  Deoxynucleotide triphosphate 
ELISA  Enzyme-linked immunosorbent assay 
FCS  Foetal calf serum 
HBSS  Hanks balanced salt solution 
HIF-1α  Hypoxia inducible factor-1α 
HRE  Hormone response element 
Ihh  Indian hedgehog 
iPTH  Intermittent PTH 
LB  Long bone osteoblasts 
LDH  Lactate dehydrogenase 
L-glut  L-glutamine 
Lrp5  Low-density lipoprotein receptor-related protein 5 
Lrp6  Low-density lipoprotein receptor-related protein 6 
mA  Milliamp 
M-CSF  Macrophage colony stimulating factor 
MgCl2  Magnesium chloride Appendix II Abbreviations 
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MGP  Matrix gla protein 
mRNA  Messenger ribonucleic acid 
MSC  Mesenchymal stem cell 
N2  Nitrogen 
NADH  Nicotinamide adenine dinucleotide (reduced form) 
NFATc1  Nuclear factor of activated T cells 1 
O2  Oxygen 
OCN  Osteocalcin 
Oligo-dT  Oligo deoxythymidylic acid 
OPG  Osteoprotegrin 
OPN  Osteopontin 
OSX  Osterix 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction  
PDGF  Platelet derived growth factor 
PHD  Prolyl hydroxylase 
pO2  Partial pressure of oxygen 
PO4
3-  Phosphate ion 
PPARγ  Peroxisome proliferator-activated receptor gamma 
PTH  Parathyroid hormone 
PTHR1  Parathyroid hormone receptor 1 
PTHrP  Parathyroid hormone related protein Appendix II Abbreviations 
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pVHL  Von Hippel Lindau protein 
qRT-PCR  Quantitative real-time polymerase chain reaction 
RANK  Receptor activator for nuclear factor κ B 
RANKL  Receptor activator for  nuclear factor κ B ligand 
rh-PTH  Recombinant human parathyroid hormone 
RNA  Ribonucleic acid 
RNase  Ribonuclease 
RT-PCR  Reverse transcriptase polymerase chain reaction 
Runx2  Runt-related transcription factor 2 
Scl-Ab  Sclerostin antibody 
SEM  Standard error of the mean 
SOST  Sclerostin 
Sox5/6  SRY (sex determining region Y)-box 5/6 
Sox9  SRY (sex determining region Y)-box 9  
TEM  Transmission electron microscopy 
TGFβ  Transforming growth factor-β 
TNFα  Tumour necrosis factor-α 
Ub  Ubiquitin 
UV  Ultraviolet 
VEGF  Vascular endothelial growth factor 
w/v  Weight / volume 
Wnt  Wingless-type  MMTV integration site Appendix II Abbreviations 
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β-actin  Beta actin 
βAPN  Beta aminoproprionitrile 
β-GP  Beta glycerophosphate  
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 1.  Introduction 
Osteoblasts are derived from mesenchymal stem cells and are responsible for bone formation.  A number of 
different approaches have been developed to study osteoblasts  in vitro, including bone organ cultures, 
primary cell cultures and immortalized osteoblast-like cell lines.  Combined these methods have provided 
abundant information about the regulation of osteoblast proliferation, differentiation and function.   
Osteoblastic cell lines are widely used as a convenient source of large numbers of cells with a relatively 
stable phenotype.   However, many of these osteoblast-like cells do not express the whole range of bone-
specific genes and/or form bone in vitro.  Furthermore, repeated passaging has been shown to cause the 
loss of the osteoblastic phenotype in some cell lines (1). 
  Primary bone cell cultures were first described in 1964 by Peck and colleagues (2), who isolated cells 
from the parietal and frontal bones of fetal and neonatal rat calvariae using collagenase digestion.  The 
isolated cells proliferated in vitro and exhibited high alkaline phosphatase (ALP) activity, although the cultures 
were contaminated with other cell types such as fibroblasts.  In 1974, Wong and Cohn (3) used sequential 
collagenase digestion to obtain a more homogenous population of osteoblastic cells.  The first description of 
the formation of bone nodules by differentiating osteoblasts released enzymically from calvarial bones and 
cultured with β-glycerophosphate ascorbate and dexamethasone was by Bellows and colleagues in 1986 (4).     
  This chapter describes the isolation, culture and staining of primary osteoblasts from the calvaria and 
long bones of neonatal rats (see note 1).  The osteoblast bone formation assay has a number of advantages.  
Firstly, it allows the key function of osteoblasts, namely bone formation, to be studied quantitatively (5). Bone 
formation in this essentially 2-dimensional culture system appears to recapitulate the intramembranous 
(woven) bone formation seen in histological sections from developing animals – i.e. large-scale structures 
resembling trabeculae appear.  Secondly, it offers the opportunity to study separately the processes of bone 
matrix deposition and mineralisation (6).  Thirdly, it allows the extracellular environment to be tightly 
regulated (e.g.  pH, pO2) in a manner which is not possible using bone organ cultures or in vivo (7,8).  
Fourthly, osteoblast activity can be studied in an environment that is relatively free from the influence of other 
cell types normally found in bone such as endothelial cells, nerves and haematopoietic cells.  Lastly, 
osteoblasts can be studied at clearly identified stages of differentiation from the immature, proliferating cells 
present early in the cultures through to the mature bone-forming osteoblasts in late stage cultures.  
   Two important pitfalls should be highlighted here.  The first concerns the use of inappropriately high 
concentrations of the alkaline phosphatase substrate, β-glycerophosphate in many published descriptions of 
osteoblast cultures.   At high concentrations, β-glycerophosphate causes generalised mineral deposition and 
impaired cell viability (the osteoblasts effectively fossilise), with the result that the cultures fail to progress 
beyond the formation of small nodules.   The second, related pitfall concerns the frequent confusion between 
mineral deposition (which also occurs on teeth, in caves and in kettles) and true bone formation, which 
involves selective mineralisation of a collagenous matrix deposited in characteristic patterns.  Osteoblast cell 
lines (and many other cell types) express alkaline phosphatase and can mineralise in the presence of 
sufficient β-glycerophosphate – but this is not bone formation. 
 2.  Materials 
All solutions, instruments and tissue culture plastics should be sterile. 
1.  Animals:  The cells are obtained from the calvariae and long bones of neonatal (2-3 day old) rats.  
The number of animals to use depends on the experiments to be performed; typically one animal will 
yield 10
7 and 5 x 10
6 cells from the calvaria and long bones, respectively (see notes 1 and 2).  
2.  Phosphate buffered saline (PBS): For storing tissues prior to use and washing cells. 
3.  Supplemented Dulbecco’s modified essential medium (sDMEM):  Add 10% foetal calf serum 
(FCS), 2mM L-glutamine and 100U/ml penicillin, 100µg/ml streptomycin, 0.25µg/ml amphotericin 
(mixture is known as antibiotic/antimitotic or AB/AM).   This supplemented DMEM (sDMEM) should 
be stable at 4
oC for at least 4 weeks. 
4.  Osteogenesis DMEM (osDMEM); to the sDMEM described above add 2mM β-glycerophosphate 
(see note 3), 10nM dexamethasone and 50µg/ml ascorbate.  Always make fresh on day of use. 
5.  Sodium hydroxide (NaOH): 6M NaOH to alter the pH of the culture medium if required (see note 4). 
6.  Trypsin: 1% (w/v) trypsin solution (free of calcium and magnesium, which inhibit trypsin activity).  
7.  Collagenase: 0.2% (w/v) collagenase solution made up in Hank’s balanced salt solution (HBSS); 
filter sterilise.  Note that HBSS contains calcium, which is required for collagenase activity. 
8.  Fixative: 2.5% glutaraldehyde in dH2O or 70% ethanol; prepare fresh before use. 
9.  Alizarin red stain for mineralised bone nodules: 1% (w/v) alizarin red in dH2O; prepare fresh 
before use. 
10. Alkaline phosphatase (ALP) staining: alkaline phosphatase kit (Sigma kit 86C-1KT). 
11. Sirius red stain for deposited collagen: Sircol™ dye reagent (Biocolor kit S1005)  
12. Tissue culture plastics: Large petri dishes (100mm), 5ml flat bottomed tubes, 15ml and 50ml 
centrifuge tubes, 75cm
2 tissue culture flasks and 24 well tissue culture plates. 
13. Dissection tools: Scalpels and blades (no.20), tweezers and scissors 
3.  Methods 
To keep the cell cultures sterile, normal techniques for working under sterile conditions should be employed 
(working in a flow cabinet, use of sterile media and instruments, etc). 
3.1. Isolation and culture of primary osteoblasts from neonatal rat calvaria 
1.  Sacrifice 2 neonatal (2-3 days old) rats and sterilise with 70% ethanol.  Place each cadaver in a large 
petri dish. 
2.  Remove the head using large scissors; transfer the body to a separate petri dish for long bone 
isolation (see section 3.2.) 
3.  Grasp the head at the nape of the neck and make a small incision along the base of the skull (small 
scissors will make the cleanest cut).  Carefully remove the skin and the brain tissue from the skull 
using a scapel and tweezers. 4.  Cut away the jaw and scrape off any  excess tissue and cartilage from around the edge of the 
calvaria. 
5.  Cut the calvaria in half and place in a flat- bottomed 5ml tube; wash with PBS. 
6.  Repeat steps 2-5 for the second animal. 
7.  Incubate the calvariae in 1% trypsin (1ml/calvarial bone) for 10 minutes at 37°C.  Remove and 
discard the trypsin solution; wash in sDMEM (serum and calcium will inactivate any residual trypsin). 
8.  Incubate in 0.2% collagenase solution (800 µl / calvarial bone) for 30 minutes at 37°C. 
9.  Remove the collagenase digest, discard and replace with fresh solution for a further 60 minutes at 
37°C. 
10. Keep the final digest and transfer to a 15ml conical base centrifuge tube. Wash calvaria with sDMEM 
(5ml), transfer the solution to the 15ml tube containing the final digest. 
11. Spin the cell solution at 1,500 g for 5 minutes at room temperature.  Discard the supernatant and 
resuspend the cell pellet in sDMEM (1ml/calvarial bone).  Pool the cell suspensions. 
12. Add 20ml of sDMEM to 2 x 75cm
2 flasks; add 1ml of cell suspension to each flask. 
13. Incubate the flask at 37°C/5% CO2 until the cells reach confluency (~3 days). 
3.2.  Isolation and culture of primary osteoblasts from the long bones of neonatal rats 
1.  Take the bodies of the animals used for the calvarial osteoblast isolation (see section 3.1). 
2.  Remove the limbs from the body by cutting with sharp scissors at the point closest to the body, 
preserving as much of the limb as possible.  
3.  Using a scalpel cut off the paws and cut the limb in half (at the joint). 
4.  Remove the skin and scrape away the soft tissue from the limbs. 
5.  Cut off the epiphyses and place the bone fragments into a flat- bottomed 5ml tube. Wash and vortex 
in PBS. 
6.  Incubate the bone fragments in 1% trypsin (1ml / animal) for 10 minutes at 37°C.  Remove and 
discard the trypsin solution; wash in sDMEM. 
7.  Incubate in 0.2% collagenase solution (1ml) for 30 minutes at 37°C. 
8.  Remove the collagenase digest, discard and replace with fresh solution for a further 60 minutes at 
37°C. 
9.  Keep the final digest and transfer to a 15ml conical base centrifuge tube. Wash remaining bone 
fragments with sDMEM (5ml), transfer the solution to the 15ml tube containing the final digest. 
10. Spin the cell solution at 1,500 g for 5 minutes at room temperature.   Discard the supernatant and 
resuspend the cell pellet in sDMEM (1ml). 
11. Add 20ml of sDMEM to a 75cm
2 flasks; add cell suspension. 
12. Incubate the flask at 37°C/5% CO2 until the cells reach confluency (~3 days). 
3.3.  Bone formation assay 
This protocol is used for osteoblasts from both calvarial and long bone isolations. 1.  Once the cells in the 75cm
2 have reached confluency (~3 days), remove the sDMEM and wash with 
PBS.  Add 1% trypsin (2ml/flask) and incubate for 10 minutes at 37°C. 
2.  Inactivate the trypsin by adding 10ml of sDMEM; transfer the cell suspension to a 15ml centrifuge 
tube. 
3.  Spin the cell solution at 1,500 g for 5 minutes at room temperature.   Discard the supernatant and 
resuspend the cell pellet in sDMEM (1ml/flask).  Pool the cell suspensions. 
4.  Perform a cell count using a haemocytometer; seed the cells in 24 well tissue culture trays at a 
density of 2.5 x 10
4 cells/well in osDMEM. 
5.  Half the medium should be exchanged every 2-3 days.  Cultures will typically be fully confluent by 
day 4; they will begin to form discrete bone nodules from about day 10, with extensive networks of 
mineralising ‘trabeculae’ developing from day 14 (Figs. 1 & 2). 
6.  The pH should be monitored at every medium change and maintained at ~pH 7.4 by the addition of 
6M NaOH if required (see notes 4 and 5).   
7.  ALP activity (ALP assay kit, Biotron) and soluble collagen production (Sircol Red assay, Biocolor) 
can be assayed throughout the 14 day culture period using commercially available kits. 
3.4.  Fixation and staining 
1.  On termination of the experiment, carefully wash the cell layers with PBS. 
2.  Transfer to fixative:  2.5% glutaraldehyde for 5 minutes for alizarin red and ALP staining, 70% 
ethanol for one hour for Sirius red staining. 
3.  Wash twice with PBS and leave to air dry (Sirius red staining only). 
4.  For cell layers to be stained with alizarin red or for ALP, wash three times with 70% ethanol and 
leave to air dry.  
5.  Stain as required (Fig. 2): 
-  Alizarin red for 5 minutes followed by three washes with 50% ethanol; allow to air dry. 
-  ALP for ~30 minutes in the dark; wash with dH2O and allow to air dry. 
-  Sirius red for 1 hour; wash with dH2O and allow to air dry. 
3.5. Quantification of mineralised bone formation 
1.  Once fully dry, scan plates at 2000 dots/cm
2 on a high-resolution flat-bed scanner.   We use an 
Epson Perfection 4990 photo/slide scanner.  Transmitted light scanning of alizarin red-stained plates 
is commonly used but unstained cell layers also yield excellent high-contrast images in both 
transmitted and reflected light modes (the latter showing the white bone trabeculae against a dark 
background) (Fig. 2). 
2.  Apply a circular mask to the image of each cell well and convert to a binary image (e.g. using ‘Adobe 
Photoshop’). 3.  Use an image analysis program (e.g.  ‘Image J’ –  available free from http://rsbweb.nih.gov/ij/) to 
determine the number and surface area of mineralised bone nodules in the binary images of each 
individual well, using constant threshold and minimum particle size levels.  
3.6.  Statistics 
We routinely use one-way analysis of variance (ANOVA) to analyse experiments.  Although often neglected, 
adjustments for multiple comparisons between treatment groups (eg, the Bonferroni correction) are 
frequently needed (see note 6).  
4.  Notes 
1.  Calvarial cells vs. long bone cells:   Although the flat bones of the skull and the limb bones are 
formed by different developmental processes, osteoblasts derived from either source appear to 
behave similarly in culture.    
2.  Young cells vs. old cells:  An important reason why the rat osteoblast culture system described 
here is able to form bone is that the initial cell population is obtained from neonates – and thus has 
considerable growth potential.  Cells derived from adult animals (including human donors), may have 
progressed too far towards their ‘Hayflick limits’ to be capable of the rapid expansion to high cell 
density required for true osteogenic differentiation.     
3.  Concentration  of  β-glycerophosphate:  Bone mineralisation requires a supply of calcium and 
orthophosphate (Pi), both of which are required for hydroxyapatite crystal formation.  A key source of 
phosphate in bone is alkaline phosphatase, which hydrolyzes a range of phosphate-containing 
substrates including adenosine triphosphate (ATP) and inorganic pyrophosphate (6).   An additional 
important mechanism by which ALP promotes mineralisation, however, is by hydrolysing 
pyrophosphate, a ubiquitous physicochemical inhibitor of calcium phosphate deposition.  To form 
mineralised bone nodules in vitro, an additional source of phosphate is required.  The most widely 
used phosphate source is β-glycerophosphate (β-GP), although phosphate itself can also be used.  
Fig. 3 illustrates the critical importance of β-GP concentration in this culture system (see also Orriss 
et al, 2007) (6).  In osteoblast cultures lacking β-GP, organic matrix is deposited but mineralisation 
fails to occur.  Osteoblasts cultured with 2mM β-GP reproducibly form abundant bony structures with 
characteristic “trabecular” morphology; alizarin red staining shows that mineralisation is confined to 
these matrix structures.  In contrast, culture with 5-10mM β-GP causes a widespread, dystrophic 
deposition of mineral as soon as the differentiating osteoblasts begin to express significant amounts 
of ALP, leading to mineralisation of the cells themselves (Fig. 3A).  This impairs cell viability (Fig. 
3B), with the result that only small mineralised nodules are able to form (rather than the striking 
trabecular  structures  evident  with  lower  concentrations  of  β-GP).  Thus, it is critical that a low 
concentration of β-glycerophosphate is used in this assay. 4.  The importance of pH:  Extracellular pH is an important factor in the regulation of bone 
mineralisation (7).  Acidosis causes a selective, inhibitory action on matrix mineralisation by inhibiting 
alkaline phosphatase expression and activity, whilst increasing mineral solubility (7).  For example, 
even a reduction in pH from pH 7.43 to pH 7.32 will reduce bone nodule formation in vitro by ~60% 
(Fig. 4).  Due to its high bicarbonate concentration, DMEM is more alkaline than some media (such 
as minimum essential medium, MEM); in equilibrium with 5% CO2, it is buffered to pH ~7.4.  The 
metabolic activity of osteoblasts will cause progressive acidification, particularly in mature, bone 
forming cultures when cells numbers are high.  To ensure that pH does not affect bone mineralisation 
in this assay it may sometimes be necessary to add a small volume of OH
- ions (as 6M NaOH) to the 
culture medium to ensure an average running pH of 7.4. 
5.  Measuring the medium pH:  Accurate measurement of the operating pH of mammalian osteoblast 
cultures is important for meaningful comparison of results from different laboratories.  For HCO3
-/CO2 
buffered media, accurate pH measurement can only be achieved by the use of a standardized blood 
gas analyser.  We use a Radiometer ABL 705 blood gas analyser (Radiometer, Crawley, UK), which 
features a multi-electrode system to measure pH, pCO2 and pO2 in a 200µl injected sample (cyclic 
time ~ 2 minutes).  The first medium measurement taken immediately after removing the culture 
plates from the incubator is assumed to provide a pCO2 value that is identical for all wells and that 
reflects the actual pCO2 during incubation.  It should be noted that opening the incubator door during 
experiments, may cause perturbations in CO2 levels that affects the measured pH and pCO2 values.  
6.  Statistics: Because of interassay variability, statistical comparisons should be performed only within 
one assay, and not between different assays. 
 Figure 1.  Orriss et al, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Phase contrast microscopy of primary rat osteoblast cultures.   Representative images are of 
unstained cell layers.   By day 4 of culture, a confluent monolayer of cells is evident.  At day 7, the cells are 
more compacted and organic matrix is beginning to be deposited (as shown by the arrow).  By day 10, there 
is abundant deposition of unmineralised collagenous matrix and mineralisation (dark area at lower left of 
image) is commencing.  After 14 days of culture, there is widespread formation of mineralised matrix 
networks.  Scale bar = 25µm.    
 
 
 
 
 
 
 Figure 2.  Orriss et al, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Different staining methods in primary rat osteoblast cultures.    Images show 14 day 
osteoblast cultures either left unstained, or stained with alizarin red (to demonstrate calcium), alkaline 
phosphatase (ALP) or sirius red (to demonstrate collagen).  Bone formed in these cultures exhibits a typical 
“trabecular” morphology, with discrete mineralisation confined to matrix nodules, as shown in the unstained 
and alizarin red-stained images.   In the unstained image at lower left, unmineralised matrix appears brown 
and mineralised matrix black.  Intense ALP staining (also ‘trabecular’) is evident in mature, bone forming 
osteoblasts.  Sirius red staining shows the presence of collagen fibres in these cultures.  Scale bars = 0.1cm 
(cell well scans, upper row) and 25µm (phase contrast images, lower row). 
 
 
 
 
 
 
 
 Figure 3.  Orriss et al, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  The effect of the β-glycerophsophate concentration on bone mineralisation and osteoblast 
viability in vitro.  (A)  Rat calvarial osteoblasts were cultured for 14 days before staining with alizarin red to 
demonstrate mineral deposition.  Rat long bone osteoblasts were cultured for 28 days before fixation and 
transmission electron microscopy (TEM).  In the absence of β-glycerophosphate (β-GP), bone mineralisation 
fails to occur due to insufficient inorganic phosphate; widespread, unmineralised collagenous matrix is 
evident in the phase contrast and TEM images.  Bone formed in the presence of 2mM β-GP exhibits a typical 
“trabecular” morphology; mineralisation is confined to these structures.  In the presence of 5-10mM β-GP, 
widespread, non-specific (dystrophic) deposition of bone mineral occurs across the cell monolayer, with 
inhibition of normal matrix deposition.  Intracellular deposition of mineral that causes damage to cell 
membranes and organelles is also evident.  (B) Increased β-GP concentration is associated with decreased 
osteoblast viability, assessed as lactate dehydrogenase (LDH) release after 14 days in culture.  Values are 
means ± standard error of the mean (SEM) (n = 6); significantly different from control *** = p <0.001, ** = p < 
0.01.  Scale bars = 0.1cm (cell well scans), 25µm (phase contrast images) and 1µm (TEM).  Figure 4.  Orriss et al, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Inhibitory effect of acidosis of bone mineralisation by cultured rat osteoblasts.  In 14 day 
cultures, decreasing pH caused progressive reduction in the formation of mineralised nodules stained with 
alizarin red, with complete inhibition at pH 6.93.  Values are means ± standard error of the mean (SEM) (n = 
6); significantly different from control (pH 7.43) value, ** = p <0.001, * = p < 0.05. 
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